US 20120115934A1 ( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n ( 10 ) Pub. N0. : US 2012 / 0115934 A1 DE FOUGEROLLES et al. ( 43 ) Pub. Date : May 10 , 2012 ( 54 ) ORGANIC COMPOSITIONS T0 TREAT ( 60 ) Pr0Visi0na1 app1icati0n N0. 61 / 333 , 398 , ﬁ1ed 0n May BETA - ENAC - RELATED DISEASES 11 , 2010 , pr0Visi0na1 app1icati0n N0. 61 / 327 , 379 , ﬁ1ed 0n Apr. 23 , 2010. ( 75 ) 1nVent0rs : Ant0nin DE FOUGEROLLES , Cambridge , MA ( US ) ; J0hn L. Publicati0n Classiﬁcati0n DIENER , Cambridge , MA ( US ) ; ( 51 ) Int. Cl. Emma HICKMAN , HOI ' S118m A61K 31 / 713 ( 2006.01 ) ( GB ) ; Greg0ry HINKLEa c0711 14 / 00 ( 2006.01 ) Cambndge , MA ( US ) , Stuart A61P 7 / 00 ( 2006.01 ) MILSTEIN , Cambrldge , MA ( US ) ; A6IP 3 / 00 ( 2006.01 ) Anne - Marie PULICHINO , A 61P 9 / 12 ( 2006.01 ) Cambﬂdgea MA W$ ) 3 MMer A61P 13 / 12 ( 2006.01 ) SPRAGUE , Cambr1dge , MA ( US ) C07H 21 / 02 ( 2006.01 ) _ C07K 14 / 79 ( 2006.01 ) ( 73 ) ASS‘gnee‘ N0VARTIS AG BaSe1 ( CH ) ( 52 ) U. s. Cl. 514 / 44 A ; 536 / 24.5 ; 530 / 350 ; 530 / 380 ( 21 ) App1. N0. : 13 / 355 , 930 ( 57 ) ABSTRACT ( 22 ) F H e d : Jan. 23 2012 The present discl0sure re1ates t0 RNAi agents usefu1 in meth - 0ds 0f treating Beta - ENaC - re1ated diseases such as cystic W 00 ( 62 ) DiVisi0n of app1icati0n N0 , 13 / 090 , 580 , ﬁ1ed 0n Apr. sity - ass0ciated hypertensi0n , using a therapeutica11y effec - . 20 , 2011. tiVe an10unt 0f a RNAi agent t0 Beta - ENaC. EEE EUEmnmmc : w : c=3 : o= 33 36 SS EEE H a m dm NSNSHESK. 15. rmwmmod. mwmmmod wmmmwod. wmwomma. mmmoNDa. . beta ENaC. . Emmaz. . mmmE4. . §mm. m w 0 9 5. . 150~. 1. B : 5 m : a.._mmamcm&zm : %. FIG. 1. Ewomnz wwwmma4 Egmma. mmwamQa mamamad. mmm ENaC. Emmn2. . mmand. . . yama. u — 0 a 5. . w a 1. 1 51 } - . A _E m : o : wmon=w&sz$. EEE EUEmnmmc : w : c=3 : o= 33 36 SS EEE N a m dm NSNSHESK. 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m A 2 _ _ a I >Umomwm Umsz t S Q m 11 >832 mmzmo e n f T1 3 m_mZ> oo : : o_ b m m 11 : m© Oo_3_. o_ 9 . w w m w o m w w m 2 B. H mm m w m m m _. _ _ _ G AmE ; oV mo : m_. w_mmm_ I mcm5EmEmcE / r mmEm>< F f 1 >omommm cmzmo O. n . . m I >Umo._©._ mmzmo. .ﬁ. b m C a m. x. z> ooaa_ n a H N . . m E 11 : 8 Oo : =o_ o. m m m m m m m o n 1 1 . . . u. A t. coEoo.6 mmﬂcmewe m._. u_o. 2 EEEEE : oﬁce. EEEE omzm. wﬁai EUEmec : w : c=3 : o= 33 HP SS EEE m a m dm SSSSSS 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A 3. N + >BomwN cmzmo R. m w “ >US._S mmzmo a. N : m mﬁz } Oo : : o_ m : 8 Oo : .=. o_ b . memmmmmmm0 . A_o._E8 66. mmch. mu._m. Qv : o_mmm._me omzm SS. FIG. 2. T1 _ _ 7 A SSS cmzmo. . . . 1 >Umo._©._ mmZmO. . . 3C mRNA. . N 11 n : m m. mz> Oo : .=. o_ E. . . . . . . . . 1 : 8 . Oo : : o_. . . . . . . . . . . . . n . 22E8 B c mmmmEmeme : o_mwm§xm omzm EQE. US 2012 / 0115934 A1. ORGANIC COMPOSITIONS TO TREAT BETA - ENAC - RELATED DISEASES. [ 0001 ] This app1icati0n is a diVisi0na1 app1icati0n 0f U. S. Uti1ity patent app1icati0n Ser. N0. 13 / 090 , 580 ﬁ1ed 20 Apr. 2011 , Which c1aims pri0rity to U. S. Pr0Visi0na1App1icati0n Ser. N0. 61 / 333 , 398 ﬁled 11 May 2010 and U. S. Pr0Visi0na1 App1icati0n Ser. N0. 61 / 327 , 379 ﬁ1ed 23 Apr. 2010 , the 00n - tents 0f Which are inc0rp0rated herein by reference in their entirety. BACKGROUND OF THE INVENTION. [ 0002 ] The muc0sa1 surface betWeen the enVir0nment and the b0dy has many pr0tectiVe mechanisms. One f0rm 0f defense is c1eansing the surface With quuid. The quantity 0f 1iquid reﬂects the ba1ance betWeen epithe1ia1 1iquid secreti0n ( Which 0ften reﬂects ani0n secreti0n c0up1ed With Water and a cati0n c0unter - i0n ) and 1iquid abs0rpti0n ( Which 0ften reﬂects Na + abs0rpti0n , c0upled With Water and c0unter ani0n ) . Many diseases 0f muc0saI surfaces are caused by tO0 1itt1e 1iquid , as caused by an imba1ance betWeen secreti0n ( t00 1itt1e ) and abs0rpti0n ( t00 much ) . One meth0d t0 ba1ance the 1iquid 1ayer is to decrease Na + channe1 - mediated 1iquid abs0rpti0n. [ 0003 ] N0nV01tage - gated , ami10ride - sensitiVe s0dium channe1s c0ntr01 ﬂuid and e1ectr01yte transp0rt acr0ss epithe - 11a in many 0rgans. Ihe apicaI membranes 0f many tight epithe1ia c0ntain sOdium channe1s that are primarin characterized by their high afﬁnity t0 the diuretic b10cker ami10ride. These channe1s mediate the ﬁrst step 0f actiVe sodium reab - s0rpti0n essentia1 f0r the maintenance 0f b0dy sa1t and Water h0me0stasis. In Vertebrates , the channeIs c0ntr01 reabs0rp - ti0n 0f sodium in the kidney , 00l0n , 1ung and sWeat g1ands ; they a1s0 p1ay a r01e in taste percepti0n. [ 0004 ] The rate - 1imiting step 0f Na + and quuid abs0rpti0n is mediated by the epithe1ia1 s0dium ( Na + ) channe1 ( ENaC ) . These s0dium channe1s are heter0meric c0mp1eXes c0nsisting 0f 3 subunits : A1pha - ENaC , Beta - ENaC , and GammaENaC. [ 0005 ] Beta - ENaC ( a1s0 kn0Wn as SCNN1B ) enc0des the beta subunit 0f this s0dium channe1 , and mutati0ns in and / 0r a1tered expressi0n 0f this gene haVe been ass0ciated With seVera1 diseases ( and / 0r ass0ciated With treatments 0f diseases ) , inc1uding cystic ﬁbr0sis , pseud0hyp0a1d0ster0nism type 1 ( PHA1 ) , Lidd1es syndr0me , hypertensi0n , a1ka10sis , hyp0ka1emia , and 0besity - ass0ciated hypertensi0n. [ 0006 ] There eXists the need f0r treatments re1ated t0 BetaENaC - re1ated diseases. BRIEF SUMMARY OF THE INVENTION. [ 0007 ] The present disc10sure enc0mpasses RNAi agents t0 Beta - ENaC , Which are usefu1 in the treatment 0f Beta - ENaC - re1ated diseases , such as cystic ﬁbr0sis , pseud0hyp0a1d0ster - 0nism type 1 ( PHA1 ) , Lidd1es syndr0me , hypertensi0n , a1ka10sis , hyp0ka1emia , and 0besity - ass0ciated hypertensi0n. The present disc10sure a1s0 enc0mpasses a meth0d 0f treating a human subject haVing a path010gica1 state mediated at 1east in part by a1pha - ENaC eXpres si0n , the meth0d c0mprising the step 0f admini stering to the subject a therapeutica11y effectiVe am0unt 0f a RNAi agent Beta - ENaC. [ 0008 ] The present discl0 sure pr0Vides speciﬁc RNAi agents and meth0ds that are usefu1 in reducing Beta - ENaC. May 10 , 2012. 1eVe1s in a subject , e. g. , a mammaI , such as a human. The present disc10sure speciﬁca11y pr0Vides d0uble - stranded RNAi agents c0mprising at 1east 15 0r m0re c0ntigu0us nuc1e0tides 0f Beta - ENaC. In particu1ar , the present disc10 - sure pr0Vides agents c0mprising sequences 0f 15 0r m0re 00ntigu0us nuc1e0tides differing by 0 , 1 , 2 01 3 fr0m th0se 0f the RNAi agents pr0Vided , e. g. , in Tab1e 1. The RNAi agents particu1ar1y can in 0ne emb0diment c0mprise 1ess than 30 nuc1e0tides per strand , e. g. , such as 18 - 23 nuc1e0tides , and / 0r. 19 - 21 nuc1e0tides , and / 0r such as th0se pr0Vided , e. g. , in Tab1e 1. [ 0009 ] The d0ub1e - stranded RNAi agents can haVe b1unt ends 0r 0Verhangs 0f 1 , 2 , 3 0r 4 nuc1e0tides ( i. e. , 1 - 4 nt ) fr0m 0ne 0r b0th 3‘ and / 0r 5 ' ends. The d0uble - stranded RNAi agents can a1s0 0pti0na1ly c0mprise 0ne 0r tW0 3 ' caps and / 0r 0ne 0r m0re m0diﬁed nuc1e0tides. M0diﬁed Variants 0f sequences as pr0Vided herein inc1ude th0 se that are 0therWise identica1 but c0ntain substituti0ns 0f a natura11y 0ccurring nuc1e0tide f0r a 00rresp0nding m0diﬁed nucle0tide. [ 0010 ] Further , the RNAi agent can either c0ntain 0n1y natura1ly - 0ccurring rib0nuc1e0tide subunits , 0r 0ne 0r m0re m0diﬁcati0ns t0 the sugar , ph0sphate 0r base 0f 0ne 0r m0re 0f the rep1acement nuc1e0tide subunits , Whether they c0m - prise rib0nuc1e0tide subunits 0r de0Xyrib0nuc1e0tide subunits. In 0ne emb0diment , m0diﬁed Variants 0f the disc10sed RNAi agents inc1ude RNAi agents With the same sequence , but With 0ne 01 m0re m0diﬁcati0ns t0 0ne 01 ' m0re 0f the sugar , ph0sphate 01 base 0f 0ne 01 m0re 0f the nuc1e0tide subunits. In 0ne emb0diment , the m0diﬁcati0ns impr0Ve efﬁ - cacy , stabi1ity and / 0r reduce immun0genicity 0f the RNAi agent. One aspect 0f the present disc10 sure re1ates t0 a d0ubIestranded 01ig0nucIe0tide c0mprising at Ieast 0ne n0n - naturaI nuc1e0base. In certain emb0diments , the n0n - natura1 nuc1e0 - base is diﬂu0r0t01y1 , nitr0ind01y1 , nitr0pyrr01y1 , 0r nitr0imidaz01y1. In a particu1ar emb0diment , the n0n - natura1 nuc1e0 - base is diﬂu0r0t01yI. In certain emb0diments , 0n1y 011e 0f the tW0 01ig0nuc1e0tide strands 00ntains a n0n - naturaI nucle0 - base. In certain emb0diments , b0th 0f the 01ig0nuc1e0tide strands c0ntain a n0n - natura1 nuc1e0base. [ 0011 ] The RNAi agent ( s ) can 0pti0naI1y be attached t0 a 1i gand se1ected t0 impr0Ve 0ne 0r m0re characteristic , such as , e. g. , stabi1ity , distributi0n and / 0r ce11u1ar uptake 0f the agent , e. g. , ch01ester01 0r a deriVatiVe there0f. Ihe RNAi agent ( s ) can be is01ated 0r be part 0f a pharmaceuticaI c0mp0siti0n used f0r the meth0ds described herein. ParticularIy , the pharmaceutica1 00mp0siti0n can be f0rmu1ated f0r de1iVery t0 the 1ungs 0r nasa1 passage 0r f0rmu1ated f0r parenta1 admini stra - ti0n. Ihe pharmaceutica1 c0mp0siti0ns can 0pti0na1ly c0m - pri se tW0 0r m0re RNAi agents , each 0ne directed t0 the same 0r a different segment 0f the Beta - ENaC mRNA. Opti0na11y , the pharmaceutica1 c0mp0siti0ns can further c0mprise 0r be. used in c0njuncti0n With any kn0Wn treatment f0r any BetaENaC - re1ated disease. [ 0012 ] The present disc10sure further pr0Vides meth0ds f0r reducing the 1eVe1 0f Beta - ENaC mRNA in a ce11 , particu1ar1y in the case 0f a disease characterized by 0Ver - eXpressi0n 0r hyper - actiVity 0f ENaC. Ihe present disc10sure aIs0 enc0m - passes a meth0d 0f treating a human subject haVing a path0 - 10gica1 state mediated at 1east in part by Beta - ENaC eXpres - si0n , the meth0d c0mprising the step 0f administering to the subject a therapeutica11y effectiVe am0ur1t 0f a RNAi agent Beta - ENaC. Such meth0ds c0mprise the step 0f administering 0ne 0f the RNAi agents 0f the present disc10sure t0 a subject , as further described be10W. The present meth0ds. US 20l2 / 0ll5934 Al. utilize the cellular mechanisms inV0lVed in RNA interference t0 selectiVely degrade the target RNA in a cell and are c0m - prised 0f the step 0f c0ntacting a cell With 0ne 0f the RNAi agents 0f the present discl0sure. Such meth0ds can be per - f0rmed directly 0n a cell 0r can be perf0rmed 0n a mammalian subject by administering t0 a subject 0ne 0f the RNAi agents / pharmaceutical c0mp0siti0ns 0f the present discl0sure. Reducti0n 0f target Beta - ENaC RNA in a cell results in a reducti0n in the am0unt 0f enc0ded Beta - ENaC pr0tein pr0 - duced. In an 0rganism , this can result in reducti0n 0f epithelial p0tential difference , balanced ﬂuid abs0rpti0n and increased muc0ciliary clearance. [ 0013 ] The meth0ds and c0mp0siti0ns 0f the present dis - cl0sure , e. g. , the meth0ds and. [ 0014 ] Beta - ENaC RNAi agent c0mp0siti0ns , can be used With any d0sage and / 0r f0rmulati0n described herein , as Well as With any r0ute 0f administrati0n described herein. [ 0015 ] The details 0f 0ne 0r m0re emb0diments 0f the present discl0 sure are set f0rth in the acc0mpanying draWings and the descripti0n bel0W. Other features , 0bj ects , and adVantages 0f the present discl0sure Will be apparent fr0m this descripti0n , the draWings , and fr0m the claims. BRIEF DESCRIPTION OF THE FIGURES. [ 0016 ] FIGS. 1A - 1B depict the ability 0f RNAi agents AD20807 , AD20826 , AD20832 , AS20834 , AD20848 , and AD2086l t0 kn0ck - d0Wn Beta - ENaC actiVity in ViV0. [ 0017 ] FIGS. 2A - 2C depict the in Vitr0 effect 0f BetaENaC RNAi Agent AD20832 0n ENaC channel functi0nal actiVity in human br0nchial epithelial cells. DETAILED DESCRIPTION OF THE INVENTION. [ 0018 ] The present discl0sure enc0mpasses RNAi agents t0 Beta - ENaC , Which are useful in treatment 0f Beta - ENaCrelated diseases ( e. g. , diseases ass0ciated With mutati0ns in and / 0r altered expressi0n , leVel and / 0r actiVity 0f Beta - ENaC , and / 0r diseases treatable by m0dulating the eXpressi0n , leVel and / 0r actiVity 0f Beta - ENaC ) , such as cystic ﬁbr0sis , pseud0hyp0ald0ster0nism type 1 ( PHAl ) , Liddles syn - dr0me , hypertensi0n , alkal0sis , hyp0kalemia , and 0besityass0ciated hypertensi0n. The present discl0sure als0 pr0Vides meth0ds 0f treating a human subject haVing a path0l0gical state mediated at least in part by Beta - ENaC eXpressi0n , the meth0d 00mprising the step 0f administering t0 the subject a therapeutically effectiVe am0ur1t 0f a RNAi agent BetaENaC. [ 0019 ] Vari0us Emb0diments 0f the Present Discl0sure Include : . [ 0020 ] A RNAi Agent C0mprising an Antisense Strand Described Herein. [ 0021 ] In 0ne emb0diment , the present discl0 sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent speciﬁc t0 Beta - ENaC ( 0r any set 0f 0Verlapping RNAi agents speciﬁc t0 Beta - ENaC ) pr0Vided , e. g. , in Table 1. In an0ther emb0diment , the present discl0sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising a sense and an antisense strand , Wherein the anti - sense strand c0mprises at least 15 c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle - 0tides fr0m the anti - sense strand 0f a RNAi agent fr0m any sequence pr0Vided herein. In an0ther emb0diment , the. May 10 , 2012. present discl0sure relates to a c0mp0siti0n c0mprising a RNAi agent c0mprising a ﬁrst strand and a sec0nd strand , Wherein the ﬁrst strand c0mprises at least 15 c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the sequence 0f the ﬁrst strand , and the sec0nd strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the sequence 0f the sec0nd strand 0f any RNAi agent pr0Vided herein. [ 0022 ] Particular dupleXes include the f0ll0Wing , Wherein each dupleX c0mprises a set 0f SEQ ID NOs , Wherein the ﬁrst SEQ ID NO 00rresp0nds to a ﬁrst strand ( e. g. , a sense strand ) , and the sec0nd SEQ ID NO c0rresp0nds to a sec0nd strand ( e. g. , an anti - sense strand ) : AD - 20805 ( SEQ ID NOs. 111 and 112 ) ; AD - 20806 ( SEQ ID NOs. 113 and 114 ) ; AD - 20807 ( SEQ ID NOs. llS and ll6 ) ; AD - 20808 ( SEQ ID NOs. ll7 and ll8 ) ; AD - 20809 ( SEQ ID NOs. 1 l9 and l20 ) ; AD - 208l0 ( SEQ ID NOs. 121 and 122 ) ; AD - 20811 ( SEQ ID NOs. 123 and 124 ) ; AD - 20812 ( SEQ ID NOs. 125 and 126 ) ; AD - 20813 ( SEQ ID NOs. 127 and 128 ) ; AD - 20814 ( SEQ ID NOs. 129 and l30 ) ; AD - 208 l 5 ( SEQ ID NOs. l31 and l32 ) ; AD - 208l6 ( SEQ ID NOs. l33 and 134 ) ; AD - 208l7 ( SEQ ID NOs. l35 and 136 ) ; AD - 20818 ( SEQ ID NOs. 137 and 138 ) ; AD - 20819 ( SEQ ID NOs. 139 and 140 ) ; AD - 20820 ( SEQ ID NOs. 141 and l42 ) ; AD - 2082l ( SEQ ID NOs. l43 and l44 ) ; AD - 20822 ( SEQ ID NOs. l45 and 146 ) ; AD - 20823 ( SEQ ID NOs. l47 and l48 ) ; AD - 20824 ( SEQ ID NOs. 149 and lS0 ) ; AD - 20825 ( SEQ ID NOs. 151 and 152 ) ; AD - 20826 ( SEQ ID NOs. 153 and 154 ) ; AD - 20827 ( SEQ ID NOs. 155 and 156 ) ; AD - 20828 ( SEQ ID NOs. lS7 and 158 ) ; AD - 20829 ( SEQ ID NOs. lS9 and l60 ) ; AD - 20830 ( SEQ ID NOs. l61 and l62 ) ; AD - 2083l ( SEQ ID NOs. 163 and 164 ) ; AD - 20832 ( SEQ ID NOs. 165 and 166 ) ; AD - 20833 ( SEQ ID NOs. 167 and 168 ) ; AD - 20834 ( SEQ ID NOs. 169 and 170 ) ; AD - 20835 ( SEQ ID NOs. 171 and l72 ) ; AD - 20836 ( SEQ ID NOs. l73 and l74 ) ; AD - 20837 ( SEQ ID NOs. l75 and 176 ) ; AD - 20838 ( SEQ ID NOs. l77 and 178 ) ; AD - 20839 ( SEQ ID NOs. 179 and 180 ) ; AD - 20840 ( SEQ ID NOs. 181 and 182 ) ; AD - 20841 ( SEQ ID NOs. 183 and 184 ) ; AD - 20842 ( SEQ ID NOs. 185 and 186 ) ; AD - 20843 ( SEQ ID NOs. l87 and 188 ) ; AD - 20844 ( SEQ ID NOs. l89 and l90 ) ; AD - 20845 ( SEQ ID NOs. l91 and l92 ) ; AD - 20846 ( SEQ ID NOs. 193 and 194 ) ; AD - 20847 ( SEQ ID NOs. 195 and 196 ) ; AD - 20848 ( SEQ ID NOs. 197 and 198 ) ; AD - 20849 ( SEQ ID NOs. 199 and 200 ) ; AD - 20850 ( SEQ ID NOs. 201 and 202 ) ; AD - 2085l ( SEQ ID NOs. 203 and 204 ) ; AD - 20852 ( SEQ ID NOs. 205 and 206 ) ; AD - 2086l ( SEQ ID NOs. 207 and 208 ) ; AD - 20862 ( SEQ ID NOs. 209 and 210 ) ; AD - 20863 ( SEQ ID NOs. 211 and 212 ) ; AD - 20864 ( SEQ ID NOs. 213 and 214 ) ; AD - 20865 ( SEQ ID NOs. 215 and 216 ) ; AD - 20866 ( SEQ ID NOs. 217 and 218 ) ; and AD - 20867 ( SEQ ID NOs. 2l9 and 220 ) , and m0diﬁed Variants there0f. [ 0023 ] One emb0diment pr0Vides m0diﬁed Variants 0f particular duplexes , Wherein each dupleX c0mprises a set 0f SEQ ID NOs , Wherein the ﬁrst SEQ ID NO c0rresp0nds t0 a ﬁrst strand ( e. g. , a sense strand ) , and the sec0nd SEQ ID NO c0rresp0nds t0 a sec0nd strand ( e. g. , an anti - sense strand ) that are selected fr0m the gr0up c0nsisting 0f : AD - 20805 ( SEQ ID NOs. l and 2 ) ; AD - 20806 ( SEQ ID NOs. 3 and 4 ) ; AD - 20807 ( SEQ ID NOs. 5 and 6 ) ; AD - 20808 ( SEQ ID NOs. 7 and 8 ) ; AD - 20809 ( SEQ ID NOs. 9 and 10 ) ; AD - 20810 ( SEQ ID NOs. 11 and l2 ) ; AD - 208ll ( SEQ ID NOs. l3 and l4 ) ; AD - 208l2 ( SEQ ID NOs. lS and l6 ) ; AD - 208l3 ( SEQ ID NOs. l7 and l8 ) ; AD - 208l4 ( SEQ ID NOs. l9 and 20 ) ; AD - 20815 ( SEQ ID NOs. 21 and 22 ) ; AD - 20816 ( SEQ ID NOs. 23 and 24 ) ; AD - 20817 ( SEQ ID NOs. 25 and 26 ) ; . US 20l2 / 0ll5934 Al. AD - 208l8 ( SEQ ID NOs. 27 and 28 ) ; AD - 208l9 ( SEQ ID NOs. 29 and 30 ) ; AD - 20820 ( SEQ ID NOs. 3l and 32 ) ; AD - 20821 ( SEQ ID NOs. 33 and 34 ) ; AD - 20822 ( SEQ ID NOs. 35 and 36 ) ; AD - 20823 ( SEQ ID NOs. 37 and 38 ) ; AD - 20824 ( SEQ ID NOs. 39 and 40 ) ; AD - 20825 ( SEQ ID NOs. 41 and 42 ) ; AD - 20826 ( SEQ ID NOs. 43 and 44 ) ; AD - 20827 ( SEQ ID NOs. 45 and 46 ) ; AD - 20828 ( SEQ ID NOs. 47 and 48 ) ; AD - 20829 ( SEQ ID NOs. 49 and 50 ) ; AD - 20830 ( SEQ ID NOs. 51 and 52 ) ; AD - 20831 ( SEQ ID NOs. 53 and 54 ) ; AD - 20832 ( SEQ ID NOs. 55 and 56 ) ; AD - 20833 ( SEQ ID NOs. 57 and 58 ) ; AD - 20834 ( SEQ ID NOs. 59 and 60 ) ; AD - 20835 ( SEQ ID NOs. 61 and 62 ) ; AD - 20836 ( SEQ ID NOs. 63 and 64 ) ; AD - 20837 ( SEQ ID NOs. 65 and 66 ) ; AD - 20838 ( SEQ ID NOs. 67 and 68 ) ; AD - 20839 ( SEQ ID NOs. 69 and 70 ) ; AD - 20840 ( SEQ ID NOs. 71 and 72 ) ; AD - 20841 ( SEQ ID NOs. 73 and 74 ) ; AD - 20842 ( SEQ ID NOs. 75 and 76 ) ; AD - 20843 ( SEQ ID NOs. 77 and 78 ) ; AD - 20844 ( SEQ ID NOs. 79 and 80 ) ; AD - 20845 ( SEQ ID NOs. 81 and 82 ) ; AD - 20846 ( SEQ ID NOs. 83 and 84 ) ; AD - 20847 ( SEQ ID NOs. 85 and 86 ) ; AD - 20848 ( SEQ ID NOs. 87 and 88 ) ; AD - 20849 ( SEQ ID NOs. 89 and 90 ) ; AD - 20850 ( SEQ ID NOs. 91 and 92 ) ; AD - 2085l ( SEQ ID NOs. 93 and 94 ) ; AD - 20852 ( SEQ ID NOs. 95 and 96 ) ; AD - 20861 ( SEQ ID NOs. 97 and 98 ) ; AD - 20862 ( SEQ ID NOs. 99 and 100 ) ; AD - 20863 ( SEQ ID NOs. 101 and 102 ) ; AD - 20864 ( SEQ ID NOs. 103 and 104 ) ; AD - 20865 ( SEQ ID NOs. lO5 and lO6 ) ; AD - 20866 ( SEQ ID NOs. 107 and lO8 ) ; and AD - 20867 ( SEQ ID NOs. lO9 and llO ) . [ 0024 ] Particular C0mp0siti0ns. [ 0025 ] In 0ne emb0diment , the present discl0 sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising an antisense strand , Wherein the antisense strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle - 0tides fr0m the antisense strand 0f a RNAi agent t0 BetaENaC selected fr0m any sequence ( 0r 0Verlapping set 0f sequences ) pr0Vided in a table here ( e. g. , Table 1 ) . In 0ne emb0diment , the present discl0sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising a sense strand and an antisense strand , Wherein the antisense strand 00mprises at least 15 c0ntigu0us nucle0tides differing by 0 , 1 , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m any sequence ( 0r 0Verlapping set 0f sequences ) pr0Vided in a table here ( e. g. , Table l ) . In an0ther emb0diment , the present discl0sure relates to a c0mp0siti0n c0mprising a RNAi agent c0mprising a sense and an antisense strand , Wherein the anti - sense strand c0mprises at least 15 00ntigu0us nucle0tides differing by 0 , 1 , 2 , 0r 3 nucle - 0tides fr0m the anti - sense strand 0f a RNAi agent fr0m any sequence pr0Vided herein. In an0ther emb0diment , the present discl0sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising a ﬁrst strand and a sec0nd strand , Wherein the ﬁrst strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the sequence 0f the ﬁrst strand , and the sec0nd strand 00mpri ses at least l5 c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the sequence 0f the sec0nd strand 0f any RNAi agent pr0Vided herein. Particular dupleXes include th0se speciﬁc dupleXes pr0Vided ab0Ve and as listed in any 0ne 0r m0re 0f Table l. Additi0nal m0diﬁed sequences ( e. g. , sequences c0mprising 0ne 0r m0re m0diﬁed base ) 0f each 0f the c0mp0siti0ns ab0Ve are als0 c0ntemplated as part 0f the present discl0sure. May 10 , 2012. [ 0026 ] Table Al , bel0W , pr0Vides the SEQ ID NOs f0r the unm0diﬁed and an example m0diﬁed sequence 0f the sense and an anti - sense strands 0f Vari0us RNAi agents t0 BetaENaC. The base c0mp0siti0n 0f each is speciﬁc sequence represented by the SEQ ID NOs is pr0Vided in m0re detail in Table l , and p0rti0ns there0f are pr0Vided in Table 2. TABLE Al. . SEQ ID NOs f0r a ﬁrst and a sec0nd strand ( e. g. , sense ( “SS” ) and antisense ( “AS” ) strand ) f0r RNAi agents t0 Beta - ENaC. . . M0diﬁed Unm0diﬁed RNAi agent - sequence sequence dup1eX name SEQ ID NO SEQ ID NO AD - 20805 Sense 1 111 Anti - Sense 2 112 AD - 20806 Sense 3 113 Anti - Sense 4 114 AD - 20807 Sense 5 115 Anti - Sense 6 116 AD - 20808 Sense 7 117 Anti - Sense 8 118 AD - 20809 Sense 9 119 Anti - Sense 10 120 AD - 20810 Sense 11 121 Anti - Sense 12 122 AD - 20811 Sense 13 123 Anti - Sense 14 124 AD - 20812 Sense 15 125 Anti - Sense 16 126 AD - 20813 Sense 17 127 Anti - Sense 18 128 AD - 20814 Sense 19 129 Anti - Sense 20 130 AD - 20815 Sense 21 131 Anti - Sense 22 132 AD - 20816 Sense 23 133 Anti - Sense 24 134 AD - 20817 Sense 25 135 Anti - Sense 26 136 AD - 20818 Sense 27 137 Anti - Sense 28 138 AD - 20819 Sense 29 139 Anti - Sense 30 140 AD - 20820 Sense 31 141 Anti - Sense 32 142 AD - 20821 Sense 33 143 Anti - Sense 34 144 AD - 20822 Sense 35 145 Anti - Sense 36 146 AD - 20823 Sense 37 147 Anti - Sense 38 148 AD - 20824 Sense 39 149 Anti - Sense 40 150 AD - 20825 Sense 41 151 Anti - Sense 42 152 AD - 20826 Sense 43 153 Anti - Sense 44 154 AD - 20827 Sense 45 155 Anti - Sense 46 156 AD - 20828 Sense 47 157 Anti - Sense 48 158 AD - 20829 Sense 49 159 Anti - Sense 50 160 AD - 20830 Sense 51 161 Anti - Sense 52 162 AD - 20831 Sense 53 163 Anti - Sense 54 164 AD - 20832 Sense 55 165 Anti - Sense 56 166 AD - 20833 Sense 57 167 Anti - Sense 58 168 AD - 20834 Sense 59 169 Anti - Sense 60 170. US 20l2 / 0ll5934 Al. TABLE A1 - c0ntinued. . SEQ ID NOs f0r a ﬁrst and a sec0nd strand ( e. g. , sense ( “SS” ) and antisense ( “AS” ) strand ) f0r RNAi agents t0 Beta - ENaC. . . M0diﬁed Unm0diﬁed RNAi agent - sequence sequence duplex name SEQ ID NO SEQ ID NO AD - 20835 Sense 61 171 Anti - Sense 62 172 AD - 20836 Sense 63 173 Anti - Sense 64 174 AD - 20837 Sense 65 175 Anti - Sense 66 176 AD - 20838 Sense 67 177 Anti - Sense 68 178 AD - 20839 Sense 69 179 Anti - Sense 70 180 AD - 20840 Sense 71 181 Anti - Sense 72 182 AD - 20841 Sense 73 183 Anti - Sense 74 184 AD - 20842 Sense 75 185 Anti - Sense 76 186 AD - 20843 Sense 77 187 Anti - Sense 78 188 AD - 20844 Sense 79 189 Anti - Sense 80 190 AD - 20845 Sense 81 191 Anti - Sense 82 192 AD - 20846 Sense 83 193 Anti - Sense 84 194 AD - 20847 Sense 85 195 Anti - Sense 86 196 AD - 20848 Sense 87 197 Anti - Sense 88 198 AD - 20849 Sense 89 199 Anti - Sense 90 200 AD - 20850 Sense 91 201 Anti - Sense 92 202 AD - 20851 Sense 93 203 Anti - Sense 94 204 AD - 20852 Sense 95 205 Anti - Sense 96 206 AD - 20861 Sense 97 207 Anti - Sense 98 208 AD - 208 62 Sense 99 209 Anti - Sense 100 210 AD - 20863 Sense 101 211 Anti - Sense 102 212 AD - 20864 Sense 103 213 Anti - Sense 104 214 AD - 20865 Sense 105 215 Anti - Sense 106 216 AD - 20866 Sense 107 217 Anti - Sense 108 218 AD - 20867 Sense 109 219 Anti - Sense 110 220. . [ 0027 ] F0r example , in Table Al , an exemplary m0diﬁed sequence 0f RNAi agent AD - 20805 is represented by SEQ ID NO : 1 ( the sense strand ) and SEQ ID NO : 2 ( the anti - sense strand ) . The unm0diﬁed sequence 0f AD - 20805 is represented by SEQ ID NO : 111 ( the sense strand ) and SEQ ID NO : 112 ( the anti - sense strand ) . Thus , Table A1 presents the SEQ ID NO identiﬁers 0f a ﬁrst and sec0nd strand 0f the unm0diﬁed sequence and at least 0ne exemplary m0diﬁed sequence f0r each 0f the Vari0us RNAi agents t0 Beta - ENaC. [ 0028 ] An RNAi Agent C0mprising an Anti - Sense Strand Described Herein. [ 0029 ] In 0ne particular speciﬁc emb0diment , the present discl0sure relates t0 a c0mp0siti0n c0mprising a RNAi agent c0mprising an anti - sense strand , Wherein the anti - sense. May 10 , 2012. strand c0mpri ses at least lS c0ntigu0us nucle0tides differing by 0 , 1 , 2 , 0r 3 nucle0tides fr0m the anti - sense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m th0se anti - sense strands in the speciﬁc duplexes pr0Vided herein and as listed , e. g. , in Table l. [ 0030 ] Vari0us speciﬁc emb0diments 0f this emb0diment are described bel0W. [ 0031 ] In 0ne emb0diment , the c0mp0siti0n ﬁ1rther c0m - prises a sec0nd RNAi agent t0 Beta - ENaC. In Vari0us emb0diments , the sec0nd RNAi agent is physically separate fr0m the ﬁrst , 0r the tW0 are physically c0nnected ( e. g. , c0Valently linked 0r 0therWise c0njugated ) . [ 0032 ] In 0ne emb0diment , the antisense strand is ab0ut 30 0r feWer nt in length. [ 0033 ] In 0ne emb0diment , the sense strand and the antisense strand f0rm a duplex regi0n 0f ab0ut lS t0 ab0ut 30 nucle0tide pairs in length. [ 0034 ] In 0ne emb0diment , the antisense strand is ab0ut 15 t0 ab0ut 36 nt in length , including ab0ut l8 t0 ab0ut 30 nt in length , and ﬁ1rther including ab0ut l9 t0 ab0ut 23 nt in length. In 0ne emb0diment , the antisense strand has at least the length selected fr0m ab0ut 15 nt , ab0ut 16 nt , ab0ut 17 nt , ab0ut 18 nt , ab0ut 19 nt , ab0ut 20 nt , ab0ut 21 nt , ab0ut 22 nt , ab0ut 23 nt , ab0ut 24 nt , ab0ut 25 nt , ab0ut 26 nt , ab0ut 27 nt , ab0ut 28 nt , ab0ut 29 nt and ab0ut 30 nt. [ 0035 ] In 0ne emb0diment , the RNAi agent 00mprises a m0diﬁcati0n that causes the RNAi agent t0 haVe increased stability in a bi0l0gical sample 0r enVir0nment , e. g. , bl00d serum 01 intestinal laVage ﬁuid. [ 0036 ] In 0ne emb0diment , the RNAi agent c0mprises at least 0ne sugar backb0ne m0diﬁcati0n ( e. g. , ph0sph0r0thi0 - ate linkage ) and / 0r at least 0ne 2 ' - m0diﬁed nucle0tide. In 0ne emb0diment , all the pyrimidines are 2 ' O - methyl - m0diﬁed nucle0tides. [ 0037 ] In 0ne emb0diment , the RNAi agent 00mprises : at least 0ne 5 ' - uridine - adenine - 3 ' ( 5 ' - ua - 3 ' ) dinucle0tide , Wherein the uridine is a 2 ' - m0diﬁed nucle0tide ; and / 0r at least 0ne 5‘ - uridine - guanine - 3 ' ( 5 ' - ug - 3‘ ) dinucle0tide , Wherein the 5 ' - uridine is a 2‘ - m0diﬁed nucle0tide ; and / 0r at least 0ne 5 ' - cytidine - adenine - 3 ' ( 5 ' - ca - 3‘ ) dinucle0tide , Wherein the 5 ' - cytidine is a 2 ' - m0diﬁed nucle0tide ; and / 0r at least 0ne 5 ' - uridine - uridine - 3 ' ( 5 ' - uu - 3 ) dinucle0tide , Wherein the 5 ' - uridine is a 2 ' - m0diﬁed nucle0tide. [ 0038 ] In 0ne emb0diment , the RNAi agent 00mprises a 2 ' - m0diﬁcati0n selected fr0m the gr0up c0nsisting 0f : 2 ' - de0xy , 2 ' - de0xy - 2‘ - ﬁu0r0 , 2 ' - O - methyl , 2‘ - O - meth0xyethyl ( 2‘ - O - MOE ) , 2 ' - O - amin0pr0pyl ( 2‘ - O - AP ) , 2 ' - O - dimethylamin0ethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylamin0pr0 - pyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylamin0ethyl0xyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O—N - methylacetamid0 ( 2 ' - O - NMA ) . In 0ne emb0diment , all the pyrimidines are 2 ' O - methyl - m0di - ﬁed nucle0tides. [ 0039 ] In 0ne emb0diment , the RNAi agent c0mprises a blunt end. [ 0040 ] In 0ne emb0diment , the RNAi agent c0mprises an 0Verhang haVing l to 4 unpaired nucle0tides. [ 0041 ] In 0ne emb0diment , the RNAi agent c0mprises an 0Verhang at the 3 ' - end 0f the antisense strand 0f the RNAi agent. [ 0042 ] In 0ne emb0diment , the RNAi agent is ligated to 0ne 0r m0re diagn0stic c0mp0und , rep0rter gr0up , cr0ss - linking agent , nuclease - resistance c0nferring m0iety , natural 0r unusual nucle0base , lip0philic m0lecule , ch0lester0l , lipid , lectin , ster0id , uVa0l , hecigenin , di0sgenin , terpene , triter - . US 20l2 / 0ll5934 Al. pene , sarsasap0genin , Friedelin , epifriedelan0l - deriVatized lith0ch0lic acid , Vitamin , carb0hydrate , dextran , pullulan , chitin , chit0san , synthetic carb0hydrate , 01ig0 lactate 15 - mer , natural p0lymer , 10W - 0r medium - m0lecular Weight p0lymer , inulin , cycl0dextrin , hyalur0nic acid , pr0tein , pr0tein - binding agent , integrin - targeting m0lecule , p0lycati0nic , peptide , p0lyamine , peptide mimic , and / 0r transferrin. [ 0043 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 60% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0044 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 70% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0045 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 80% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0046 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 90% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0047 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0.1 nM. [ 0048 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0.01 nM. [ 0049 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0.00l nM. [ 0050 ] A RNAi Agent C0mprising a First and a Sec0nd Strand Described Herein. [ 0051 ] In 0ne particular speciﬁc emb0diment , the present discl0sure relates t0 a 00mp0siti0n 00mprising a RNAi agent c0mprising a ﬁrst strand and a sec0nd strand , Wherein the ﬁrst strand and sec0nd strand c0mprise at least 15 c0ntigu0us nucle0tides , each diﬁering by 0 , 1 , 2 , 0r 3 nucle0tides fr0m the ﬁrst and sec0nd strand , respectiVely , 0f a RNAi agent t0 Beta - ENaC selected fr0m the speciﬁc duplexes pr0Vided herein and listed , e. g. , in Table l. [ 0052 ] Vari0us speciﬁc emb0diments 0f this emb0diment are described bel0W. [ 0053 ] In 0ne emb0diment , the c0mp0siti0n further c0m - prises a sec0nd RNAi agent t0 Beta - ENaC. In Vari0us emb0diments , the sec0nd RNAi agent is physically separate fr0m the ﬁrst , 0r the tW0 are physically c0nnected ( e. g. , 00Valently linked 0r 0therWise c0njugated ) . [ 0054 ] In 0ne emb0diment , the antisense strand is ab0ut 30 0r feWer nt in length. [ 0055 ] In 0ne emb0diment , the sense strand and the antisense strand f0rm a duplex regi0n 0f ab0ut lS t0 ab0ut 30 nt pairs in length. [ 0056 ] In 0ne emb0diment , the antisense strand is ab0ut lS t0 ab0ut 36 nt in length , including ab0ut l8 t0 ab0ut 23 nt in length , and including ab0ut 19 t0 ab0ut 23 nt in length. [ 0057 ] In 0ne emb0diment , the antisense strand has at least the length selected fr0m ab0ut 15 nt , ab0ut 16 nt , ab0ut 17 nt , ab0ut 18 nt , ab0ut 19 nt , ab0ut 20 nt , ab0ut 21 nt , ab0ut 22 nt , ab0ut 23 nt , ab0ut 24 nt , ab0ut 25 nt , ab0ut 26 nt , ab0ut 27 nt , ab0ut 28 nt , ab0ut 29 nt and ab0ut 30 nt. [ 0058 ] In 0ne emb0diment , the RNAi agent c0mprises a m0diﬁcati0n that causes the RNAi agent t0 haVe increased stability in a bi0l0gical sample 0r enVir0nment , e. g. , bl00d serum 0r intestinal laVage ﬁuid. [ 0059 ] In 0ne emb0diment , the RNAi agent 00mprises at least 0ne sugar backb0ne m0diﬁcati0n ( e. g. , ph0sph0r0thi0 - ate linkage ) and / 0r at least 0ne 2 ' - m0diﬁed nucle0tide. In 0ne emb0diment , all the pyrimidines are 2 ' O - methyl - m0diﬁed nucle0tides. May 10 , 2012. [ 0060 ] In 0ne emb0diment , the RNAi agent c0mprises : at least 0ne 5 ' - uridine - adenine - 3 ' ( 5 ' - ua - 3 ' ) dinucle0tide , Wherein the uridine is a 2 ' - m0diﬁed nucle0tide ; and / 01 at least 0ne 5 ' - uridine - guanine - 3 ' ( 5 ' - ug - 3 ' ) dinucle0tide , Wherein the 5 ' - uridine is a 2 ' - m0diﬁed nucle0tide ; and / 0r at least 0ne 5 ' - cytidine - adenine - 3 ' ( 5 ' - ca - 3 ' ) dinucle0tide , Wherein the 5 ' - cytidine is a 2 ' - m0diﬁed nucle0tide ; and / 0r at least 0ne 5 ' - uridine - uridine - 3 ' ( 5 ' - uu - 3 ' ) dinucle0tide , Wherein the 5 ' - uridine is a 2 ' - m0diﬁed nucle0tide. [ 0061 ] In 0ne emb0diment , the RNAi agent c0mprises a 2 ' - m0diﬁcati0n selected fr0m the gr0up 00nsisting 0f : 2 ' - de0xy , 2 ' - de0xy - 2 ' - ﬁu0r0 , 2 ' - O - methyl , 2 ' - O - meth0xyethyl ( 2 ' - O - MOE ) , 2 ' - O - amin0pr0pyl ( 2 ' - O - AP ) , 2 ' - O - dimethylamin0ethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylamin0pr0 - pyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylamin0ethyl0xyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O7N - methylacetamid0 ( 2 ' - O - NMA ) . [ 0062 ] In 0ne emb0diment , the RNAi agent c0mprises a blunt end. [ 0063 ] In 0ne emb0diment , the RNAi agent c0mprises an 0Verhang haVing 1 t0 4 unpaired nucle0tides. [ 0064 ] In 0ne emb0diment , the RNAi agent 00mprises an 0Verhang at the 3 ' - end 0f the antisense strand 0f the RNAi agent. [ 0065 ] In 0ne emb0diment , the RNAi agent is ligated t0 0ne 01 m0re diagn0stic 00mp0und , rep0rter gr0up , cr0ss - linking agent , nuclease - resistance c0nferring m0iety , natural 0r unusual nucle0base , lip0philic m0lecule , ch0lester0l , lipid , lectin , ster0id , uVa0l , hecigenin , di0sgenin , terpene , triterpene , sarsasap0genin , Friedelin , epifriedelan0l - deriVatized lith0ch0lic acid , Vitamin , carb0hydrate , dextran , pullulan , chitin , chit0san , synthetic carb0hydrate , 01ig0 lactate lS - mer , natural p0lymer , 10W - 0r medium - m0lecular Weight p0lymer , inulin , cycl0dextrin , hyalur0nic acid , pr0tein , pr0tein - binding agent , integrin - targeting m0lecule , p0lycati0nic , peptide , p0lyamine , peptide mimic , and / 0r transferrin. [ 0066 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 60% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0067 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 70% at a c0ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0068 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 80% at a 00ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0069 ] In 0ne emb0diment , the RNAi agent is capable 0f inhibiting expressi0n 0f the Beta - ENaC gene by at least ab0ut 90% at a 00ncentrati0n 0f lO nM in H44l cells in Vitr0. [ 0070 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0. l nM. [ 0071 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0.01 nM. [ 0072 ] In 0ne emb0diment , the RNAi has an EC50 0f n0 m0re than ab0ut 0.001 nM. [ 0073 ] A Meth0d 0f Treatment Using a RNAi Agent Described Herein. [ 0074 ] In 0ne particular speciﬁc emb0diment , the present discl0sure relates to a meth0d 0f treating a Beta - ENaC - related disease in an indiVidual , c0mprising the step 0f administering t0 the indiVidual a therapeutically effectiVe am0unt 0f a c0mp0siti0n c0mprising a RNAi agent c0mprising at least an antisense strand , Wherein the antisense strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m the speciﬁc duplexes pr0Vided. US 20l2 / 0ll5934 Al. herein and as listed , e. g. , in Table l. In an0ther emb0diment , the present discl0sure relates to such meth0d , Wherein the c0mp0siti0n c0mprising a RNAi agent further c0mprises a sense strand , Wherein the sense strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the sense strand 0f a RNAi agent to Beta - ENaC selected fr0m the speciﬁc duplexes pr0Vided herein and as listed , e. g. , in Table 1. [ 0075 ] Vari0us particular speciﬁc emb0diments 0f this emb0diment are described bel0W. [ 0076 ] In 0ne emb0diment , the Beta - ENaC - related disease is cystic ﬁbr0sis , pseud0hyp0ald0ster0nism type 1 ( PHAl ) , Liddles syndr0me , hypertensi0n , alkal0sis , hyp0kalemia , and / 01 0besity - ass0ciated hypertensi0n. [ 0077 ] In 0ne emb0diment , the Beta - ENaC - related disease is cystic ﬁbr0sis. [ 0078 ] In 0ne emb0diment , the meth0d further 00mprises the administrati0n 0f an additi0nal treatment. In 0ne emb0diment , the additi0nal treatment is a therapeutically effectiVe am0unt 0f a 00mp0siti0n. [ 0079 ] In 0ne emb0diment , the additi0nal treatment is a meth0d ( 0r pr0cedure ) . [ 0080 ] In 0ne emb0diment , the additi0nal treatment and the RNAi agent can be administered in any 0rder , 0r can be administered simultane0usly. [ 0081 ] In 0ne emb0diment , the meth0d further 00mprises the step 0f administering an additi0nal treatment f0r cystic ﬁbr0sis , pseud0hyp0ald0ster0nism type 1 ( PHA1 ) , Liddles syndr0me , hypertensi0n , alkal0sis , hyp0kalemia , and / 0r 0besity - ass0ciated hypertensi0n. [ 0082 ] In 0ne emb0diment , the meth0d further 00mprises the step 0f administering an additi0nal treatment 0r therapy selected fr0m the list 0f an additi0nal antag0nist t0 ENaC , a p0tassium - sparing diuretic , amil0ride , triamterene , regula - ti0n 0f dietary salt intake , antibi0tics , DNase therapy , albutr0l , N - acetylcysteine , breathing therapy , percussiVe therapy , and aer0bic exercise. [ 0083 ] In 0ne emb0diment , the c0mp0siti0n c0mprises a sec0nd RNAi agent tO Beta - ENaC. In Vari0us emb0diments , the sec0nd RNAi agent is physically separate fr0m the ﬁrst , 0r the tW0 are physically 00nnected ( e. g. , 00Valently linked 0r 0therWise c0njugated ) . [ 0084 ] In 0ne emb0diment , the meth0d further c0mprises the step 0f administering an additi0nal RNAi agent Which c0mprises at least 15 c0ntigu0us nucle0tides differing by 0 , 1 , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m the speciﬁc duplexes pr0Vided herein and as listed , e. g. , in Table l. [ 0085 ] A Meth0d 0f Inhibiting the Expressi0n 0f BetaENaC , Using a RNAi Agent Described Herein. [ 0086 ] In 0ne particular speciﬁc emb0diment , the present discl0sure relates t0 a meth0d 0f inhibiting the expressi0n 0f the Beta - ENaC gene in an indiVidual , 00mprising the step 0f administering t0 the indiVidual a therapeutically effectiVe am0unt 0f a c0mp0siti0n c0mprising a RNAi agent 0f the present discl0sure. In 0ne emb0diment , the RNAi agent c0m - prises at least an anti - sense strand , and / 0r c0mprises a sense and an anti - sense strand , Wherein the anti - sense strand c0m - prises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the anti - sense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m th0se speciﬁc duplex pr0Vided herein and as listed , e. g. , in Table 1. May 10 , 2012. [ 0087 ] Vari0us emb0diments 0f this aspect 0f the inVenti0n are described bel0W. [ 0088 ] In 0ne emb0diment , the indiVidual is afﬁicted With 0r susceptible to a Beta - ENaC - related disease. [ 0089 ] In 0ne emb0diment , the Beta - ENaC - related disease is cystic ﬁbr0sis , pseud0hyp0ald0ster0nism type 1 ( PHAl ) , Liddles syndr0me , hypertensi0n , alkal0sis , hyp0kalemia , and / 0r 0besity - ass0ciated hypertensi0n. [ 0090 ] In 0ne emb0diment , the Beta - ENaC - related disease is cystic ﬁbr0sis. [ 0091 ] In 0ne emb0diment , the meth0d further c0mprises the administrati0n 0f an additi0nal treatment. In 0ne emb0diment , the additi0nal treatment is a therapeutically effectiVe am0unt 0f a c0mp0siti0n. [ 0092 ] In 0ne emb0diment , the additi0nal treatment is a meth0d ( 0r pr0cedure ) . [ 0093 ] In 0ne emb0diment , the additi0nal treatment and the RNAi agent can be administered in any 0rder 0r can be administered simultane0usly. [ 0094 ] In 0ne emb0diment , the meth0d further c0mprises the step 0f administering an additi0nal treatment f0r cystic ﬁbr0sis , pseud0hyp0ald0ster0nism type 1 ( PHAl ) , Liddles syndr0me , hypertensi0n , alkal0sis , hyp0kalemia , and / 0r 0besity - ass0ciated hypertensi0n. [ 0095 ] In 0ne emb0diment , the meth0d further c0mprises the step 0f administering an additi0nal treatment 0r therapy selected fr0m the list 0f an additi0nal antag0nist tO ENaC , a p0tassium - sparing diuretic , amil0ride , triamterene , regula - ti0n 0f dietary salt intake , antibi0tics , DNase therapy , albutr0l , N - acetylcysteine , breathing therapy , percussiVe therapy , and aer0bic exercise. [ 0096 ] In 0ne emb0diment , the c0mp0siti0n 00mprises a sec0nd RNAi agent t0 Beta - ENaC. In Vari0us emb0diments , the sec0nd RNAi agent is physically separate fr0m the ﬁrst , 0r the WW are physically c0nnected ( e. g. , c0Valently linked 01 0therWise c0njugated ) . [ 0097 ] In 0ne emb0diment , the meth0d further c0mprises the step 0f administering an additi0nal RNAi agent Which c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m the speciﬁc duplexes pr0Vided herein and as listed , e. g. , in Table 1. [ 0098 ] Pharmaceutical F01mulati0ns 0f a RNAi Agent t0 Beta - ENaC. [ 0099 ] In 0ne particular speciﬁc emb0diment , the present discl0sure relates t0 a 00mp0siti0n c0mprising a RNAi agent 0f the present discl0 sure. In 0ne emb0diment , the RNAi agent c0mprises at least an anti - sense strand , and / 0r c0mprises a sense and an anti - sense strand , Wherein the anti - sense strand c0mprises at least 15 c0ntigu0us nucle0tides differing by 0 , 1 , 2 , 0r 3 nucle0tides fr0m the anti - sense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m th0se speciﬁc duplex pr0Vided herein and as listed , e. g. , in Table l , Wherein the c0mp0siti0n is in a pharmaceutically effectiVe f0rmulati0n. [ 0100 ] In 0ne emb0diment , the present discl0sure pertains t0 the use 0f a RNAi agent in the manufacture 0f a medicament f0r treatment 0f a Beta - ENaC - related disease , Wherein the RNAi agent c0mprises a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS c0ntigu0us nucle0tides differing by 0 , l , 2 , 0r 3 nucle0tides fr0m the antisense strand 0f a RNAi agent t0 Beta - ENaC selected fr0m th0se speciﬁc duplex pr0Vided herein and as listed , e. g. , in Table 1. US 20l2 / 0ll5934 Al. [ 0101 ] ENaC. [ 0102 ] By “ENaC” is meant the epithelial sodium channel , a membrane protein made of three different but homologous subunits ( Alpha , Beta and Gamma ) . [ 0103 ] ENaC is present in the apical membrane of epithelial cells of the distal nephron ( cortical and medullary collecting tubule ) and distal col0n and in the airWays and in the excretory ducts of seVeral glands. ENaC is also expressed in placenta , brain and urinary bladder. It proVides a controlled entry pathWay for Na + from the lumen of these organs into the epithelial cells , and , together With the Na + / K + - ATPase located in the basolateral membrane of the same cells , and is responsible for the actiVe , Vectorial transport of Na + from the external medium through the epithelial cells into the extracellular ﬁuid and toWard the blood. ENaC is located on the apical membrane facing the lumen , and alloWs moVement of sodium from the lumen into the epithelial cell. The sodium reabsorbed Via ENaC is then extruded from the epithelial cell back into the bloodstream by the Na + / K + - ATPase. The reabsorption of sodium by the ENaC is accompanied by an osmotic uptake of Water to maintain a constant extracellular Na + concentration. This changes bl0od Volume and consequently affects blood pressure. Ihus , ENaC plays an important role in electrolyte homeostasis and the control of blood Volume and blood pressure. See , e. g. , Saxena et al. l998 Biochem. Biophys. Res. Comm. 252 : 208 - 213. [ 0104 ] ENaC has different functional roles in Various organs in Which it is expressed. In the kidney ( collecting tubule ) , the modulated reabsorption of Na + through ENaC pr0Vides the primary mechanism of the regulation of urinary Na + excretion and thus alloWs the ﬁne control of the Whole organism Na + balance under the honnonal control of aldosterone. By its depolarizing effect on the apical membrane potential , the Na + channel also proVides the driVing force for tubular K + secretion. [ 0105 ] Speciﬁc inhibitors of ENaC promote urinary Na + excretion and inhibit K + secretion ; these drugs ( including amiloride and triamterene ) , are therefore used as K + - sparing diuretics. ENaC has a similar functional role in the distal colon , preVenting excessiVe Na + loss in the stools. In airWays , an important role is the reabsorption of the ﬁuid that ﬁlls the airWays at birth , promoting the shift from ﬁuid secretion ( before birth ) to ﬁuid reabsorption ( postnatal ) . [ 0106 ] With the cystic ﬁbrosis transmembrane conductance regulator , it also participates in the delicate regulation of the ﬁuid balance in the airWays that maintains a thin mucosal ﬁuid ﬁlm necessary for mucus clearance. In the excretory ducts of the saliVary and sWeat glands , the actiVity of ENaC tends to decrease the luminal Na + concentration , alloWing the excretion of a less salty saliVa and preVenting major loss of Na + in the sWeat ﬁuid. See , for example , Hummler et al. 1999 pm. J. Physiol. Gastrointest. LiVer Physiol. 276 : 567 - 571 and references cited therein. [ 0107 ] Alterations and mutations in the sequence and / or expression of ENaC can lead to oVer - expression or hyperactiVity of ENaC. ProViding RNAi agents of this disclosure restores balance to the modulated reabs0rption of Na + by reducing the leVel of the Beta - ENaC. [ 0108 ] Beta - ENaC. [ 0109 ] By “Beta - ENaC” is meant the gene or protein amiloride - sensitiVe sodium channel subunit beta ( or any nucleic acid encoding this protein ) , also Variously designated : . sodium channel , nonVoltage - gated 1 , beta ; SCNN1B ; bENaC ; ENaCb ; ENaC - beta ; SCNEB , or 0 - ENaC. Addi - . May 10 , 2012. tional identiﬁers include : OMIM : 600760 ; MGI : lO4696 ; HomoloGene : 284 ; and GeneCards : SCNN1B. Additional information can be found : Human : Entrez 6338 ; Ensembl ENSG00000l68447 ; UniProt P5l l68 ; RefSeq ( mRNA ) NM_000336 ; RefSeq ( protein ) NP_000327 ; Location ( UCSC ) Chr 16 : 23.22 - 23.3 Mb. M0use : Entrez 20277 ; Ensembl ENSMUSG00000030873 ; UniProt Q3TP51 ; RefSeq ( mRNA ) NM_011325 RefSeq ( protein ) NP_035455 ; Location ( UCSC ) Chr 7 : l2l.66 - l2l .7l Mb. [ 0110 ] The amino acid sequence of human Beta - ENaC is proVided in Saxena et al. l998 Biochem. Biophys. Res. Comm. 252 : 208 - 2l3. [ 0111 ] The functional domains of Beta - ENaC haVe been delineated. The protein has an intracellular N - terminal domain [ amino acids ( “aa” ) 1 to 50 ] , a ﬁrst transmembrane domain ( aa 51 to 71 ) , an extracellular loop ( aa 72 to 533 ) , a second transmembrane domain ( aa 534 to 553 ) , and a C - terminal intracellular domain ( aa 554 to 640 ) . [ 0112 ] The C - terminal intracellular domain contains tWo regions Wherein mutations relate to Liddles syndrome and other diseases : in the region fr0m amino acid 564 to 595 and the “PY” motif [ With the amino acid consensus sequence PPXY at aa ( amino acids ) 615 to 618 ] . See , e. g. , Saxena et al. 1998. [ 0113 ] The Beta - ENaC RNAi agent 0f the present disclosure can interact With a portion of the mRNA corresponding t0 a speciﬁc ﬁmctional domain or domains of Beta - ENaC. In Various embodiments , the RNAi agents herein speciﬁcally bind to Beta - ENaC mRNA , in a sequence corresponding to a ﬁmctional domain , e. g. , in the N - terminal intracellular domain , in the ﬁrst transmembrane domain , in the extracellular loop , in the second transmembrane domain , or in the C - terminal intracellular d0main , or , more speciﬁcally , in the region from amino acid 564 to 595 , 0r in the PY motif ( amino acids 6l5 to 6l8 ) . [ 0114 ] In Various embodiments , the RNAi agents of the present disclosure bind to the 5 ' or 3 ' UTR ( i. e. , untranslated region ( s ) ) . [ 0115 ] In Various embodiments , the RNAi agents of the present disclosure bind to Beta - ENaC mRNA , but not in a sequence corresponding to a particular ﬁmctional domain , e. g. , not in the N - terminal intracellular domain , not in the ﬁrst transmembrane domain , not in the extracellular loop , not in the second transmembrane domain , or not in the C - terminal intracellular domain , or , more speciﬁcally , not in the region from amino acid 564 to 595 , or not in the PY motif ( amino acids 615 to 618 ) . [ 0116 ] In embodiments herein , binding of a RNAi agent to a particular region of the Beta - ENaC mRNA leads to reduced expression , leVel and / or actiVity of Beta - ENaC. [ 0117 ] The efﬁcacy of a RNAi agent in reducing the leVel of Beta - ENaC can be measured directly , e. g. , by measuring the leVels of Beta - ENaC mRNA abundance or leVels of the protein itself. AlternatiVely , the efﬁcacy of the RNAi can be measured indirectly by measuring the leVel of any one or more of the knoWn actiVities of Beta - ENaC or by measuring changes in the actiVities of pathWay components doWnstream of Beta - ENaC. [ 0118 ] The proteins chief actiVity is to form , along With Alpha - ENaC and Gamma - ENaC , and , possibly at times , Delta - ENaC , the sodium channel ENaC. Beta - ENaC , Gamma - ENaC and Delta - ENaC may also form a particular type of channel found in the pancreas , testes and oVaries. Beta - ENaC has also been shoWn to interact With WWP2 and. US 20l2 / 0ll5934 Al. NEDD4. See. , e. g. , McDonald et al. ( 2002 ) . Am. J. Physiol. Renal Physiol. 283 ( 3 ) : F43l - 6 ; HarVey et al. 2001. J. Biol. Chem. 276 ( 1 1 ) : 8597 - 601 ; Farr et al. ( 2000 ) . Biochem. J. 345 Pt 3 : 503 - 9. The actiVity of Beta - ENaC can be measured , for example , by its ability to bind and form functional units With these other biological components. The efﬁcacy of a RNAi agent can also be measured indirectly by measuring the amount of surface liquid on mucus membranes , and Via histological studies of tissues expressing Beta - ENaC. [ 0119 ] Beta - ENaC Sequences in Various Species. [ 0120 ] A RNAi agent speciﬁc to Beta - ENaC can be designed such that the sequence thereof completely matches that of the mRNA corresponding to the human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC. Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. May 10 , 2012. gene and the homologous gene from a test animal. Thus , the exact same RNAi agent can be used in both test animals ( e. g. , rat , mouse , cynomolgus monkey , etc. ) and humans. The sequences for the Various ENaC genes haVe been determined in many species , including humans , mouse , rat , boVine and chicken , as described in , inter alia , Garty et al. 1997 Physiol. ReV. 77 : 359 - 396 ; andAhn et al. 1999 um. J. Physiol. 277 : F 12 1 - F 1 29. [ 0121 ] The Beta - ENaC sequence in cynomolgus monkey ( Macacafascicularis , or “cyno” ) has been determined. [ 0122 ] The alignment ofthe cyno Beta - ENaC mRNA ( SEQ ID NO : 221 ) and human Beta - ENaC mRNA ( SEQ ID NO : . 222 ) sequences is shoWn beloW. GTGCTTCCCCGCCCCTGAACCTGCTCCCTCCCAGTCGGTCTCGCCGCGCT. ——————————————————————————————————— GGTACCCAGCTTGCT. CGCCGGGTGTCCCAGTGTCACCAACACTCGGCCGCCGCCGCCAGCTTGGC 4 44444444. TGTTCTTTTTGCAGAAGCTCAGAATAAACGCTCAACTTTGGCAGATCAAT GCGCACCGCCGCCTCCGCCACCGCCGACAGCGCGCATCCTCCGTGTCCCC. * * * * * * * * * * * * . TCCCCGGGGATCCGA - ATTCGCCACCAIQCACGTGAAGAAGTACCTGCTG. GCTCCGCCGCCCGAGCAGGTGCCACTAIGCACGTGAAGAAGTACCTGCTG 4 444 4 4 4 44444 444444444444444444444444. AAGTGCCTGCACCGGCTGCAGAAGGGCCCCGGCTACACGTACAAGGAGCT AAGGGCCTGCATCGGCTGCAGAAGGGCCCCGGCTACACGTACAAGGAGCT. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GCTGGTGTGGTACTGCGATAACACCAACACCCACGGCCCCAAGCGTATCA. GCTGGTGTGGTACTGCGACAACACCAACACCCACGGCCCCAAGCGCATCA 444444444444444444 44444444444444444444444444 4444. TCTGCGAGGGGCCCAAGAAGAAAGCCGTGTGGTTCCTGCTCACCCTGCTC. TCTGTGAGGGGCCCAAGAAGAAAGCCATGTGGTTCCTGCTCACCCTGCTC 4444 444444444444444444444 44444444444444444444444. TTCACTGCTCTCGTCTGCTGGCAGTGGGGCATCTTCATCAGGACCTACTT TTCGCCGCCCTCGTCTGCTGGCAGTGGGGCATCTTCATCAGGACCTACTT. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GAGCTGGGAGGTCAGCGTCTCCCTCTCCGTAGGCTTCAAGACCATGGACT GAGCTGGGAGGTCAGCGTCTCCCTCTCCGTAGGCTTCAAGACCATGGACT. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . TCCCCGCCGTCACCATCTGCAATGCTAGCCCCTTCAAGTATTCCAAAGTC. TCCCTGCCGTCACCATCTGCAATGCTAGCCCCTTCAAGTATTCCAAAATC 4444 444444444444444444444444444444444444444444 44. AAGCATTTGCTGAAGGACCTGGATGAGCTGATGGAAGCTGTCCTGGAGAG AAGCATTTGCTGAAGGACCTGGATGAGCTGATGGAAGCTGTCCTGGAGAG. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . AATCCTGGCTCCTGAGCTAAGCCATGCCAATGCCACCAGGACCCTGAACT AATCCTGGCTCCTGAGCTAAGCCATGCCAATGCCACCAGGAACCTGAACT. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . CTTCCATCTGGAACCACACACCACTGGTCCTTATTGATGAACGGAACCCC. TCTCCATCTGGAACCACACACCCCTGGTCCTTATTGATGAACGGAACCCC 44444444444444444444 444444444444444444444444444. CACCACCCCATGGTCCTCGATCTCTTTGGAGATAACCACAATGGCTTAAC CACCACCCCATGGTCCTTGATCTCTTTGGAGACAACCACAATGGCTTAAC. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . AAACAGCTCAGCATCAGAAAAGATCTGTAATGCCCATGGGTGCAAAATGG AAGCAGCTCAGCATCAGAAAAGATCTGTAATGCCCACGGGTGCAAAATGG. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . 50 lS lOO. 65 lS0. ll4 20O. l64 250. 214 3OO. 264 35O. 3l4 400. 364 450. 4l4 500. 464 550. 514 600. 564 650. 6l4 7OO. 664 75O. US 20l2 / 0ll5934 Al. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. —continued. CCATGAGACTATGTAGCCTCAACGGGACCCAGTGCACCTTCCGGAACTTC CCATGAGACTATGTAGCCTCAACAGGACCCAGTGTACCTTCCGGAACTTC. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . 714 800. ACCAGCGCTACCCAGGCAGTGACAGAGTGGTACAGCCTGCAGGCCACCAA. ACCAGTGCTACCCAGGCATTGACAGAGTGGTACATCCTGCAGGCCACCAA 44444 444444444444 444444444444444 444444444444444. 764 850. CATCTTTGCGCAGGTGCCGCAGCAGGAGCTGGTGGAGATGAGCTACCCCG. CATCTTTGCACAGGTGCCACAGCAGGAGCTAGTAGAGATGAGCTACCCCG 444444444 44444444 44444444444 44 4444444444444444. 814 900. GCGAGCAGATGATCCTGGCCTGCCTGTTTGGAGCTGAGCCCTGCAACTAC GCGAGCAGATGATCCTGGCCTGCCTATTCGGAGCTGAGCCCTGCAACTAC. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . 864 95O. CGGAACTTCACGTCCATCTTCTACCCTCACTATGGCAACTGTTACATCTT 914. CGGAACTTCACGTCCATCTTCTACCCTCACTATGGCAACTGTTACATCTT 1000 44444444444444444444444444444444444444444444444444. CAACTGGGGCATGACAGAGAAGGCACTTCCTTCGGCCAACCCTGGACCTG 964 CAACTGGGGCATGACAGAGAAGGCACTTCCTTCGGCCAACCCTGGAACTG105O. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . AATTTGGCCTGAAGTTGATCCTGGACATAGGCCAGGAAGACTACGTCCCC1014. AATTCGGCCTGAAGTTGATCCTGGACATAGGCCAGGAAGACTACGTCCCC 110O 4444 444444444444444444444444444444444444444444444. TTCCTCGCGTCCACGGCTGGGGTCAGGCTGATGCTTCACGAGCAGAGGTC1064 TTCCTTGCGTCCACGGCCGGGGTCAGGCTGATGCTTCACGAGCAGAGGTC llSO. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . ATACCCCTTCATCAGAGACGAGGGCATCTATGCCATGTCGGGGACAGAGA1114. ATACCCCTTCATCAGAGATGAGGGCATCTACGCCATGTCGGGGACAGAGA12OO 444444444444444444 44444444444 4444444444444444444. CGTCCATCGGGGTACTCGTGGACAAGCTTCAGCGCATGGGGGAGCCCTAC1164. CGTCCATCGGGGTACTCGTGGACAAGCTTCAGCGCATGGGGGAGCCCTAC1250 44444444444444444444444444444444444444444444444444. AGCCCGTGCACCGTGAATGGCTCCGAGGTCCCCGTCCAAAACTTCTACAG1214. AGCCCGTGCACCGTGAATGGTTCTGAGGTCCCCGTCCAAAACTTCTACAG13OO 44444444444444444444 44 44444444444444444444444444. TGACTACAACACGACCTACTCCATCCAGGCCTGTCTTCGCTCCTGCTTCC1264. TGACTACAACACGACCTACTCCATCCAGGCCTGTCTTCGCTCCTGCTTCC1350 44444444444444444444444444444444444444444444444444. AAGACCACATGATCCGTAGCTGCAAGTGTGGGCACTACCTCTACCCACTG1314. AAGACCACATGATCCGTAACTGCAACTGTGGCCACTACCTGTACCCACTG1400 444444444444444444 444444 44444 44444444 444444444. CCCCGTGGGGAGAAATACTGCAACAACCGGGACTTCCCAGACTGGGCCCA1364 CCCCGTGGGGAGAAATACTGCAACAACCGGGACTTCCCAGACTGGGCCCA1450. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . TTGCTACTCAGATCTGCAGATGAGCGTGGCGCAGAGAGAGACCTGCATTG1414. TTGCTACTCAGATCTACAGATGAGCGTGGCGCAGAGAGAGACCTGCATTG150O 444444444444444 4444444444444444444444444444444444. GCATGTGCAAGGAATCCTGCAATGACACCCAGTACAAGATGACTATCTCC1464 GCATGTGCAAGGAGTCCTGCAATGACACCCAGTACAAGATGACCATCTCC 1550. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . ATGGCTGACTGGCCTTCTGAGGCCTCTGAGGACTGGATTTTCCACGTCTT1514 ATGGCTGACTGGCCTTCTGAGGCCTCCGAGGACTGGATTTTCCACGTCTT1600. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GTCTCAGGAGCGGGACCAAAGCACCAATATCACCCTGAGCAGGAAGGGAA1564. GTCTCAGGAGCGGGACCAAAGCACCAATATCACCCTGAGCAGGAAGGGAA165O 44444444444444444444444444444444444444444444444444. TTGTCAAGCTCAACATCTACTTCCAAGAATTTAACTATCGCACCATTGAA1614 TTGTCAAGCTCAACATCTACTTCCAAGAATTTAACTATCGCACCATTGAA1700. ‘it * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . May 10 , 2012. US 20l2 / 0ll5934 Al. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta - ENaC. Human Beta—ENaC. Cyno Beta - ENaC Human Beta—ENaC. Cyno Beta - ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta - ENaC. Cyno Beta—ENaC Human Beta - ENaC. 10. —continued GAATcAGCAGCcAATAACcTcGTCTGGCTGCTCTCAAATCTGGGTGGCCA1664. GAATCAGCAGCCAATAACATCGTCTGGCTGCTCTCGAATCTGGGTGGCCA175O 444444444444444444 4444444444444444 44444444444444. GTTTGGCTTCTGGATGGGGGGCTCTGTGCTGTGCCTCATCGAGTTTGGGG1714 GTTTGGCTTCTGGATGGGGGGCTCTGTGCTGTGCCTCATCGAGTTTGGGG1800. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . AGATCATCATCGACTTTGTGTGGATCACCATCATCAAGCTGGTGGCCTTG1764 AGATCATCATCGACTTTGTGTGGATCACCATCATCAAGCTGGTGGCCTTG1850. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GCCAAGAGCCTCCGGCAGCGGCGAGCCCAAGCCAGCTACTCCGGCCCACC1814. GCCAAGAGCCTACGGCAGCGGCGAGCCCAAGCCAGCTACGCTGGCCCACC190O 44444444444 444444444444444444444444444 4 44444444. GCCCACGGTGGCTGAGCTGGTGGAGGCCCACACCAACTTCGGCTACCAGC 1864. GCCCACCGTGGCCGAGCTGGTGGAGGCCCACACCAACTTTGGCTTCCAGC 195O 444444 44444 44444444444444444444444444 4444 44444. CTGACACGGCCCCCCGCAGCCCCAACACCGGGCCCTACCCCAGTGAGCAG1914 CTGACACGGCCCCCCGCAGCCCCAACACTGGGCCCTACCCCAGTGAGCAG2000. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GCCCTGCCCATCCCGGGCACCCCGCCCCCCAACTATGACTCCCTGCGTCT 1964 GCCCTGCCCATCCCAGGCACCCCGCCCCCCAACTATGACTCCCTGCGTCT205O. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . GCAGCCACTGGACGTCATCGAGTCTGACAGTGAGGGTGATGCCATCIAA—2013. GCAGCCGCTGGACGTCATCGAGTCTGACAGTGAGGGTGATGCCATCIAAC21OO 444444 444444444444444444444444444444444444444444. ———GCGGCCGCCTAG———AAATAGCTTGATCTGGTTA——CCACTAAACCA2055 CCTGCCCCTGCCCACCCCGGGCGGCTGAAACTCACTGAGCAGCCAAGACT2150. * * * * * * * * * * * * * * * * * * * . GC - - CTCAAGAACAC - CCGAATGGAGTCTCT - - - - AAGCTACATAATACC2098 GTTGCCCGAGGCCTCACTGTATGGTGCCCTCTCCAAAGGGTCGGGAGGGT2200. * * * * * * * * * * * * * * * * * * * * . AACTTACACTTTACAAAATGTTGTCCCCCAA—AATGTAGCCATTCGTATC2147 AGCTCTCCAGGCCAGAGCTTGTGTCCTTCAACAGAGAGGCCAGCGGCAAC225O. * * * * * * * * * * * * * * * * * * * * * * * . TGCTCCTAATAAAAAGAAAGTTTCTTCACATTCTAAAAAAAAAAAAAAAA2l97 TGGTCCGTTACTGGCCAAGGGCTCTGTAGAATCACGGTGCTGGTACAGGA23OO 44 444 44 4 444. * * * * * * * . AAAAAAAAAAAAAAAAAACCCCCCCC - - CCCCCCCCCCTGCAGAGATCTG2245 TGCAGGAATAAATTGTATCTTCACCTGGTTCCTACCCTCGTCCCTACCTG2350. * * * * * * * * * * * * * * * * * * * * * CTAGCTTGAGTATTCTATAGAGTCACCTAAATACT - - - - - - - - - - - - - - - 228O TCCTGATCCTGGTCCTGAAGACCCCTCGGAACACCCTCTCCTGGTGGCAG24OO. * * * * * * * * * * * * * . GGCACCTGATTTACTCTAGAAAATAAAAGTAGAAAATACTGAGTCCA 2597 ( SEQ ID NO : 221 ) ( SEQ ID NO : 222 ) . May 10 , 2012. US 20l2 / 0ll5934 Al. [ 0123 ] The start ( ATG ) and stop ( TAA ) codons of the cyno and human sequences are underlined. Nucleotides matching betWeen the human and cyno sequences are marked With an asterisk ( * ) . [ 0124 ] In one embodiment , the Beta - ENaC RNAi agent of the present disclosure comprises a sequence Which is identical in the human , rat and cyno Beta - ENaC mRNAs. This sequence identity facilitates animal testing prior to human testing. In another embodiment , the Beta - ENaC RNAi agent comprises a sequence Which is identical in the human , mouse and cyno Beta - ENaC mRNAs. [ 0125 ] Additional Embodiments of a RNAi Agent to BetaENaC. [ 0126 ] In one embodiment , the Beta - ENaC RNAi agent comprises a sequence Which does not match that of any other mRNA 01 gene. In one emb0diment , the Beta - ENaC RNAi agent comprises a sequence Which differs from all other knoWn non - Beta - ENaC mRNAs or genes by at least 0 , l , 2 or 3 nucleotides. [ 0127 ] In one embodiment , the Beta - ENaC RNAi agent of the present disclosure is administered to a patient in need thereof ( e. g. , a patient suffering from cystic ﬁbr0sis , pseudohypoaldosteronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkalo sis , hypokalemia , and 0besity - as sociated hypertension ) . [ 0128 ] The patient can also be administered more than one RNAi agent speciﬁc to Beta - ENaC. In one emb0diment , the Beta - ENaC RNAi agent ( s ) of the present disclosure can optionally be administered along With one or more additional pharmaceutical agent appropriate for that disease. In one embodiment , the Beta - ENaC RNAi agent ( s ) of the present disclosure can be opti0nally administered along With any other appropriate additional treatment , Wherein the additional treatment can be a composition or a method. [ 0129 ] In the case of cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHA1 ) , Liddles syndrome , hypertension , alkal0sis , hypokalemia , and / or obesity - associated hypertension , the RNAi agent ( s ) and additional disease treatment ( s ) can be administered in any order , simultaneously or sequentially , or in one or multiple doses oVer time. DEFINITIONS. [ 0130 ] For conVenience , the meaning of certain terms and phrases used in the speciﬁcation , examples , and appended claims , are proVided below If there is an apparent discrepancy betWeen the usage of a term in other parts of this speci - ﬁcation and its deﬁnition proVided in this section , the deﬁnition in this section shall preVail. [ 0131 ] RNAi Agent. [ 0132 ] In one embodiment , the present disclosure pertains to a Beta - ENaC RNAi agent or other composition comprising at least an antisense nucleic acid sequence c0mplementary to a Beta - ENaC nucleic acid ( or portion thereof ) , or pertains to a recombinant expression Vector encoding the siRNA or compositi0n comprising the antisense nucleic acid that can function as an RNAi as deﬁned below As used herein , an “antisense” nucleic acid comprises a nucleotide sequence complementary to a “sense” nucleic acid encoding the BetaENaC protein ( e. g. , complementary to the coding strand of a double - stranded DNA , complementary to an mRNA or complementary to the coding strand of a Beta - ENaC gene or nucleic acid ) . [ 0133 ] As used herein , the term “RNAi agent to BetaENaC , ” “RNAi agent speciﬁc to Beta - ENaC , ” “iRNA agent. May 10 , 2012. to Beta - ENaC , ” “siRNA to Beta - ENaC” , “Beta - ENaC siRNA” and the like refer to a siRNA ( short inhibitory RNA ) , shRNA ( short or small hairpin RNA ) , iRNA ( interference RNA ) agent , RNAi ( RNA interference ) agent , dsRNA ( double - stranded RNA ) , mi croRNA , and the like , and refer to a 00mp0sition Which speciﬁcally targets , is speciﬁc to , and / or binds to a Beta - ENaC mRNA. As used herein , the term “antisense nucleic acid” or “composition comprising an anti - sense nucleic acid” and the like is broadly meant to encompass any composition comprising at least one nucleic acid strand Which is anti - sense to its target ; this includes , but is not limited to , any siRNA , shRNA , iRHA , dsRNA , microRNA , antisense oligonucleotide , and any other composition comprising an anti - sense nucleic acid. As used herein , the tenns “iRNA” and “RNAi” refers to an agent that contains RNA ( or a deriVatiVe thereof ) , and Which mediates the targeted cleaVage of another RNA transcript Via an RNA - induced silencing complex ( RISC ) pathWay. In one embodiment , the RNAi agent is an oligonucleotide composition that actiVates the RISC complex / pathWay. In another embodiment , the RNAi agent comprises an antisense strand sequence ( antisense oli - g0nucleotide ) . [ 0134 ] The RNAi agent ( s ) of the present disclosure target ( e. g. , bind to , anneal to , etc. ) the Beta - ENaC mRNA. The use of the RNAi agent speciﬁc to Beta - ENaC results in a decrease of Beta - ENaC actiVity , leVel and / or expression , e. g. , a “knock - doWn” or “knock - out” of the target gene or target sequence. Particularly in one embodiment , in the case of a disease state characterized by oVer - expression or hyper - actiVity of Beta - ENaC , administration of a RNAi agent to BetaENaC knocks doWn the Beta - ENaC target enough to restore a normal leVel of Beta - ENaC actiVity and / or a normal leVel of Na + reabs0rption. [ 0135 ] In one emb0diment , the RNAi comprises a single strand ( such as an shRNA , as described herein ) . [ 0136 ] In Various embodiments , one or both strands are nicked. [ 0137 ] In one embodiment , a single - stranded RNAi agent oligonucleotide or polynucleotide can comprise the sense and / or antisense strand. See , e. g. , Sioud 2005 J. Mol. Biol. 348 : 1079 - 1090 , and references cited therein. Thus the present disclosure encompasses RNAi agents With a single strand comprising either the sense or antisense strand of a RNAi agent described herein. [ 0138 ] siRNAs that are particularly useful for this disclosure include those Which can bind speciﬁcally to a region of the Beta - ENaC mRNA , and haVe one or more of the folloWing qualities : binding in the coding segment of Beta - ENaC ; binding at or near the junction of the 5 ' untranslated region and the start of the coding segment ; binding at or near the translational start site of the mRNA ; binding at , across or near junctions of exons and introns ; little or no binding to the mRNAs or transcripts of other genes ( little or no “off - target effects” ) ; binding to the Beta - ENaC mRNA in or near a region or regions that is not double - stranded 0r a stem regi0n , e. g. , in a loop or single - stranded portion ; eliciting little or no immunogenicity ; binding in a segment of the Beta - ENaC mRNA sequence Which is conserVed among Various animal species ( including human , mouse , rat , cyno , etc . ) , as the presence of a conserVed sequence facilitates testing using Various laboratory animals ; binding to double - stranded region ( s ) of the mRNA ; binding to an AT - rich region ( e. g. , at least about 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , or 60% AT - rich ) ; and / or lacking particular sequences knoWn or suspected to decrease. US 20l2 / 0ll5934 Al. siRNA actiVity , e. g. , the presence of a GG sequence at the 5 ' end , Which may decrease separation of the double - stranded portion of the siRNA. In one embodiment , the RNAi agent speciﬁc to Beta - ENaC can be a double - stranded RNA haVing any one or more of these qualities. [ 0139 ] The term “double - stranded RNA” or “dsRNA , ” as used herein , refers to a RNAi agent comprising a ﬁrst and a second strand ; e. g. , a compositi0n that includes an RNA molecule or complex of molecules haVing a hybridized duplex region ( i. e. , a region Where the nucleotide bases from the ﬁrst strand and the second strand are paired ) that comprises tWo anti - parallel and substantially complementary nucleic acid strands , Which Will be referred to as haVing “sense” and “antisense” orientations With respect to a target RNA. The antisense strand , With respect to the mRNA target , is also called the “guide” strand , and the sense strand is also called the “passenger” strand. The passenger strand can include at least one or more of the folloWing : one or more extra nucleotides ( e. g. , a bulge or 1 nt loop ) compared to the other strand , a nick , a gap , etc. , compared to the other strand. In Various embodiments , the RNAi agent comprises a ﬁrst strand and a second strand. In Various embodiments , the ﬁrst strand is the sense strand and the second strand is the antisense strand. In other embodiments , the ﬁrst strand is the anti - sense strand , and the second strand is the sense strand. [ 0140 ] The duplex region can be of any length that permits speciﬁc degradation of a desired target RNA through a RISC pathWay , but Will typically range from 9 to 36 base pairs ( “bp” ) in length , e. g. , 15 - 30 by in length. Considering a duplex betWeen 9 and 36 bp , the duplex can be any length in this range , for example , 9 , lO , ll , l2 , l3 , l4 , lS , l6 , l7 , l8 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , or 36 by and any sub - range therebetWeen , including , but not limited t0 15 - 30 bp , lS - 26 bp , 15 - 23 bp , 15 - 22 bp , 15 - 21bp , lS - 20 bp , lS - l9 bp , lS - l8 bp , lS - l7 bp , l8 - 30 bp , l8 - 26 bp , l8 - 23 bp , l8 - 22 bp , l8 - 2l bp , l8 - 20 bp , l9 - 30 bp , l9 - 26 bp , 19 - 23 bp , 19 - 22 bp , 19 - 21 bp , 19 - 20 bp , 19 bp , 20 - 30 bp , 20 - 26 bp , 20 - 25 bp , 20 - 24 bp , 20 - 23 bp , 20 - 22 bp , 20 - 21 bp , 20 basepairs , 21 - 30 bp , 21 - 26 bp , 21 - 25 bp , 21 - 24 bp , 21 - 23 bp , 2l - 22 bp , 2l bp , 22 bp , or 23 bp. The dsRNAs generated in the cell by processing With Dicer and similar enzymes are generally in the range of about 19 to about 22 by in length. One strand of the duplex region of a dsRNA comprises a sequence that is substantially complementary to a region of a target RNA. The tWo strands forming the duplex structure can be from a single RNA molecule haVing at least one selfcomplementary duplex region , or can be formed from tWo or more separate RNA molecules that hybridize to form the duplex. Where the duplex region is formed from tWo self - c0mplementary regi0ns of a single molecule , the molecule can haVe a duplex region separated by a single - stranded chain of nucleotides ( herein referred to as a “hairpin loop” , e. g. , such as found in an shRNA construct ) betWeen the 3 ' - end of one strand and the 5 ' - end of the respectiVe other strand forming the duplex structure. The hairpin loop can comprise at least one unpaired nucleotide ; in some embodiments the hairpin loop can comprise at least 3 , at least 4 , at least 5 , at least 6 , at least 7 , at least 8 , at least 9 , at least 10 , at least 20 , at least 23 or more unpaired nucleotides. Where the tWo substantially c0mplementary strands of a dsRNA are comprised by separate RNA molecules , those molecules need not , but can be coValently connected. Where the tWo strands are connected coValently by a hairpin loop , the construct is generally referred to herein and in the art as a “shRNA”. Where the tWo. May 10 , 2012. strands are connected coValently by means other than a hairpin loop , the connecting structure is referred to as a “linker.”. [ 0141 ] RNA Interference. [ 0142 ] RNA interference ( RNAi ) is a post - transcriptional , targeted gene - silencing technique that uses double - stranded RNA ( dsRNA ) to degrade messenger RNA ( mRNA ) containing the same sequence as the dsRNA. The process of RNAi occurs When ribonuclease III ( Dicer ) cleaVes the longer dsRNA into shorter fragments called siRNAs. siRNAs ( small interfering RNAs ) are typically about 2l to 23 nucleotides long and comprise about 19 base pair duplexes. The smaller RNA segments then mediate the degradation of the target mRNA. Dicer has also been implicated in the excision of 2 l - and 22 - nucleotide small temporal RNAs ( stRNAs ) from precursor RNA of conserVed structure that are implicated in translational control. HutVagner et al. 2001 , Science , 293 , 834. The RNAi response also features an end0nuclease complex , common1y referred to as an RNA - induced silencing complex ( RISC ) , Which mediates cleaVage of single - stranded mRNA complementary to the antisense strand of the siRNA. CleaVage 0f the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex. [ 0143 ] In one aspect , an RNA interference agent includes a single - stranded RNA that interacts With a target RNA sequence to direct the cleaVage of the target RNA. Without Wishing to be bound by theory , long d0uble - stranded RNA introduced into plants and inVertebrate cells is broken doWn into siRNA by a Type III endonuclease knoWn as Dicer ( Sharp et al. , Genes DeV. 2001 , 15 : 485 ) . Dicer , a ribonuclease - 1l ' - like enzyme , processes the dsRNA into 19 - 23 base pair short interfering RNAs With characteristic tWo base 3 ' oVerhangs ( Bernstein , et al. , ( 200l ) Nature 409 : 363 ) . The siRNAs are then incorporated into an RNA - induced silencing complex ( RISC ) Where one or more helicases unWind the siRNA duplex , enabling one of the noW unpaired siRNA strands to act as a “guide” strand to guide target recognition ( Nykanen , et al. , ( 200l ) Cell lO7 : 309 ) . Upon binding of the antisense guide strand to the appropriate target mRNA , one or more endonucleases Within the RISC cleaVes the target to induce silencing ( Elbashir , et al. , ( 2001 ) Genes DeV. lS : 188 ) . Thus , in one aspect the present disclosure relates to a singlestranded RNA that promotes the formation of a RISC complex to effect silencing of the target gene. [ 0144 ] RNA interference has also been studied in a Variety of systems. Work in Dr0s0phi / a embryonic lysates ( Elbashir et al. 2001 EMBO J. 20 : 6877 and Tuschl et al. International PCT Publicati0n N0. WO 01 / 75l64 ) has reVealed certain requirements for siRNA length , structure , chemical composition , and sequence that are essential to mediate efﬁcient RNAi actiVity in a Variety of systems , including especially mammals. These studies haVe shoWn that 21 - nucleotide siRNA duplexes are m0st actiVe When c0ntaining 3 ' - terminal dinucleotide oVerhangs. Substitution of the 3 ' - terminal siRNA oVerhang nucleotides With 2 ' - deoxy nucleotides ( 2 ' - H ) Was tolerated. In addition , a 5 ' - phosphate on the targetcomplementary strand of a siRNA duplex is usually required f0r siRNA actiVity. Most importantly for therapeutic use , siRNA duplexes shorter than 50 by or so do not actiVate the interferon response in mammalian cells. See , e. g. , Tusch1 et al. , WO 01 / 752164. [ 0145 ] The dsRNA molecules ( RNAi agents ) described herein are thus useful in RNA interference of Beta - ENaC. US 20l2 / 0ll5934 Al. [ 0146 ] Features of a RNAi Agent : Sense strand , Antisense Strand and ( Optional ) OVerhangs. [ 0147 ] In Various embodiments , the RNAi agents comprise a ﬁrst strand and a second strand , e. g. , a sense strand and an antisense strand and , optionally , one or both ends of the duplex containing unpaired nucleotides referred to herein as oVerhangs. [ 0148 ] The term “antisense strand” refers to the strand of a RNAi agent Which includes a region that is substantially complementary to a target sequence. As used herein , the term “region 0f complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence , for example a target sequence , as deﬁned herein. Where the region of complementarity is not ﬁ111y complementary to the target sequence , the mismatches may be in the internal or terminal regions 0f the molecule. Generally , the most tolerated mismatches are in the tenninal regions , e. g. , Within 5 , 4 , 3 , or 2 nucleotides of the 5 ' and / or 3 ' terminus. [ 0149 ] The term “sense strand , ” as used herein , refers to the strand of a RNAi agent that includes a region that is substantially c0mplementary to a region of the antisense strand as that term is deﬁned herein. [ 0150 ] The sequence of a gene may Vary from indiVidual to indiVidual , especially at Wobble positions Within the coding segment , or in the untranslated region ; indiViduals may also differ from each other in coding sequence , resulting in additional differences in mRNA. The sequence of the sense and antisense strands of the RNAi agent can thus be designed to correspond to that of an indiVidual patient , if and Where needed. RNAi agents can also be modiﬁed in sequence to reduce immun0genicity , binding to undesired mRNAs ( e. g. , “0ff - target effects” ) or to increase stability in the blood. These sequence Variants are independent of chemical modiﬁcation of the bases or 5 ' or 3 ' or other end - caps of the RNAi agents. [ 0151 ] The RNAi agents can also haVe oVerhangs of 0 , 1 , or 2 oVerhangs ; in the case of a 0 nt oVerhang , they are bluntended. A RNAi agent can haVe 0 , l or 2 blunt ends. In a “blunt - ended RNAi agent” both strands terminate in a basepair ; thus a blunt - ended molecule lacks either 3 ' or 5 ' singlestranded nucleotide oVerhangs. [ 0152 ] As used herein , the term “oVerhang” or “nucleotide oVerhang” refer to at least one unpaired nucleotide that protrudes fr0m the end of at least one of the tWo strands of the duplex structure of a RNAi agent. For example , When a 3 ' - end of one strand of a dsRNA extends beyond the 5 ' - end of the other strand , or Vice Versa , the unpaired nucleotide ( s ) form the oVerhang. A dsRNA can comprise an oVerhang of at least one nucle0tide ; altematiVely the oVerhang can comprise at least tWo nucleotides , at least three nucleotides , at least four nucleotides , at least ﬁVe nucleotides or more. An oVerhang can comprise or consist of a nucleotide / nucleoside analog , including a deoxynucleotide / nucleoside. The oVerhang ( s ) may be on the sense strand , the antisense strand or any combination thereof. Furthermore , the nucleotide ( s ) of an oVerhang can be present on the 5 ' end , 3 ' end or both ends of either an antisense or sense strand of a dsRNA. [ 0153 ] The term “cap” and the like include a chemical moiety attached to the end of a double - stranded nucleotide duplex , but is used herein to exclude a chemical moiety that is a nucleotide or nucleoside. A “3 ' Cap” is attached at the 3 ' end of a nucleotide or oligonucleotide. A “5 ' Cap” is attached at the 5 ' end of a nucleotide or oligonucleotide. In one embodi - . The RNAi agent can also optionally comprise a cap. May 10 , 2012. ment , 3 ' end caps are as disclosed in , for example , WO 2005 / 02l749 and WO 2007 / l28477. [ 0154 ] The present disclosure thus contemplates a RNAi agent speciﬁc to Beta - ENaC comprising an antisense strand ( Which may be contiguous or connected Via a linker or loop ) in a RNAi agent. In a more speciﬁc embodiment , an RNAi agent comprises an antisense strand and a sense strand Which together comprise a double - stranded or complementary region. In one embodiment , it can also 0ptionally comprise. one or tWo oVerhangs and / or one or tWo caps. The RNAi agent is used to induce RNA interference of Beta - ENaC. [ 0155 ] Target and Complementary Sequences. [ 0156 ] The RNAi agents of the present disclosure target ( e. g. , speciﬁcally bind to , anneal to , etc. ) the mRNA encoding the gene Beta - ENaC. The use of the RNAi agent speciﬁc to Beta - ENaC results in a decrease of Beta - ENaC actiVity , leVel and / or expressi0n , e. g. , a “kn0ck - doWn” or “knock - out” of the target gene or target sequence. Particularly in one embodiment , in the case of a disease state characterized by oVerexpressi0n or hyper - actiVity of Beta - ENaC , administrati0n of a RNAi agent t0 Beta - ENaC kn0cks doWn the Beta - ENaC gene enough to restore a nonnal leVel of Beta - ENaC actiVity and / or a normal leVel of Na + reab sorption. [ 0157 ] As used herein , “target sequence” or “target gene” refer to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcripti0n of a gene , e. g. , a Beta - ENaC gene , including mRNA that is a pr0duct of RNA processing of a primary transcription product. The target portion of the sequence Will be at least long enough to serVe as a substrate for iRNA - directed cleaVage at or near that portion. For example , the target sequence Will generally be from 9 - 36 nucleotides ( “nt” ) in length , e. g. , lS - 30 nt in length , including all sub - ranges therebetWeen. As non - limiting examples , the target sequence can be from lS - 30 nt , lS - 26 nt , 15 - 23 nt , 15 - 22 nt , 15 - 21nt , 15 - 20 nt , 15 - 19 nt , 15 - 18 nt , 15 - 17 nt , 18 - 30 nt , 18 - 26 nt , 18 - 23 nt , 18 - 22 nt , 18 - 21 nt , l8 - 20 nt , 19 - 30 nt , l9 - 26 nt , l9 - 23 nt , l9 - 22 nt , 19 - 2l nt , l9 - 20 nt , l9 nt , 20 - 30 nt , 20 - 26 nt , 20 - 25 nt , 20 - 24 nt , 20 - 23 nt , 20 - 22 nt , 20 - 2l nt , 20 nt , 2l - 30 nt , 2l - 26 nt , 2l - 25 nt , 21 - 24 nt , 2 1 - 23 nt , or21 - 22 nt , 21 nt , 22 nt , or 23 nt. The sense and antisense strands of the RNAi comprise a sequence complementary to that of the target nucleic acid , Beta - ENaC. [ 0158 ] As used herein , and un1ess otherWise indicated , the term “complementary” refers to the ability of an oligonucleotide or polynucleotide comprising a ﬁrst nucleotide sequence to hybridize and form a duplex structure under certain conditions With an oligonucleotide or polynucleotide comprising a sec0nd nucle0tide sequence. Such conditions can , for example , be stringent , e. g. , 400 mM NaCl , 40 mM PIPES pH 6.4 , 1 mM EDTA , 500 C. or 700 C. for l2 - l6 hours folloWed by Washing. Other conditions , such as physiologically releVant conditions as may be encountered inside an organism , can apply. The skilled person Will be able to determine the set of conditions most appropriate for a test of complementarity of tWo sequences in accordance With the ultimate application of the hybridized nucleotides. [ 0159 ] also include , or be formed entirely from , non - Watson - Crick base pairs and / or base pairs formed from non - natural and modiﬁed nucleotides , in as far as the aboVe requirements With respect to their ability to hybridize are fulﬁlled. Such nonWatson - Crick base pairs includes , but are not limited to , G : U Wobble or Hoogstein base pairing. “Complementary” sequences , as used herein , may. US 20l2 / 0ll5934 Al. [ 0160 ] The terms “complementary , ” “ﬁ111y complementary” and “substantially complementary” herein may ﬁ1rthermore be used With respect to the base matching betWeen the sense strand and the antisense strand of a dsRNA , or betWeen the antisense strand of a RNAi agent and a target sequence , as Will be understood from the context of their use. [ 0161 ] As used herein , a polynucleotide that is “substantially complementary to at least part of” a messenger RNA ( mRNA ) refers t0 a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest ( e. g. , an mRNA encoding Beta - ENaC ) . For example , a polynucleotide is complementary to at least a part 0f a Beta - ENaC mRNA if the sequence is substantially complementary to a non - interrupted portion of an mRNA encoding Beta - ENaC. [ 0162 ] Complementary sequences Within a RNAi agent , e. g. , Within a dsRNA as described herein , include base - paired oligonucleotides or polynucleotides comprising a ﬁrst nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence oVer the entire length of one or both nucleotide sequences. Such sequences can be referred to as “ﬁ111y complementary” With respect to each other herein. HOWeVer , Where a ﬁrst sequence is referred t0 as “substantially complementary” With respect to a second sequence herein , the tW0 sequences can be fully complementary , 0r they may form one or more , but generally n0t more than 5 , 4 , 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs , While retaining the ability to hybridize under the conditions mo st releVant to their ultimate application , e. g. , inhibition of gene expression Via a RISC pathWay. HoWeVer , Where tWo oligonucleotides are designed t0 form , up0n hybridization , one or more single - stranded oVerhangs , such oVerhangs shall not be regarded as mismatches With regard to the determination of complementarity. For example , a duplex comprising one oligonucleotide 2l nucleotides in length and another oligonucleotide 23 nucleotides in length , Wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is ﬁ111y complementary to the shorter oligonucleotide , may yet be referred to as “fully complementary” for the purposes described herein. The term oVerhang describes an unpaired nucleotide at the 3 ' or 5 ' end of a double - stranded nucleotide duplex , as described aboVe. In one embodiment , the oVerhang is 0 to 4 nt long and is on the 3 ' end. [ 0163 ] Thus , the RNAi agent of the present disclosure is c0mplimentary 0r substantially complimentary to a target sequence in the target Beta - ENaC and is double - stranded , comprising a sense and an antisense strand ( Which can be contiguous , linked Via a loop , or otherWise joined ) , Where the double - stranded region an be 9 to 36 by long ( particularly for example , l9 - 22 by or l9 - 23 by long ) , and can furthermore optionally comprise a 3 ' or 5 ' oVerhang , and the RNAi agent can furthermore comprise a 3 ' cap. The RNAi agent mediates RNA interference , doWn - regulating or inhibiting the leVel , expression and / or actiVity of Beta - ENaC , and / or establishing or re - establishing an approximately normal leVel of ENaC and / or Beta - ENaC actiVity , or other biological ﬁmction related to ENaC. [ 0164 ] RNAi Agents LoWering Beta - ENaC LeVel , Expression and / or ActiVity. [ 0165 ] RNAi agents for targeting Beta - ENaC include those Which bind to a Beta - ENaC sequence proVided herein and. May 10 , 2012. Which Work to reduce Beta - ENaC through a RNAi mechanism. Exemplary siRNAs to Beta - ENaC are proVided , e. g. , in Table 1. [ 0166 ] The RNAi agents of the present disclosure silence , inhibit the expression of , doWn - regulate the expression of , and / or suppress the expression of the Beta - ENaC gene , such that an approximately normal leVel of Beta - ENaC actiVity , expression and / or leVel and / or Na + reabsorption is achieVed. [ 0167 ] In addition , in Various embodiments , depending on the disease condition and biological context , it is acceptable t0 use the RNAi agents of the present disclosure t0 establish a leVel of Beta - ENaC expression , actiVity and / or leVel Which is bel0W the normal leVel , or aboVe the normal leVel. [ 0168 ] Any method knoWn in the art can be use to measure changes in Beta - ENaC actiVity , leVel and / or expression induced by a Beta - ENaC siRNA. Measurements can be performed at multiple timepoints , prior to , during and after administration of the siRNA , to determine the effect of the siRNA. [ 0169 ] The terms “silence , ” “inhibit the expression of , ” “doWn - regulate the expression of , ” “suppress the expression of , ” and the like , in so far as they refer to a Beta - ENaC gene , herein refer to the at least partial suppression of the expression of a Beta - ENaC gene , as manifested by a reduction of the amount of Beta - ENaC mRNA Which may be isolated from or detected in a ﬁrst cell or group of cells in Which a Beta - ENaC gene is transcribed and Which has or haVe been treated such that the expression of a Beta - ENaC gene is inhibited , as compared to a second cell 0r group of cells substantially identical to the ﬁrst cell or group of cells but Which has or haVe not been so treated ( control cells ) . The degree of inhibition is usually expressed in terms of. ( mRNA in control cells ) — ( mRNA in treated cells ) Equation 1. . lO0% ( mRNA 1n contro1 cells ) . . [ 0170 ] AlternatiVely , the degree of inhibition may be giVen in terms of a reducti0n of a parameter that is functionally linked to Beta - ENaC gene expression , e. g. , the amount of protein encoded by a Beta - ENaC gene , alteration in lung ﬁuid leVels or mucus leVels , etc. In principle , Beta - ENaC gene silencing may be determined in any cell expressing BetaENaC , either 00nstitutiVely or by genomic engineering , and by any appropriate assay. HoWeVer , When a reference or control is needed in order to determine Whether a giVen RNAi agent inhibits the expression of the Beta - ENaC gene by a certain degree and therefore is encompassed by the instant disclosure , the assays proVided in the Examples beloW shall serVe as such reference. [ 0171 ] For example , in certain instances , expression of a Beta - ENaC gene is suppressed by at least about 10% , 15% , 20% , 25% , 30% , 35% , 40% , 45% , or 50% by administration of a RNAi agent featured in the present disclosure. In some embodiments , a Beta - ENaC gene is suppressed by at least about 60% , 70% , or 80% by administration of a RNAi agent featured in the present disclosure. In some embodiments , a Beta - ENaC gene is suppressed by at least about 85% , 90% , or 95% or more by administration of a RNAi agent , as described herein. [ 0172 ] The ability of a RNAi agent to suppress Beta - ENaC can be ﬁrst tested in Vitro ( e. g. , using test cells such as H441 ) . [ 0173 ] RNAi agents Which can suppress Beta - ENaC in Vitro can then be tested for immunostimulation using , for. US 20l2 / 0ll5934 Al. example , a PBMC ( peripheral blood mononuclear cell ) assay. RNAi agents can also be tested in animal tests. Test and control animals include those Which oVer - express or underexpress Beta - ENaC , as described in , for example , Hummer et al. 2005 J . Am. Soc. Nephrol. l6 : 3l60 - 3l66 ; Randrianarison et al. 2007 um. J. Physiol. Lung Cell. Mol. Physiol. 294 : 409 - 416 ; Cao et al. 2006 um. J. Physiol. Renal Physiol. , and references cited therein. RNAi agents Which suppress or alter the leVel , actiVity and / or expression of Beta - ENaC can be used in medicaments to treat Various Beta - ENaC - related diseases. [ 0174 ] By “loWer” in the context of Beta - ENaC or a symptom of a Beta - ENaC - related disease is meant a statistically signiﬁcant decrease in such leVel. The decrease can be , for example , at least lO% , at least 20% , at least 30% , at least 40% or more. If , for a particular disease , or for an indiVidual suffering from a particular disease , the leVels or expression of Beta - ENaC are eleVated , treatment With a Beta - ENaC RNAi agent of the present disclosure can particularly reduce the leVel or expression of Beta - ENaC to a leVel considered in the literature as Within the range of normal for an indiVidual Without such dis0rder. The leVel 0r expression of Beta - ENaC can be measured by eValuation 0f mRNA ( e. g. , Via Northern blots or PCR ) , or protein ( e. g. , Western blots ) . The effect of a RNAi agent on Beta - ENaC expression can be determined by measuring Beta - ENaC gene transcription rates ( e. g. , Via Northern bl0ts ; or reVerse transcriptase polymerase chain reaction or real - time polymerase chain reaction ) . RT - PCR has been used to shoW that mRNA leVels 0f Beta - ENaC are high in kidney , pancreas and prostate , and medium in liVer and spleen. Brauner - Osbome et al. 2001. Biochim. Biophys. Acta 15 1 8 : 237 - 248. Direct measurements can be made of leVels of Beta - ENaC ( Which is expressed by the cell surface ) , e. g. by Western bl0ts of tissues in Which Beta - ENaC is expressed. [ 0175 ] As used herein , “doWn - regulates” refers to any statistically signiﬁcant decrease in a biological actiVity and / or expression of Beta - ENaC , including full blocking of the actiVity ( i. e. , complete inhibition ) and / or expression. For example , “doWn - regulation” can refer to a decrease of at least about lO , 20 , 30 , 40 , 50 , 60 , 70 , 80 , 90 or lO0% in Beta - ENaC leVel , actiVity and / or expression. [ 0176 ] As used herein , the term “inhibit” or “inhibiting” Beta - ENaC refers to any statistically signiﬁcant decrease in biological leVel , actiVity and / or expression of Beta - ENaC , including full blocking of the actiVity and / or expression. For example , “inhibition” can refer to a decrease of at least about 10 , 20 , 30 , 40 , 50 , 60 , 70 , 80 , 90 or 100% in Beta - ENaC leVel , actiVity and / or expression. As used herein , the term “inhibit” similarly refers to a signiﬁcant decrease in leVel , actiVity and / or expression , While referring to any other biological agent or composition. [ 0177 ] By “leVel” , it is meant that the Beta - ENaC RNAi agent can alter the leVel of Beta - ENaC , e. g. , the leVel of Beta - ENaC mRNA or the leVel of Beta - ENaC protein , or the leVel of actiVity of Beta - ENaC. [ 0178 ] Some diseases , such as cystic ﬁbrosis , are characterized by excessiVe ENaC - mediated Na + absorption. Particularly in one embodiment , in the case of a disease characterized by oVer - expression and / or hyper - actiVity of BetaENaC , administration of a RNAi agent to Beta - ENaC reduces the leVel , expression and / or actiVity of Beta - ENaC. HoWeVer , excessiVely loW leVels of Beta - ENaC can also lead to impairment of lung ﬁuid clearance and renal dysfunction. Randrianarison et al. 2007 um. J. Physiol. Lung Cell. Mol. Physiol. May 10 , 2012. 294 : 409 - 4l6. Thus , in Various embodiments , administration of a RNAi agent to Beta - ENaC particularly establishes or re - establishes a normal or approximately normal leVel of Beta - ENaC actiVity , expression and / or leVel. [ 0179 ] By “nom1al” or “approximately normal” in terms of leVel , expression and / or actiVity , is meant at least : about 50% , about 60% , about 70% , about 80% , about 90% , and / or about lO0% ; and / or no more than : about 100% , about 120% , about l30% , about l40% , or about lS0% of the leVel , expression or actiVity of Beta - ENaC in a healthy cell , tissue , or organ. This can be measured using , for example , lung or kidney homogenates , as described in Gambling et al. 2004 Kidney Intl. 65 : l774 - 1781. Particularly in one embodiment , administration of the appropriate amount of the appr0priate Beta - ENaC RNAi agent restores Beta - ENaC leVel , actiVity and / or expression and / or Na + reabsorption leVels to about 50% to about 150% , more particularly about 60% to about l40% , more particularly to about 70% to about 130% , more particularly to about 80% to about l20% , m0re particularly to about 90% to about llO% , and most particularly to about lO0% of that of a healthy cell , tissue or organ. The leVel of Beta - ENaC actiVity can also be indirectly measured by lung ﬁuid balance. Lung ﬁuid balance can be estimated by calculating bloodless , Wet - to - dry lung Weight ratios , Which reﬁect the amount of extraVascular lung Water. Randrianarison et al. 2007 um. J. Physiol. Lung Cell. Mol. Physiol. 294 : 409 - 416. The leVel of Beta - ENaC actiVity can also be indirectly measured by histological studies of the lung , particularly the bronchioles , alVeolar ducts , alVeolar epithelium , and blood Vessels. Randrianarison et al. 2007 ; and Zhou et al. 2008 um. J. Resp. Crit. Care Med. 178 : l245 - 1256. Administration of a Beta - ENaC RNAi to a patient With a Beta - ENaC - related disease thus particularly restores the leVel , actiVity , and / or expression of Beta - ENaC and the leVel of Na + reabsorption to an approximately normal leVel , as determined by direct measurements of Beta - ENaC mRNA or protein leVels , or indirect determinations , such as analyses of histological samples or leVels of lung ﬁuid. [ 0180 ] In addition , in Various embodiments , depending on the disease condition and biological context , it is acceptable to use the RNAi agents of the present disclosure to establish a leVel of Beta - ENaC expression , actiVity and / or leVel Which is bel0W the normal leVel , or aboVe the normal leVel. [ 0181 ] Various factors are knoWn to alter the leVel of ENaC or , speciﬁcally , Beta - ENaC. Honnones that increase the physiological actiVity of ENaC include aldosterone , Vasopressin and insulin. Beta - ENaC is speciﬁcally up - regulated by Vasopressin and Water restricti0n , as Well as during sodium - bicarbonate loading in rats. These Vari0us factors can be used as controls in determining the effect of a RNAi agent on Beta - ENaC leVel. [ 0182 ] Types of RNAi Agents and Modiﬁcation Thereof [ 0183 ] The use of RNAi agents or compositions comprising an antisense nucleic acid to doWn - modulate the expression of a particular protein in a cell is Well knoWn in the art. A RNAi agent comprises a sequence complementary to , and is capable of hydrogen binding to , the coding strand of another nucleic acid ( e. g. , an mRNA ) . Thus , in Various embodiments , the RNAi agents of the present disclosure encompass any RNAi agents Which target ( e. g. , are complementary , capable of hydrogen binding to , etc. ) any sequence presented , e. g. , in Table 1. [ 0184 ] Antisense sequences complementary to an mRNA can be complementary to the coding region , the 5 ' or 3 ' . US 20l2 / 0ll5934 Al. untranslated region of the mRNA , and / or a region bridging the coding and untranslated regions , and / or portions thereof. Furthermore , a RNAi agent or a portion thereof can be c0mplementary to a regulatory region of the gene encoding the mRNA , for instance a transcription or translation initiation sequence or regulatory element. Particularly , a RNAi agent or a portion thereof can be complementary to a region preceding or spanning the initiation codon on the coding strand or in the 3 ' untranslated region of an mRNA. [ 0185 ] RNAi agent molecules can be designed according to the rules of Watson and Crick base pairing. The RNAi agent can be complementary to the entire coding region 0f BetaENaC mRNA , but more particularly is an oligonucleotide Which is antisense to only a portion of the coding or noncoding region of Beta - ENaC mRNA. For example , the antisense oligonucleotide can be complementary to the region surrounding the translation start site 0f Beta - ENaC mRNA. An antisense oligonucleotide can be , for example , about 5 , lO , 15 , l9 , 20 , 2l , 22 , 23 , 24 , 25 , 30 , 35 , 40 , 45 or 50 nucleotides in length. [ 0186 ] The RNAi agent may haVe modiﬁcations internally , or at one or b0th ends. The modiﬁcations at the ends can help stabilize the RNAi agent , protecting it from degradation by nucleases in the blood. The RNAi agents may optionally be directed to regions of the Beta - ENaC mRNA knoWn or predicted to be near or at splice sites of the gene ; e. g. , exon - intron juncti0ns ( as described in , f0r example , Saxena et al. 1998 ) . [ 0187 ] The RNAi agents can als0 optionally be designed to anneal to knoWn or predicted exposed and / or single - stranded regions of the mRNA ( e. g. , loops ) . [ 0188 ] A RNAi agent can be constructed using chemical synthesis and enzymatic ligation reactions using procedures kn0Wn in the art. For example , RNAi agent can be chemically synthesized using naturally - 0ccurring nucleotides 0r Variously modiﬁed nucleotides designed to decrease off - target effects , and / or increase the biological stability of the molecules or to increase the physical stability of the duplex formed betWeen the antisense and sense nucleic acids , e. g. , ph0sphorothioate deriVatiVes and acridine substituted nucleotides can be used. [ 0189 ] “G , ” “C , ” “A , ” “T” and “U” each generally stand for a nucleotide that contains guanine , cytosine , adenine , thymidine and uracil as a base , respectiVely. HoWeVer , the term “ribonucleotide” or “nucleotide” can also refer t0 a modiﬁed nucleotide or a su1rogate replacement moiety. The skilled person is Well aWare that guanine , cytosine , adenine , and uracil may be replaced by other moieties Without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example , Without limitation , a nucleotide comprising inosine as its base may base pair With nucleotides containing adenine , cytosine , or uracil. Hence , nucleotides containing uracil , guanine , or adenine may be replaced in the nucleotide sequences of dsRNA featured in the present disclosure by a nucleotide c0ntaining , for example , inosine. In another example , adenine and cytosine anyWhere in the oligonucleotide can be replaced With guanine and uracil , respectiVely to form G - U Wobble base pairing With the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the present disclosure. [ 0190 ] The skilled artisan Will recognize that the term “RNA molecule” or “ribonucleic acid molecule” encompasses not only RNA molecules as expressed or found in. May 10 , 2012. nature ( i. e. , are naturally occurring ) , but also non - naturally occurring analogs and deriVatiVes of RNA comprising one or more ribonucleotide / ribonucleo side analogs or deriVatiVes as described herein or as knoWn in the art. Strictly speaking , a “ribonucleoside” includes a nucleoside base and a ribose sugar , and a “ribonucle0tide” is a rib0nucleoside With one , tWo or three phosphate moieties. HoWeVer , the terms “ribonucleoside” and “ribonucleotide” can be considered to be equiValent as used herein. The RNA can be modiﬁed in the nucleobase structure or in the ribose - phosphate backbone structure , e. g. , as described herein beloW. HoWeVer , the molecules comprising ribonucle0 side analogs or deriVatiVes must retain the ability to form a duplex. As n0n - limiting examples , an RNA molecule can also include at least one modiﬁed ribonucleoside , including but not limited to a 2 ' - O - methyl modiﬁed nucleotide , a nucle0side comprising a 5 ' phosphorothioate group , a terminal nucleoside linked to a cholesteryl deriVatiVe 0r dodecanoic acid bisdecylamide group , a locked nucleoside , an abasic nucleoside , a 2 ' - deoxy - 2 ' - ﬁuoro modi - ﬁed nucleoside , a 2 ' - amino - modiﬁed nucleoside , 2 ' - alkylmodiﬁed nucle0side , morpholin0 nucleoside , an unl0cked ribonucle0tide ( e. g. , an acyclic nucle0tide monomer , as described in WO 2008 / l 47824 ) , a pho sphoramidate or a nonnatural base comprising nucleoside , or any combination thereof. AlternatiVely , an RNA molecule can comprise at least tWo modiﬁed ribonucleosides , at least 3 , at least 4 , at least 5 , at least 6 , at least 7 , at least 8 , at least 9 , at least 10 , at least 15 , at least 20 or more , up to the entire length of the dsRNA molecule. The modiﬁcations need not be the same for each of such a plurality of modiﬁed ribonucleosides in an RNA molecule. In one embodiment , modiﬁed RNAs contemplated for use in methods and compositions described herein are peptide nucleic acids ( PNAs ) that haVe the ability to form the required duplex structure and that permit or mediate the speciﬁc degradation of a target RNA Via a RISC pathWay. [ 0191 ] Examples of modiﬁed nucleotides Which can be used to generate the RNAi agent include 5 - ﬁuorouracil , 5 - bromouracil , 5 - chlorouracil , 5 - iodouracil , hyp0xanthine , xantine , 4 - acetylcyt0sine , 5 - ( carboxyhydroxylmethyl ) uracil , 5 - carboxymethylaminomethyl - 2 - thiouridine , 5 - carboxymethylaminomethyluracil , dihydrouracil , beta - D - galactosquueosine , inosine , N6 - isopentenyladenine , 1 - meth - yl guanine , l - methylino sine , 2 , 2 - dimethyl guanine , 2 - methyladenine , 2 - methylguanine , 3 - methylcyto sine , 5 - methylcytosine , N6 - adenine , 7 - methylguanine , 5 - methylaminomethyluracil , 5 - methoxyaminomethyl - 2 - thiouracil , beta - D - mannosquueosine , 5 ' - methoxycarboxymethyluracil , 5 - methoxyuracil , 2 - methylthio - N - 6 - isopentenyladenine , uracil - 5 - oxyacetic acid ( V ) , Wybutoxosine , pseudouracil , queosine , 2 - thiocytosine , 5 - methyl - 2 - thiouracil , 2 - thiouracil , 4 - thiouracil , 5 - methyluracil , uracil - 5 - oxyacetic acid methylester , uracil - 5 - oxyacetic acid ( V ) , 5 - methyl - 2 - thiouracil , 3 - ( 3 - amino - 3 - N - 2 - carb0xypropyl ) uracil , ( acp3 ) W , and 2 , 6 - diaminopurine. [ 0192 ] In one embodiment , the present disclosure encompasses modiﬁed any modiﬁed Variant of any RNAi agent disclosed herein. The modiﬁed Variant contains the same sequence , but can be modiﬁed to contain modiﬁcations in the phosphate , sugar , base , nucleotide , etc. For example , the modiﬁed Variant can contain one or more of the modiﬁed. nucleotides listed herein , for example a C replaced by a 2 ' - modiﬁed C. [ 0193 ] In one aspect , a modiﬁed ribonucleoside includes a deoxyribonucleoside. In such an instance , a RNAi agent can. US 20l2 / 0ll5934 Al. comprise one or more deoxynucleosides , including , for example , a deoxynucleoside oVerhang ( s ) , or one or more deoxynucleosides Within the double - stranded portion of a dsRNA. HoWeVer , it is self - eVident that under no circumstances is a double - stranded DNA molecule encompassed by the term “RNAi agent.”. [ 0194 ] Replacing the 3 ' - terminal nucleotide oVerhanging segments of a 2l - mer siRNA duplex haVing tWo - nucleotide 3 ' - 0Verhangs With deoxyribonucleotides does not haVe an adVerse effect on RNAi actiVity. Replacing up to four nucleotides on each end of the siRNA With deoxyribonucleotides has been Well t0lerated , Whereas complete substitution With deoxyribonucleotides results in no RNAi actiVity. International PCT Publication No. WO 00 / 449l4 , and Beach et al. Internati0nal PCT Publication No. WO 01 / 6 8836 preliminarily suggest that siRNA may include modiﬁcations to either the pho sphate - sugar backbone or the nucleo side to include at least one of a nitrogen 0r sulfur heteroatom. Kreutzer et al. Canadian Patent Application N0. 2 , 359 , l80 , also describe certain chemical modiﬁcations for use in dsRNA constructs in 0rder t0 counteract actiVation of double - stranded RNAdependent protein kinase PKR , speciﬁcally 2 ' - amino or 2 ' - O - methyl nucleotides , and nucleotides containing a 2 ' - O or 4 ' - C methylene bridge. Additional 3 ' - terminal nucleotide oVerhangs include dT ( deoxythimidine ) , 2 ' - O , 4 ' - C - ethylene thymidine ( eT ) , and 2 - hydr0xyethyl phosphate ( hp ) . [ 0195 ] Parrish et al. 2000 Molecular Cell 6 : 1077 - 1087 tested certain chemical modiﬁcations targeting the unc - 22 gene in C. elegans using long ( >25 nt ) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide anal0gs With T7 and T3 RNA polymerase and obserVed that RNAs With tW0 phosphorothioate modiﬁed bases also had substantial decreases in effectiVeness as RNAi. Further , Parrish et al. reported that pho sphorothioate modiﬁ - cation of more than tWo residues greatly destabilized the RNAs in Vitro such that interference actiVities could not be assayed. Id. at lO8l. The authors als0 tested certain modiﬁ - cations at the 2 ' - position of the nucleotide sugar in the long siRNA transcripts and found that substituting deoxynucleotides for ribonucleotides produced a substantial decrease in interference actiVity , especially in the case of Uridine to Thymidine and / or Cytidine t0 deoxy - Cytidine substitutions. Id. In addition , the authors tested certain base modiﬁcations , including substituting , in sense and antisense strands of the siRNA , 4 - thiouracil , 5 - bromouracil , 5 - iodouracil , and 3 - ( aminoallyl ) uracil for uracil , and inosine for guanosine. Whereas 4 - thiouracil and 5 - bromouracil substitution appeared to be tolerated , Parrish reported that inosine produced a substantial decrease in interference actiVity When incorporated in either strand. Parrish also reported that incorporation of 5 - iodouracil and 3 - ( aminoallyl ) uracil in the antisense strand resulted in a substantial decrease in RNAi actiVity as Well. [ 0196 ] Those skilled in the art Will appreciate that it is possible to synthesize and modify the siRNA as desired , using any conVentional method knoWn in the art ( see Henschel et al. 2004 DEQOR : a Web - based tool for the design and quality control of siRNAs. Nucleic Acids Research 32 ( Web SerVer Issue ) : Wl l3 - Wl20 ) . Further , it Will be apparent to those skilled in the art that there are a Variety of regulatory sequences ( for example , constitutiVe or inducible promoters , tissue - speciﬁc promoters or functional fragments thereof , . May 10 , 2012. etc. ) Which are useful for the antisense oligonucleotide , siRNA , or shRNA expression construct / Vector. [ 0197 ] There are seVeral examples in the art describing sugar , base , phosphate and backbone modiﬁcations that can be introduced into nucleic acid molecules With signiﬁcant enhancement in their nuclease stability and efﬁcacy. For example , olig0nucleotides are m0diﬁed to enhance stability and / or enhance biological actiVity by modiﬁcation With nuclease resistant gr0ups , f0r example , 2 ' - amino , 2 ' - C - allyl , 2 ' - ﬁuoro , 2 ' - O - methyl , 2 ' - O - allyl , 2 ' - H , nucleotide base modiﬁcations ( for a reVieW see Usman and Cedergren 1992 TIBS. l7 : 34 ; Usman et al. l994 Nucleic Acids Symp. Ser. 3 l : l63 ; Burgin et al. l996 Biochemistry 35 : l4090 ) . Sugar modiﬁcation of nucleic acid molecules are extensiVely described in the art. [ 0198 ] Additional modiﬁcations and conjugations of RNAi agents haVe been described. Soutschek et al. 2004 Nature 432 : 173 - 178 presented 00njugation of cholesterol to the 3 ' - end of the sense strand of a siRNA molecule by means of a pyrrolidine linker , thereby generating a coValent and irreVersible conjugate. Chemical modiﬁcations ( including conjugation With other molecules ) of RNAi agents may also be made t0 improVe the in ViVo pharmacokinetic retenti0n time and efﬁciency. [ 0199 ] In Various embodiments , the RNAi agent to BetaENaC comprises at least 0ne 5 ' - uridine - adenine - 3 ' ( 5 ' - ua - 3 ' ) dinucleotide , Wherein the uridine is a 2 ' - modiﬁed nucleotide ; at least one 5 ' - uridine - guanine - 3 ' ( 5 ' - ug - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide ; at least one 5 ' - cytidine - adenine - 3 ' ( 5 ' - ca - 3 ' ) dinucleotide , Wherein the 5 ' - cytidine is a 2 ' - modiﬁed nucleotide ; and / or at least 0ne 5 ' - uridine - uridine - 3 ' ( 5 ' - uu - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide. [ 0200 ] In Various embodiments , the RNAi agent comprises a 2 ' - modiﬁcation selected from the group consisting of : 2 ' - de0xy , 2 ' - deoxy - 2 ' - ﬁu0ro , 2 ' - O - methyl , 2 ' - O - methoxyethyl ( 2 ' - O - MOE ) , 2 ' - O - aminopropyl ( 2 ' - O - AP ) , 2 ' - O - dimethylaminoethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylaminopropyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylaminoethyloxyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O—N - methylacetamido ( 2 ' - O - NMA ) . [ 0201 ] In another embodiment , the RNAi comprises a gap or missing base. For example , the phosphate - sugar backbone may be present , but the base missing. [ 0202 ] In another embodiment , the RNAi agent has a single - stranded nick ( e. g. , a break or missing bond in the backbone ) . In Various embodiments , a single - stranded nick can be in either the sense or anti - sense strand , or both. [ 0203 ] This nick can be , for example , in the sense strand , producing a small internally segmented interfering RNA , or sisiRNA , Which may haVe less off - target effects than the corresponding RNAi agent Without a nick. [ 0204 ] The antisense nucleic acid 0r RNAi agent can als0 haVe an alternatiVe backbone such as locked nucleic acids ( LNA ) , Morpholinos , peptidic nucleic acids ( PNA ) , threose nucleic acid ( TNA ) , or glycol nucleic acid ( GNA ) , and / or it can be labeled ( e. g. , radiolabeled or otherWise tagged ) . [ 0205 ] One or both strands can comprise an alternatiVe. backbone. [ 0206 ] In yet another embodiment , the RNAi agent employed by the methods of the present disclosure can include an a - anomeric nucleic acid molecule. An a - anomeric nucleic acid molecule forms speciﬁc double - stranded hybrids With complementary RNA in Which , contrary to the usual. US 20l2 / 0ll5934 Al. 6 - units , the strands run parallel to each other. Gaultier et al. 1987 Nucleic Acids. Res. 15 : 6625 - 6641. [ 0207 ] The antisense nucleic acid molecule can also comprise a 2 ' % ) 7 methylribonucleotide ( In0ue et al. l987 Nucleic Acids Res. 15 : 613 1 - 6148 ) or a chimeric RNA - DNA analogue ( In0ue et al. 1987 FEBS Lett. 215 : 327 - 330 ) . [ 0208 ] In still another emb0diment , a RNAi agent is a ribozyme. Ribozymes are catalytic RNA molecules With ribonuclease actiVity Which are capable of cleaVing a singlestranded nucleic acid , such as an mRNA , to Which they haVe a complementary region. Thus , ribozymes [ e. g. , hammerhead ribozymes ( described in Haselhoff et al. 1988 , Nature 334 : 585 - 591 ) ] can be used to catalytically cleaVe Beta - ENaC mRNA transcripts to thereby inhibit translation of BetaENaC mRNA. [ 0209 ] AlternatiVely , gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of Beta - ENaC ( e. g. , the promoter and / or enhancers ) to f0rm triple helical structures that preVent transcription of the Beta - ENaC gene. See generally , Helene 1991 Anticancer Drug Des. 6 ( 6 ) : 569 - 84 ; Helene et al. l992 Ann. N. Y. Acad. Sci. 660 : 27 - 36 ; and Maher l992 , Bioassays l4 ( l2 ) : 807 - 1 5. [ 0210 ] Production of RNAi Agents. [ 0211 ] The RNAi agent can be produced biologically using an expression Vector into Which a nucleic acid has been subcloned in an antisense orientation ( i. e. , RNA transcribed from the inserted nucleic acid Will be in an antisense orientation to a target nucleic acid of interest ) . The RNAi agent can also be pr0duced biologically using an expression Vector into Which a nucleic acid has been subcloned as an shRNA construct ( i . e. , RNA transcribed from the inserted nucleic acid Will haVe a ﬁrst region in an antisense orientation to a target nucleic acid of interest , a second region that comprises a loop or hinge , and a third region in a sense orientation to the target nucleic acid of interest , Wherein the ﬁrst and third regions of the transcript preferably hybridizes With itself , thereby forming a stemand - loop structure ) . [ 0212 ] Methods of producing RNAi agents are Well - knoWn in the art and aVailable to persons of ordinary skill in the art. [ 0213 ] Kits for synthesis of RNAi are c0mmercially aVailable from , e. g. , NeW England Biolabs and Ambion. [ 0214 ] DeliVery of RNAi Agents. [ 0215 ] RNAi agents 0f the present disclosure can be deliVered or introduced ( e. g. , to a cell in Vitro , to a test animal , or to a human ) by any means knoWn in the art. [ 0216 ] The RNAi agents of the present disclosure are typically administered to a subject or generated in situ such that they hybridize With cellular mRNA and / or genomic DNA enc0ding Beta - ENaC , and inhibit expression by inhibiting transcription and / or translation. An example of a route of administration of the RNAi agent includes direct injection at a tissue site. AlternatiVely , RNAi agents can be modiﬁed to target selected cells and then administered systemically. For example , for systemic administration , antisense molecules can be modiﬁed such that they speciﬁcally bind to receptors or antigens expressed on a selected cell surface , e. g. , by linking the antisense nucleic acid molecules to peptides or antibodies Which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be deliVered to cells using Vectors Well knoWn in the art and described in , for example , US20070l l lZ30 , the entire contents of Which are incorporated herein. To achieVe sufﬁcient intracellular concentrations of the antisense molecules , Vector constructs in. May 10 , 2012. Which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred. [ 0217 ] “Introducing into a cell , ” When referring to a RNAi agent , means facilitating or effecting uptake or absorption into the cell , as is understood by those skilled in the art. Absorption or uptake of a RNAi agent can occur through unaided diffusiVe or actiVe cellular processes , or by auxiliary agents or deVices. The meaning of this term is not limited to cells in Vitro ; a RNAi agent may also be “introduced into a cell , ” Wherein the cell is part of a liVing organism. In such an instance , introduction into the cell Will include the deliVery to the organism. For example , for in ViVo deliVery , a RNAi agent can be injected into a tissue site or administered systemically. In ViVo deliVery can also be by a beta - glucan deliVery system , such as th0se described in U. S. Pat. Nos. 5 , 032 , 401 and 5 , 607 , 677 , and U. S. Publication No. 2005 / 028l78l. In Vitro introduction into a cell includes methods kn0Wn in the art such as electroporation and lipofection. Further approaches are described herein or knoWn in the art. [ 0218 ] DeliVery of RNAi agent to tissue is a problem both because the material must reach the target organ and must also enter the cytoplasm of target cells. RNA cannot penetrate cellular membranes , so systemic deliVery of naked RNAi agent is unlikely to be successful. RNA is quickly degraded by RNAse actiVity in serum. For these reasons , other mechanisms t0 deliVer RNAi agent to target cells has been deVised. Methods kn0Wn in the art include but are not limited to : Viral deliVery ( retroVirus , adenoVirus , lentiVirus , baculoVirus , AAV ) ; liposomes ( Lipofectamine , cationic DOTAP , neutral DOPC ) or nanoparticles ( cationic polymer , PEI ) , bacterial deliVery ( thNAi ) , and also chemical modiﬁcation ( LNA ) of siRNA to improVe stability. Xia et al. 2002 Nat. Biotechnol. 20 and DeVroe et al. 2002. BMC Biotechnol. 2 l : lS , disclose incorporation of siRNA into a Viral Vector. Other systems for deliVery of RNAi agents are contemplated and the RNAi agents of the present disclosure can be deliVered by Various methods yet t0 be found and / or approVed by the FDA 0r other regulatory authorities. RNAi agents 0f the present disclosure can deliVered in a suitable pharmaceutical composition. [ 0219 ] Pharmaceutical Compositions of RNAi Agents. [ 0220 ] As used here , a “pharmaceutical composition” comprises a pharmaceutically effectiVe amount of one or more Beta - ENaC RNAi agent , a pharmaceutically acceptable carrier , and , optionally , an additional disease treatment Which Works synergistically With the RNAi agent. As used herein , “pharmacologically effectiVe amount , ” “therapeutically effectiVe amount” or simply “effectiVe amount” refers to that amount of a RNAi agent effectiVe to produce the intended pharmac0logical , therapeutic or preVentiVe result. For example , if a giVen clinical treatment is considered effectiVe Where there is at least a lO% reduction in a measurable parameter associated With a disease or disorder , a therapeutically effectiVe amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a lO% reduction in that parameter. In this embodiment , a therapeutically effectiVe amount of a RNAi agent targeting BetaENaC can reduce Beta - ENaC protein leVels by at least 10%. In additional embodiments , a giVen clinical treatment is considered effectiVe Where there is at least a lS , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 90 or 95% reduction in a measurable parameter associated With a disease or disorder , and the therapeutically effectiVe amount of a drug for the treatment of that disease or disorder is the amount necessary. US 20l2 / 0ll5934 Al. to effect atleast a lS , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 90 or 95% reduction , respectiVely , in that parameter. [ 0221 ] The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include , but are not limited to , saline , buffered saline , dextrose , Water , glycerol , ethanol , and c0mbinations thereof. The term speciﬁcally excludes cell culture medium. For drugs administered 0rally , pharmaceutically acceptable carriers include , but are not limited to pharmaceutically acceptable excipients such as inert diluents , disintegrating agents , binding agents , lubricating agents , sWeetening agents , ﬁaVoring agents , coloring agents and preserVatiVes. Suitable inert diluents include sodium and calcium carbonate , sodium and calcium phosphate , and lactose , While corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin , While the lubricating agent , if present , Will generally be magnesium stearate , stearic acid or talc. If desired , the tablets may be coated With a material such as glyceryl mono stearate or glyceryl distearate , to delay absorption in the gastrointestinal tract. Agents included in drug formulations are described further herein. [ 0222 ] The pharmaceutical compositi0ns comprising a Beta - ENaC RNAi agent can be in solid fonn , f0r example , poWders , granules , tablets , pills , gelcaps , gelatin capsules , liposomes , suppositories , cheWable forms , or patches. The pharmaceutical compositi0ns comprising a Beta - ENaC RNAi agent can also be presented in liquid form , for example , solutions , emulsions , suspensions , elixirs , or syrups. Appropriate liquid supports can be , for example , Water , organic solVents such as polyol , such as glycerol or glycols , including pr0pylene glyc0l and polyethylene glycol , or ethan0l , Cremophor EL , or mixtures thereof , in Varying proportions , in Water. The compositions can comprise nano - sized amorphous or crystalline granules coated With albumin or a surfactant. [ 0223 ] Appropriate supports can include , for example , antibacterial and antifungal agents , buffering agents , calcium phosphate , cellulose , methyl cellulose , chlorobutanol , coc0a butter , colorings , dextrin , emulsiﬁers , enteric coatings , ﬁa - Vorings , gelatin , isotonic agents , lecithin , magnesium stearate , perfuming agents , polyalcohols such as mannitol , injectable organic esters such as ethyl oleate , paraben , phenol sorbic acid , polyethylene glycol , polyVinylpyrrolidine , phosphate buffered saline ( PBS ) , preserVing agents , propylene glycol , sodium carboxymethylcellulose , sodium chloride , sorbitol , Various sugars ( including , but not limited to , sucrose , fructose , galactose , lact0se and trehalose ) , starch , supp0sitory Wax , talc , Vegetable oils , such as oliVe oil and corn oil , Vitamins , Wax , and / or Wetting agents. For Beta - ENaC RNAi agents , a preferred support comprises dextran and Water , e. g. 5% dextrose in Water ( D5W ) . [ 0224 ] The biologically inert portion of the pharmaceutical c0mposition can opti0nally be erodible , all0Wing timed release of the RNAi agent. [ 0225 ] The pharmaceutical composition can comprise additional components Which aid in deliVery , stability , eﬁi - cacy , or reduction of immunogenicity. [ 0226 ] Pharmaceutical Composition Comprising a RNAi Agent to Beta - ENaC. [ 0227 ] Additional components of a pharmaceutical composition comprising a RNAi Agent to Beta - ENaC can be added to aid in deliVery , stability , efﬁcacy , or reduction of immuno - . genicity. May 10 , 2012. [ 0228 ] Liposomes haVe been used preViously for drug deliVery ( e. g. , deliVery of a chemotherapeutic ) . Liposomes ( e. g. , cationic liposomes ) are described in PCT publications WO02 / l00435Al , WO03 / 0l5757Al , and WO040292l3A2 ; U. S. Pat. Nos. 5 , 962 , 0l6 ; 5 , 030 , 453 ; and 6 , 680 , 068 ; and U. S. Patent Application 2004 / 0208921. A process of making liposomes is also described in WO04 / 002453A1. Furthermore , neutral lipids haVe been incorporated into cationic liposomes ( e. g. , Farhood et al. l995 ) . [ 0229 ] Cationic liposomes haVe been used to deliVer RNAi agent to Vari0us cell types ( Sioud and Serensen 2003 ; U. S. Patent Application 2004 / 0204377 ; Duxbury et al. , 2004 ; Donze and Picard , 2002 ) . [ 0230 ] Use of neutral liposomes discl0sed in Miller et al. l998 , and U. S. Patent Application 2003 / 00l28l2. [ 0231 ] As used herein , the term “SNALP” refers to a stable nucleic acid - lipid particle. A SNALP represents a Vesicle of lipids coating a reduced aqueous interior comprising a nucleic acid such as an iRNA 0r a plasmid from Which an iRNA is transcribed. SNALPs are described , e. g. , in U. S. Patent Application Publication Nos. 20060240093 , 20070l35372 , and in International Application No. WO 2009082817. [ 0232 ] Chemical transfection using lipid - based , aminebased and polymer - based techniques , is disclosed in products from Ambion Inc. , Austin , Tex. ; and NoVagen , EMD Biosciences , Inc , an Aﬁﬁliate of Merck KGaA , Darmstadt , Germany ) ; OVcharenk0 D ( 2003 ) “Efﬁcient deliVery of siRNAs to human primary cells.” Ambion TechNotes lO ( 5 ) : lS - l6 ) . Additionally , Song et al. ( Nat. Med. published online ( Fete 10 , 2003 ) doi : 10.103 8 / nm828 ) and others [ Caplen etal.2001 Proc. Natl. Acad. Sci. ( USA ) , 98 : 9742 - 9747 ; and McCaffrey et al. Nature 4l4 : 34 - 39 ] disclose that liVer cells can be efﬁciently transfected by injection of the siRNA into a mammal ' s circulatory system. [ 0233 ] A Variety of molecules haVe been used for cellspeciﬁc RNAi agent deliVery. For example , the nucleic acidcondensing property of protamine has been combined With speciﬁc antibodies to deliVer siRNAs. Song et al. 2005 Nat. Biotech. 23 : 709 - 717. The self - assembly PEGylated polycation p0lyethylenimine ( PEI ) has also been used to c0ndense and pr0tect siRNAs. Schiffelers et al. 2004 Nucl. Acids Res. 32 : el49 , l4l - l lO. [ 0234 ] The siRNA - containing nanoparticles Were then successfully deliVered to integrin - oVerexpressing tumor neoVasculature. Hu - LieskoVan et al. 2005 Cancer Res. 65 : 8984 - 8992. [ 0235 ] The RNAi agents of the present disclosure can be deliVered Via , for example , Lipid nanoparticles ( LNP ) ; neutral liposomes m L ) ; polymer nanoparticles ; double - stranded RNA binding motifs ( dsRBMs ) ; or Via modiﬁcation of the RNAi agent ( e. g. , coValent attachment to the dsRNA ) . [ 023 6 ] Lipid nanoparticles ( LNP ) are self - assembling cationic lipid based systems. These can comprise , for example , a neutral lipid ( the liposome base ) ; a cationic lipid ( for siRNA loading ) ; cholesterol ( for stabilizing the liposomes ) ; and PEG - lipid ( for stabilizing the formulation , charge shielding and extended circulation in the bloodstream ) . [ 0237 ] The cationic lipid can comprise , for example , a headgroup , a linker , a tail and a cholesterol tail. The LNP can haVe , for example , good tumor deliVery , extended circulation in the blood , small particles ( e. g. , less than lO0 nm ) , and stability in the tumor microenVironment ( Which has loW pH and is hypoxic ) . US 20l2 / 0ll5934 Al. [ 0238 ] Neutral Liposomes ( NL ) are Non - Cationic Lipid Based Particles. [ 0239 ] Polymer nanoparticles are self - assembling polymer - based particles. [ 0240 ] Double - stranded RNA binding motifs ( dsRBMs ) are self - assembling RNA binding proteins , Which Will need modiﬁcations. [ 0241 ] In Various embodiments , the RNAi agent to BetaENaC is ligated to 0ne 0r more diagnostic compound , reporter group , cross - linking agent , nuclease - resistance conferring moiety , natural or unusual nucleobase , lipophilic molecule , cholesterol , lipid , lectin , steroid , uVaol , hecigenin , diosgenin , terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanol - deriVatized lithocholic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate lS - mer , natural polymer , loW - or mediummolecular Weight polymer , inulin , cyclodextrin , hyaluronic acid , protein , protein - binding agent , integrin - targeting molecule , polycationic , peptide , polyamine , peptide mimic , and / or transferrin. [ 0242 ] The RNAi agents of the present discl0sure can be prepared in a pharmaceutical composition comprising Various components appropriate f0r the particular method of administration of the RNAi agent. [ 0243 ] Administration of a RNAi Agent. [ 0244 ] The pharmaceutical composition comprising a Beta - ENaC can be administered by buccal , inhalation ( including insufﬁation and deep inhalation ) , nasal , oral , parenteral , implant , injection or infusion Via epidural , intraarterial , intra - articular , intra - capsular , intra - cardiac , intracerebroVentricular , intracranial , intradermal , intramuscular , intra - orbital , intraperitoneal , intra - spinal , intrastemal , intrathecal , intraVenous , subarachn0id , sub - capsular , subcutaneous , sub - cuticular , transendothelial , transtracheal , transVascular , rectal , sublingual , topical , and / or Vaginal routes. This may be by injection , infusion , dermal patch , or any other method knoWn in the art. The formulation can be poWdered , nebulized , aero solized , granulized or otherWise appropriately prepared for deliVery. The administration , if liquid , may be sloW or Via bolus , though , under some circumstances knoWn in the art , bolus injections may lead to loss of material through the kidneys. [ 0245 ] The pharmaceutical compositions comprising a Beta - ENaC RNAi agent can be administered With medical deVices knoWn in the art. For example , in a particular embodiment , a RNAi agent can be administered With a needle - less hypodermic injection deVice , such as the deVices disclosed in U. S. Pat. No. 5 , 399 , 163 , 5 , 383 , 851 , 5 , 312 , 335 , 5 , 064 , 413 , 4 , 94l , 880 , 4 , 790 , 824 , or 4 , 596 , 556. Examples of WellknoWn implants and modules useful in the present disclosure include : U. S. Pat. No. 4 , 487 , 603 , Which discloses an implantable micro - infusion pump for dispensing medication at a controlled rate ; U. S. Pat. No. 4 , 486 , 194 , Which discloses a therapeutic deVice for administering medications through the skin ; U. S. Pat. No. 4 , 447 , 233 , Which discloses a medication infusion pump for deliVering medication at a precise inﬁ13ion rate ; U. S. Pat. No. 4 , 447 , 224 , Which discl0ses a Variable ﬁoW implantable infusion apparatus for continuous drug deliVery ; U. S. Pat. No. 4 , 439 , l96 , Which discloses an osmotic drug deliVery system haVing multi - chamber compartments ; and U. S. Pat. No. 4 , 475 , l96 , Which discloses an osmotic drug deliVery system. Many other such implants , deliVery systems , and modules are knoWn to those skilled in the art. May 10 , 2012. [ 0246 ] In certain embodiments , the pharmaceutical compositions comprising a RNAi agent can be fom1ulated to ensure proper distribution in ViVo. Administration of a RNAi agent to Beta - ENaC can be systemic ( Whole - body ) or , particularly , targeted to tissues or organs that express ( or oVerexpress or demonstrate a hyper - actiVity of ) Beta - ENaC , such as lung , kidney , colon , and glands. Methods for targeting these particular tissues or organs are described herein , and / or are knoWn in the art. For example , they can be formulated in liposomes. For methods of manufacturing liposomes , see , e. g. , U. S. Pat. Nos. 4 , 522 , 8l l ; 5 , 374 , 548 ; and 5 , 399 , 33l. The liposomes may comprise one or more moieties Which are selectiVely transported into speciﬁc cells or organs , thus. enhance targeted drug deliVery ( see , e. g. , V. V. Ranade ( 1 98 9 ) J. Clin. Pharmacol. 29 : 685 ) . [ 0247 ] Example targeting moieties include folate or biotin ( see , e. g. , U. S. Pat. No. 5 , 4l6 , 0l 6 to LoW et al. ) ; mannosides ( UmezaWa et al. , ( 1988 ) Biochem. Biophys. Res. Commun. 153 : lO38 ) ; antib0dies ( P. G. Bloeman et al. ( 1995 ) FEBS Lett. 357 : l40 ; M. OWais et al. ( l995 ) Antimicrob. Agents Chemother. 39 : l80 ) ; surfactant protein A receptor ( Briscoe et al. ( l995 ) Am. J. Physiol. l233 : l34 ) , different species of Which may comprise the formulations of the present disclosures , as Well as 00mp0nents 0f the inVented molecules ; p120 ( Schreier et al. ( l994 ) J. Biol. Chem. 269 : 9090 ) ; see also K. Keinanen ; M. L. Laukkanen ( l 994 ) FEBS Lett. 346 : l23 ; J. J. Killion ; I. J. Fidler ( 1994 ) Immunomethods 4 : 273. [ 0248 ] The present disclosure thus encompasses pharmaceutical compositions comprising one or more RNAi agents t0 Beta - ENaC , Which can optionally 00mprise Various modi - ﬁcations and / or additional components , for use in treatment of Beta - ENaC - related diseases. [ 0249 ] Beta - ENaC - Related Diseases. [ 0250 ] The present disclosure encompasses RNAi agents to Beta - ENaC and administration of the RNAi agents to humans and non - human animals to treat Various Beta - ENaC - related diseases. [ 0251 ] By “Beta - ENaC - related disease” is meant any disease related to a dysfunction in the leVel , expression and / or actiVity of Beta - ENaC , and / or any disease Which can be treated and / or ameliorated by modulating the leVel , expression and / or actiVity of Beta - ENaC. In particular , it includes cystic ﬁbrosis , pseudohypoald0steronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and obesity - associated hypertension. [ 0252 ] By “cystic ﬁbrosis” or “CF” is meant the common hereditary disease associated With mutations in the cystic ﬁbrosis transmembrane conductance regulator ( CFTR ) gene. CFTR encodes a cAMP - dependent CI - channel and regulates the ENaC. In CF airWay epithelia , CFTR - mediated CI - secretion is defectiVe and ENaC - mediated Na + absorption is increased. These ion transp0rt defects in CF airWays cause airWay surface liquid ( ASL ) Volume depletion , defectiVe mucus clearance , and mucus adhesion , suggesting that ASL Volume depletion is a key mechanism in the pathogenesis of CF lung disease. In experimental mice , airWay - speciﬁc oVerexpression of Beta - ENaC demonstrates that accelerated Na + transport alone is sufﬁcient to produce ASL Volume depletion and CF - like lung disease , including airWay mucus obstruction , goblet cell metaplasia , chronic neutrophilic airWay inﬁammation , impaired clearance of bacterial pathogens , and ultimately mortality. See Zhou et al. 2008 , and references cited therein. US 20l2 / 0ll5934 Al. [ 0253 ] By “Liddles syndrome” is meant an autosomal dominant hereditary fonn of hypertension , characterized by an early and seVere hypertension , often accompanied by metabolic alkalosis and hypokalemia , all signs that are characteristic of an excess of aldoster0ne ( Conn ' s syndrome ) . [ 0254 ] The plasma leVels of ald0sterone are loW , hoWeVer. Thus , Liddles syndrome is also called pseudoaldosteronism. This seVere fo1m of hypertension is responsiVe to treatment With a loW - salt diet and Na + channel inhibitors ( K + - sparing diuretics ) , suggesting a primary defectiVe regulation of the ENaC. The disease is related to mutations in Gamma - ENaC , and also seVeral mutations in Beta - ENaC ( P6 1 5 S , P6 1 6L , and Y618H in the “PY” motif Which has a consensus sequence of PPXY ; and also R564st , W574st , 579de132 , Q589st , T592fr , A5 93fr , and R595fr , Where “fr” is a frameshift , “del” is a deletion , and “st” is a premature stop codon ) . [ 0255 ] These mutations cause an oVerexpression of the Na + channels that are hyperactiVe compared to the Wild - type ENaC. The mutations also preVent the doWnregulation of the channel that normally 000urs With a rise in intracellular Na ' ; ENaC channels With the Liddles mutation remain in a highly actiVe state despite a high intracellular Na + concentration. Thus , the leVel and / or actiVity of a mutated ENaC With Liddles Syndrome can be modulated by a siRNA to Beta - ENaC , or such a siRNA in combination With knoWn treatments for Liddles syndrome , such as a loW - salt diet , and Na + channel inhibitors ( K + - sparing diuretic s ) . [ 0256 ] For additional information on Beta - ENaC - related diseases , see , for example , Hummler et al. 1999. Am. J. Physiol. Gastrointest. LiVer Physiol. 276 : 567 - 571. [ 0257 ] By “obesity - associated hypertension” is meant hypertension related or ass0ciated With 0besity , and the like. Obesity is associated With hypertension. Multiple mechanisms haVe been proposed to explain this correlation , including ( in the obese ) increased sympathetic actiVity ; increased actiVity of the renin - angiotensin - aldosterone system ; increased cardiac output ; and increased mechanical pressure from interstitial fat around organs , hyperinsulinemia , and / or insulin resistance. Sodium retention by the kidney could result from any of these mechanisms. In the connecting tubule and the collecting duct , sodium reabsorption occurs through the ENaC. LeVels of Beta - ENaC Were increased in the kidney in Zucker rats ( a model animal for obesity ) . [ 0258 ] Bickel et al. 200l Am. J. Physiol. Renal Physiol. 28 l : 639 - 648. The relatiVe increases in abundance of this and other sodium transporters , Without decreases in the other sodium transporters , likely results in enhanced tubular sodium reabsorption. As a result , these alterations in renal sodium transporter abundance might play a role in the deVelopment and / or maintenance of eleVated blood pressures in obese mammals , including humans. [ 0259 ] By “pseudohypoaldosteronism type l” , “PHA1” , “PHA - 1” and the like is meant a heterologous clinical syn - dr0me characterized by mineralocortic0id end 0rgan resistance , i. e. , urinary loss of Na + and reduced K + excretion despite an eleVated leVel of aldosterone. A seVere form of this syndrome is inherited as an autosomal recessiVe trait , resulting in sometimes lethal episodes of hyponatremia , hypotension , and hyperkalemia , and shoWs alteration of Na + transport in seVeral organs , kidney , saliVary glands , sWeat glands , and colon. In seVeral families shoWing this form of PHA - l , links to mutations in any one of the three ENaC subunits are found ( including G37S in Beta - ENaC ) . May 10 , 2012. [ 0260 ] A less seVere form of PHA - l With an autosomal dominant mode of inheritance is symptomatic mostly during infancy and improVes With age. See Hummler et al. 1999 . Am. J. Physiol. Gastrointest. LiVer Physiol. 276 : 567 - 57l. [ 0261 ] RNAi agents to Beta - ENaC can be used to treat Beta - ENaC - related diseases , particularly tho se diseases as sociated With altered expression , actiVity and / or leVels of BetaENaC. [ 0262 ] Use of RNAi Agents for Treatment of Beta - ENaCRelated Diseases. [ 0263 ] The RNAi agents to Beta - ENaC described herein can be formulated into pharmaceutical 00mpositions Which can be administered to humans or non - human animals. These compositi0ns can comprise one or more RNAi agents , and , optionally , additional treatments useful for treating BetaENaC - related diseases. They can be administered as part of an early / preVentatiVe treatment , and can be administered in a therapeutically - effectiVe dosage. The pharmaceutical composition can comprise a pharmaceutical carrier and can be administered by any method kn0Wn in the art. These Various aspects of the present disclosure are described in additional detail beloW. [ 0264 ] RNAi agents to Beta - ENaC can be administered to humans and non - human animals for treatment of Beta - ENaCrelated diseases. [ 0265 ] In one embodiment of the present discl0sure , the compositions comprising a Beta - ENaC RNAi agent can be administered to non - human animals. F0r example , the compositions can be giVen to chickens , turkeys , liVestock animals ( such as sheep , pigs , horses , cattle , etc. ) , companion animals ( e. g. , cats and dogs ) and can haVe efﬁcacy in treatment of cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkal0sis , hypokalemia , and obesity - ass0ciated hypertension and similar diseases. In each case , the RNAi agent to Beta - ENaC Would be selected to match the sequence of the Beta - ENaC of the genome of the animal , and to , particularly , contain at least 1 nt mismatch from all other genes in that animals genome. The RNAi agents of the present disclosure can thus be used in treatment of Beta - ENaC - related diseases in humans and non - human animals. [ 0266 ] As used herein in the context of Beta - ENaC expression , the terms “treat , ” “treatment , ” and the like , refer to relief from 0r alleViation 0f path0logical processes mediated by Beta - ENaC expressi0n. In the context of the present disclosure insofar as it relates to any of the other conditions recited herein beloW ( other than pathological processes mediated by Beta - ENaC expression ) , the terms “treat , ” “treatment , ” and the like mean to relieVe or alleViate at least one symptom associated With such condition , or to sloW or reVerse the progression or anticipated progression of such condition , such as sloWing the progression of a lipid disorder , such as atherosclerosis. [ 0267 ] By “treatment” is also meant prophylaxis , therapy , cure , or any other change in a patients conditi0n indicating improVement or absence of degradation of physical condition. By “treatment” is meant treatment of Beta - ENaC - related disease ( e. g. , cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHA1 ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and obesity - associated hypertension ) , or any appropriate treatment of any other ailment the patient has. As used herein , the terms “treatment” and “treat” refer to both prophylactic and preVentatiVe treatment and curatiVe or disease - modifying treatment , including treatment of patients at. US 20l2 / 0ll5934 Al. risk of contracting a disease or suspected ofhaVing a disease , as Well as patients already ill or diagnosed as suffering from a condition. The terms “treatment” and “treat” also refer to the maintenance and / 0r promotion of health in an indiVidual not suffering from a disease but Who may be susceptible to deVeloping an unhealthy condition , such as nitrogen imbalance or muscle loss. In one embodiment , “treatment” does not encompass preVention of a disease state. Thus , the present disclosure is useful for suppressing expression of the BetaENaC gene and / or treating a Beta - ENaC - related disease in an indiVidual afﬁicted by a Beta - ENaC - related disease , or an indiVidual susceptible to a Beta - ENaC - related disease. An indiVidual “afﬁicted” by a Beta - ENaC - related disease has demonstrated detectable sympt0ms characteristics of the disease , or had otherWise been shoWn clinically to haVe been exposed to or to carry Beta - ENaC - related disease pathogens or markers. As n0n - limiting examples , an indiVidual afﬁicted by a Beta - ENaC - related disease can shoW outWard symp - t0ms ; or can shoW no outWard symptoms but can be shoWn With a clinical test to carry protein markers associated With a Beta - ENaC - related disease , or pr0teins 0r genetic material associated With a pathogen in the blood. [ 0268 ] Early treatment of some Beta - ENaC - related diseases may be more efﬁcacious if administered early rather than later. PreVentatiVe early administration of amiloride ( an ENaC inhibitor ) Was useful in treating CF model mice , While later administration Was not. Similarly , early interVenti0n With antimicrobial agents in CF Was m0re effectiVe than treatment after infection Was established. Zhou et al. 2008. Thus , in one particular embodiment , the RNAi agent to BetaENaC is administered early , prior to disease manifestation , and / or as a preVentatiVe agent , rather than administered after disease establishment. [ 0269 ] Treatments of Beta - ENaC - related diseases can comprise Various treatments , comprising a Beta ENaC RNAi agent , and optionally further comprising an additional treatment , Which can be a method ( or procedure ) , or an additional c0mposition ( e. g. , an agent or additional RNAi agent ) . [ 0270 ] Dosages and EffectiVe Amounts of RNAi Agents. [ 0271 ] The RNAi agents of the present disclosure are administered in a dosage of a therapeutically effectiVe amount to a patient in need thereof. [ 0272 ] An “effectiVe amount” or a “therapeutically effectiVe amount” is an amount that treats a disease or medical c0ndition of an indiVidual , or , more generally , proVides a nutritional , physiological or medical beneﬁt to an indiVidual. As used herein , the phrases “therapeutically effectiVe amount” and “prophylactically effectiVe amount” refer to an amount that proVides a therapeutic beneﬁt in the treatment , preVention , or management of pathological processes mediated by Beta - ENaC expression or an oVert symptom of pathological processes mediated by Beta - ENaC expression. The speciﬁc amount that is therapeutically effectiVe can be readily determined by an ordinary medical practitioner , and may Vary depending on factors kn0Wn in the art , such as , for example , the type of pathological processes mediated by Beta - ENaC expression , the patients history and age , the stage of pathological processes mediated by Beta - ENaC expression , and the administration of other agents that inhibit pathological pr0cesses mediated by Beta - ENaC expression. [ 0273 ] In Various embodiments of the present disclosure , . the patient is at least about l , 3 , 6 , or 9 months , or l , 5 , lO , 20 , 30 , 40 , 50 , 55 , 60 , 65 , 70 , or 75 years of age. In Various. embodiments , the patient is no more than about 1 , 3 , 6 , or 9. May 10 , 2012. months , or l , 5 , lO , 20 , 30 , 40 , 50 , 55 , 60 , 65 , 70 , 75 , 80 , 90 , or 100 years of age. In Various embodiments the patient has a body Weight ofat least about 5 , 10 , 15 , 20 , 30 , 40 , 50 , 60 , 70 , 80 , 90 , lO0 , l20 , l40 , l60 , l80 , 200 , 220 , 240 , 260 , 280 , 300 , 320 , 340 , 360 , 380 or 400 lbs. In Various embodiments , the patient has a body Weight 0f no more than about 5 , 10 , 15 , 20 , 30 , 40 , 50 , 60 , 70 , 80 , 90 , 100 , 120 , 140 , 160 , 180 , 200 , 220 , 240 , 260 , 280 , 300 , 320 , 340 , 360 , 380 or 400 lbs. [ 0274 ] In Various embodiments of the present disclosure , the dosage [ measuring only the actiVe ingredient ( s ) ] can be at least about 1 , 5 , 10 , 25 , 50 , 100 , 200 , 250 , 300 , 250 , 400 , 450 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 or 1000 ng , 1 , 5 , 10 , 25 , 50 , 100 , 200 , 250 , 300 , 250 , 400 , 450 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 or lO00 micrograms , l , 5 , lO , 25 , 50 , lO0 , 200 , 250 , 300 , 250 , 400 , 450 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 or 1000 mg. In Various embodiments , the dosage can be no more than about 10 , 25 , 50 , 100 , 200 , 250 , 300 , 250 , 400 , 450 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 or lO00 mg. In Various embodiments , the dosage can be administered at least more than once a day , daily , more than once a Weekly , Weekly , bi - Weekly , monthly , and / or eVery 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 or 12 months , or a combination thereof. [ 0275 ] In Various embodiments , the dosage is correlated to the body Weight or body surface area 0f the indiVidual. The actual do sage leVel can be Varied to obtain an amount of actiVe agent Which is effectiVe for a particular patient , composition and mode 0f administration , Without being toxic to the patient. The selected dose Will depend on a Variety of pharmacokinetic fact0rs , including the actiVity of the particular RNAi agent employed , the route of administration , the rate of excretion of the RNAi agent , the duration of the treatment , other drugs , compounds and / 0r materials used in combination With the RNAi agent , the age , sex , Weight , conditi0n , general health and prior medical history of the patient , and like factors Well knoWn in the medical arts. A physician or Veterinarian haVing ordinary skill in the art can readily determine the effectiVe amount of the RNAi agent required. A suitable dose Will be that amount Which is the loWest dose effectiVe to produce a therapeutic effect , or a dose loW enough to produce a therapeutic effect Without causing side effects. [ 0276 ] In addition to a therapeutically - effectiVe dosage of one or more RNAi agents to Beta - ENaC , the pharmaceutical compositi0ns of the present disclosure can comprise or be used in conjunction With an additional disease treatment Which Works synergistically With the RNAi agent. For example , the pharmaceutical composition can comprise an additional antagonist to ENaC , such as potassium - sparing diuretics , amil0ride and triamterene. Additional treatments can be administered along With the pham1aceutical composition , including , as a non - limiting example , regulation of dietary salt intake. When used to treat cystic ﬁbrosis , the pharmaceutical composition can be used in conjunction With Various medicaments and therapies knoWn in the art , including , but not limited to , antibiotics , DNase therapy , albutrol , N - acetylcysteine , breathing therapy , percussiVe therapy , aerobic exercise , and Various medicaments and therapies to treat ailments associated With cystic ﬁbrosis ( e. g. , diarrhea , osteopor0sis , diabetes , bleeding , etc. ) . [ 0277 ] Additional Embodiments of RNAi Agents to BetaENaC. [ 0278 ] In a particular embodiment , the present disclosure encompasses a composition comprising one or more BetaENaC RNAi agents. In one embodiment , the present disclo - . US 20l2 / 0ll5934 Al. sure comprises a RNAi agent comprising a sense strand and an antisense strand. In one embodiment , the antisense strand consists of , consists essentially of , or comprises the sequence of the antisense strand of a RNAi agent listed , e. g. , in Table l . In one embodiment , the antisense strand consists of , consists essentially of , or comprises a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of any RNAi agent listed , e. g. , in Table l . In one embodiment , the antisense strand consists of the sequence of the antisense strand of a RNAi agent listed , e. g. , in Table 1 , and further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nucleotides. In one embodiment , the antisense strand consists of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of a RNAi agent listed , e. g. , in Table l , and further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nucleotides. [ 0279 ] In another embodiment , the composition of the claimed disclosure does not comprise any particular indiVidual RNAi agent listed , e. g. , in Table 1. In another embodiment of the present disclosure , the RNAi agent to Beta - ENaC does not comprise a sequence of any Beta - ENaC RNAi agent disclosed in the patent or scientiﬁc literature , e. g. , U. S. Patent App. No. 60 / 346 , 069 ( PCT / US02 / 4l850 ) , and Hyde et al. 2009 , The 23m North American Cystic Fibrosis Conference , Minneapolis , Oct. 14 - 17 , 2009 ; or that aVailable as sc - 42418 ( and related products ) from Santa Cruz Biotechnology , Santa Cruz , Calif. [ 0280 ] Speciﬁc Embodiments of RNAi Agents to BetaENaC. [ 0281 ] Various speciﬁc embodiments of a RNAi agent to Beta - ENaC are disclosed herein. Example duplex sequences are proVided herein and , e. g. , in Table l. Speciﬁc embodiments of the present disclosure include RNAi agents Which comprise sequences differing by 0 , 1 , 2 , or 3 nt or by ( e. g. , With 0 , 1 , 2 or 3 mismatches ) from those of the RNAi agents listed , e. g. , in Table l. [ 0282 ] A mismatch is deﬁned herein as a difference betWeen the base sequence or length When tWo sequences are maximally aligned and compared. A mismatch is deﬁned as a position Wherein the base of one sequence does not match the base of the other sequence. Thus , a mismatch is counted , for example , if a position in 0ne sequence has a particular base ( e. g. , A ) , and the corresponding position on the 0ther sequence has a different base ( e. g. , G ) . [ 0283 ] sequence has a base ( e. g. , A ) , and the corresponding position on the other sequence has no base ( e. g. , that position is an abasic nucleotide Which comprises a phosphate - sugar backbone but no base ) . A single - stranded nick in either sequence ( or in the sense or antisense strand ) is not counted as mismatch. Thus , as a non - limiting example , no mismatch Would be counted if one sequence comprises the sequence AG , but the other sequence comprises the sequence AG With a singlestranded nick betWeen the A and the G. A base modiﬁcation is also not considered a mismatch. Thus , if one sequence comprises a C , and the other sequence comprises a modiﬁed C ( e. g. , 2 ' - modiﬁcation ) at the same position , no mismatch Would be counted. A mismatch is also counted , e. g. , if a position in one. [ 0284 ] In one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20807 ( SEQ ID NOs : 5 and 6 , or SEQ ID NOs : 115 and 116 ) . May 10 , 2012. [ 0285 ] In another particular embodiment , the siRNA also further comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand of AD - 20807. [ 0286 ] In another particular embodiment , the siRNA comprises AD - 20807. [ 0287 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20807. [ 0288 ] In one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of : AD - 20826 ( SEQ ID NOs : 43 and 44 , or SEQ ID NOs : l53 and lS4 ) . [ 0289 ] In another particular embodiment , the siRNA also ﬁ1rther comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand 0f AD - 20826. [ 0290 ] In another particular embodiment , the siRNA comprises AD - 20826. [ 0291 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20626. [ 0292 ] In one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of : AD - 20832 , Which comprises SEQ ID NOs : 55 and 56 , or SEQ ID NOs : l 65 and 166. [ 0293 ] In another particular embodiment , the siRNA also ﬁ1rther comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand of AD - 20832. [ 0294 ] In another particular embodiment , the siRNA comprises AD - 20832. [ 0295 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20832. [ 0296 ] In one particular embodiment , the present disclosure comprises a RNAi agent c0mprising a antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20834 , Which comprises SEQ ID NOs : 59 and 60 , or SEQ ID NOs : 169 and l70. [ 0297 ] In another particular embodiment , the siRNA also ﬁ1rther comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand of AD - 20834. [ 0298 ] In another particular embodiment , the siRNA comprises AD - 20834. [ 0299 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20834. [ 0300 ] In one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of : AD - 20848 , Which comprises SEQ ID NOs : 87 and 88 , or SEQ ID NOs : l 97 and l98. [ 03 01 ] In another particular emb0diment , the siRNA also further comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand of AD - 20848. [ 03 02 ] In another particular embodiment , the siRNA comprises AD - 20848. [ 03 03 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20848. US 20l2 / 0ll5934 Al. [ 0304 ] In one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of : AD - 2086l , Which comprises SEQ ID NOs : 97 and 98 , or SEQ ID NOs : 207 and 208. [ 0305 ] In another particular embodiment , the siRNA also further comprises a sense strand comprising at least 15 con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand of AD - 2086l. [ 03 06 ] In another particular embodiment , the siRNA comprises AD - 2086l. [ 03 07 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 2086l. [ 0308 ] In one embodiment , the present disclosure comprises a RNAi agent demonstrating at least about 80% knockdoWn ( no more than about 20% residual gene actiVity ) of the Beta - ENaC gene at an in Vitro concentration of lO nM in H441 cells. [ 0309 ] Thus , in one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; or AD - 20834. [ 0310 ] In another particular embodiment , the siRNA also further comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; or AD - 20834. [ 0311 ] In another particular embodiment , the siRNA comprises AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; or AD - 20834. [ 0312 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; or AD - 20834. [ 0313 ] In one embodiment , the present disclosure comprises a RNAi agent demonstrating at least about 70% knockdoWn ( no more than about 30% residual gene actiVity ) of the Beta - ENaC gene at an in Vitro concentration of lO nM in H441 cells. [ 0314 ] Thus , in one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; AD - 20834 ; AD - 20806 ; AD - 2085l ; AD - 20865 ; AD - 208ll ; AD - 208l9 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; or AD - 20867. [ 0315 ] In another particular embodiment , the siRNA also further comprises a sense strand comprising at least 15 con - ti guous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; AD - 20834 ; AD - 20806 ; AD - 2085l ; AD - 20865 ; AD - 208ll ; AD - 208l9 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; or AD - 20867. [ 0316 ] In another particular embodiment , the siRNA comprises AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; or AD - 20867. [ 0317 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20832 ; AD - 20848 ; . May 10 , 2012. AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; or AD - 20867. [ 0318 ] In one emb0diment , the present disclosure comprises a RNAi agent demonstrating at least about 60% knock - d0Wn ( n0 more than about 40% residual gene actiVity ) of the Beta - ENaC gene at an in Vitro concentration of lO nM in H44l cells. [ 0319 ] Thus , in one particular embodiment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 2085l ; AD - 20865 ; AD - 208l1 ; AD - 208l9 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 20813 ; AD - 20823 ; AD - 20805 ; AD - 20831 ; AD - 20862 ; AD - 20808 ; or AD - 20827. [ 0320 ] In another particular embodiment , the siRNA also ﬁ1rther comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 20813 ; AD - 20823 ; AD - 20805 ; AD - 20831 ; AD - 20862 ; AD - 20808 ; or AD - 20827. [ 0321 ] In another particular embodiment , the siRNA comprises : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 208l1 ; AD - 208l9 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 208l3 ; AD - 20823 ; AD - 20805 ; AD - 20831 ; AD - 20862 ; AD - 20808 ; or AD - 20827. [ 0322 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 208l3 ; AD - 20823 ; AD - 20805 ; AD - 2083l ; AD - 20862 ; AD - 20808 ; orAD - 20827. [ 0323 ] In one embodiment , the present disclosure comprises a RNAi agent demonstrating at least about 50% knockdoWn ( no more than about 50% residual gene actiVity ) of the. Beta - ENaC gene at an in Vitro concentration of 10 nM in H441 cells. [ 0324 ] Thus , in one particular emb0diment , the present disclosure comprises a RNAi agent comprising a antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 2085l ; AD - 20865 ; AD - 208ll ; AD - 208l9 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 208l3 ; AD - 20823 ; AD - 20805 ; AD - 2083l ; AD - 20862 ; AD - 20808 ; AD - 20827 ; AD - 20828 ; AD - 20812 ; AD - 20836 ; orAD - 20822. [ 0325 ] In another particular emb0diment , the siRNA als0 ﬁ1rther comprises a sense strand comprising at least lS con - ti guous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 208l3 ; AD - 20823 ; AD - 20805 ; AD - 2083l ; AD - 20862 ; AD - 20808 ; AD - 20827 ; AD - 20828 ; AD - 20812 ; AD - 20836 ; or AD - 20822. [ 0326 ] In another particular embodiment , the siRNA comprises AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; . US 20l2 / 0ll5934 Al. AD - 20837 ; AD - 2086l ; AD - 20834 ; AD - 20806 ; AD - 2085l ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 20813 ; AD - 20823 ; AD - 20805 ; AD - 2083l ; AD - 20862 ; AD - 20808 ; AD - 20827 ; AD - 20828 ; AD - 208l2 ; AD - 20836 ; or AD - 20822. [ 03 27 ] In another particular embodiment , the siRNA has a sequence consisting of that of AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 2086l ; AD - 20834 ; AD - 20806 ; AD - 20851 ; AD - 20865 ; AD - 20811 ; AD - 20819 ; AD - 20839 ; AD - 20835 ; AD - 20825 ; AD - 20867 ; AD - 20813 ; AD - 20823 ; AD - 20805 ; AD - 20831 ; AD - 20862 ; AD - 20808 ; . AD - 20827 ; AD - 20828 ; AD - 208l2 ; AD - 20836 ; or AD - 20822. [ 0328 ] Various Embodiments of a RNAi Agent to Beta - . ENaC. [ 0329 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand 0f AD - 20805. [ 0330 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20806. [ 0331 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20807. [ 0332 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand c0mprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20808. [ 0333 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20809. [ 0334 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20810. [ 0335 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 208 1 1. [ 0336 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20812. 25. May 10 , 2012. [ 0337 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand ofAD - 20813. [ 0338 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 208l4. [ 0339 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand ofAD - 20815. [ 0340 ] In one emb0diment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand ofAD - 20816. [ 0341 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 208l7. [ 0342 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 208l8. [ 0343 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand ofAD - 20819. [ 0344 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20820. [ 0345 ] In one emb0diment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 2082l. [ 0346 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20822. [ 0347 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at. US 20l2 / 0ll5934 Al. least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20823. [ 0348 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand c0mprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20824. [ 0349 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20825. [ 0350 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand 0f AD - 20826. [ 0351 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand c0mprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20827. [ 0352 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20828. [ 0353 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand 0f AD - 20829. [ 0354 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20830. [ 0355 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 2083l. [ 0356 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20832. [ 0357 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand 0f AD - 20833. [ 0358 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at. May 10 , 2012. least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20834. [ 0359 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20835. [ 0360 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20836. [ 0361 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20837. [ 0362 ] In one emb0diment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20838. [ 0363 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20839. [ 0364 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20840. [ 0365 ] In one emb0diment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 2084l. [ 0366 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20842. [ 0367 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20843. [ 0368 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20844. US 20l2 / 0ll5934 Al. [ 0369 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand 0f AD - 20845. [ 0370 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20846. [ 0371 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20847. [ 0372 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand c0mprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20848. [ 0373 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20849. [ 0374 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20850. [ 0375 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20851. [ 0376 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20852. [ 0377 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand 0f AD - 2086l. [ 0378 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20862. [ 0379 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at. May 10 , 2012. least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20863. [ 0380 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20864. [ 0381 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of AD - 20865. [ 0382 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20866. [ 0383 ] In one embodiment , the present disclosure comprises a RNAi agent comprising a sense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the sense strand and / or an antisense strand comprising at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of AD - 20867. [ 0384 ] Various Embodiments of a RNAi Agent to BetaENaC. [ 0385 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20805 , Which comprises SEQ ID NOs. 111 - 112 , and modiﬁed Variants thereof. [ 0386 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS c0ntiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20806 , Which comprises SEQ ID NOs. ll3 - l l4 , and modiﬁed Variants thereof. [ 03 87 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense strand of : AD - 20807 , . Which comprises SEQ ID NOs. llS - l l6 , and modiﬁed Variants thereof. [ 03 88 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS c0ntiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20808 , Which comprises SEQ ID NOs. ll7 - l l8 , and modiﬁed Variants thereof. [ 03 89 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20809 , Which comprises SEQ ID NOs. 119 - 120 , and m0diﬁed Variants thereof. US 20l2 / 0ll5934 Al. [ 0390 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 208l0 , Which comprises SEQ ID NOs. 121 - 122 , and modiﬁed Variants thereof. [ 0391 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides fr0m the antisense strand of : AD - 2081l , Which comprises SEQ ID NOs. 123 - 124 , and modiﬁed Variants thereof. [ 03 92 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand 00mprises at least 15 contiguous nucle0tides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20812 , Which comprises SEQ ID NOs. l25 - l26 , and modiﬁed Variants thereof. [ 03 93 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 208l3 , Which comprises SEQ ID NOs. 127 - 128 , and modiﬁed Variants thereof. [ 03 94 ] In one embodiment , the present disclosure relates to a compositi0n comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20814 , Which comprises SEQ ID NOs. 129 - 130 , and modiﬁed Variants thereof. [ 03 95 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20815 , Which comprises SEQ ID NOs. l3l - l32 , and modiﬁed Variants thereof. [ 0396 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 208l6 , . Which comprises SEQ ID NOs. l33 - l34 , and modiﬁed Variants thereof. [ 03 97 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 208l7 , Which comprises SEQ ID NOs. l35 - l36 , and modiﬁed Variants thereof. [ 03 98 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 208l8 , Which comprises SEQ ID NOs. 137 - 138 , and modiﬁed Variants thereof. May 10 , 2012. [ 03 99 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 208l9 , Which comprises SEQ ID NOs. 139 - 140 , and m0diﬁed Variants thereof. [ 0400 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , 0r 3 nucle0tides from the antisense strand of : AD - 20820 , Which comprises SEQ ID NOs. 141 - 142 , and m0diﬁed Variants thereof. [ 0401 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20821 , Which comprises SEQ ID NOs. l43 - l44 , and m0diﬁed Variants thereof. [ 0402 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20822 , Which comprises SEQ ID NOs. 145 - 146 , and modiﬁed Variants thereof. [ 0403 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20823 , Which comprises SEQ ID NOs. 147 - 148 , and modiﬁed Variants thereof. [ 0404 ] In one embodiment , the present disclosure relates t0 a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20824 , Which comprises SEQ ID NOs. l49 - l 50 , and m0diﬁed Variants thereof. [ 0405 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense strand of : AD - 20825 , . Which comprises SEQ ID NOs. lS l - l 52 , and modiﬁed Variants thereof. [ 0406 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS c0ntiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20826 , Which comprises SEQ ID NOs. lS3 - l 54 , and modiﬁed Variants thereof. [ 0407 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20827 , Which comprises SEQ ID NOs. 155 - 156 , and m0diﬁed Variants thereof. US 20l2 / 0ll5934 Al. [ 0408 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20828 , Which comprises SEQ ID NOs. 157 - 158 , and modiﬁed Variants thereof. [ 0409 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides fr0m the antisense strand of : AD - 20829 , Which comprises SEQ ID NOs. 159 - 160 , and modiﬁed Variants thereof. [ 0410 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand 00mprises at least 15 contiguous nucle0tides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20830 , Which comprises SEQ ID NOs. l6l - l 62 , and modiﬁed Variants thereof. [ 0411 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 2083l , Which comprises SEQ ID NOs. 163 - 164 , and modiﬁed Variants thereof. [ 0412 ] In one embodiment , the present disclosure relates to a compositi0n comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20832 , Which comprises SEQ ID NOs. 165 - 166 , and modiﬁed Variants thereof. [ 0413 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20833 , Which comprises SEQ ID NOs. l67 - l 68 , and modiﬁed Variants thereof. [ 0414 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20834 , . Which comprises SEQ ID NOs. l69 - l70 , and modiﬁed Variants thereof. [ 0415 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20835 , Which comprises SEQ ID NOs. l7l - l72 , and modiﬁed Variants thereof. [ 0416 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20836 , Which comprises SEQ ID NOs. 173 - 174 , and modiﬁed Variants thereof. May 10 , 2012. [ 0417 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20837 , Which comprises SEQ ID NOs. 175 - 176 , and m0diﬁed Variants thereof. [ 0418 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , 0r 3 nucle0tides from the antisense strand of : AD - 2083 8 , Which comprises SEQ ID NOs. 177 - 178 , and m0diﬁed Variants thereof. [ 0419 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 2083 9 , Which comprises SEQ ID NOs. l79 - l 80 , and m0diﬁed Variants thereof. [ 0420 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20840 , Which comprises SEQ ID NOs. 181 - 182 , and modiﬁed Variants thereof. [ 0421 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20841 , Which comprises SEQ ID NOs. 183 - 184 , and modiﬁed Variants thereof. [ 0422 ] In one embodiment , the present disclosure relates t0 a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20842 , Which comprises SEQ ID NOs. l85 - l 86 , and m0diﬁed Variants thereof. [ 0423 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense strand of : AD - 20843 , . Which comprises SEQ ID NOs. lS7 - l 88 , and modiﬁed Variants thereof. [ 0424 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS c0ntiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20844 , Which comprises SEQ ID NOs. l89 - l 90 , and modiﬁed Variants thereof. [ 0425 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20845 , Which comprises SEQ ID NOs. 191 - 192 , and m0diﬁed Variants thereof. US 20l2 / 0ll5934 Al. [ 0426 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20846 , Which comprises SEQ ID NOs. 193 - 194 , and modiﬁed Variants thereof. [ 0427 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides fr0m the antisense strand of : AD - 20847 , Which comprises SEQ ID NOs. 195 - 196 , and modiﬁed Variants thereof. [ 0428 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand 00mprises at least 15 contiguous nucle0tides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20848 , Which comprises SEQ ID NOs. l97 - l 98 , and modiﬁed Variants thereof. [ 0429 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20849 , Which comprises SEQ ID NOs. 199 - 200 , and modiﬁed Variants thereof. [ 0430 ] In one embodiment , the present disclosure relates to a compositi0n comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20850 , Which comprises SEQ ID NOs. 201 - 202 , and modiﬁed Variants thereof. [ 0431 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 2085l , Which comprises SEQ ID NOs. 203 - 204 , and modiﬁed Variants thereof. [ 043 2 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20852 , . Which comprises SEQ ID NOs. 205 - 206 , and modiﬁed Variants thereof. [ 043 3 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 2086l , Which comprises SEQ ID NOs. 207 - 208 , and modiﬁed Variants thereof. [ 043 4 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20862 , Which comprises SEQ ID NOs. 209 - 210 , and modiﬁed Variants thereof. May 10 , 2012. [ 0435 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20863 , Which comprises SEQ ID NOs. 211 - 212 , and m0diﬁed Variants thereof. [ 043 6 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of : AD - 20864 , Which comprises SEQ ID NOs. 2l3 - 2l4 , and modiﬁed Variants thereof. [ 0437 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20865 , Which comprises SEQ ID NOs. 2l 5 - 2l 6 , and m0diﬁed Variants thereof. [ 0438 ] In one embodiment , the present disclosure relates to a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 00ntiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of : AD - 20866 , Which comprises SEQ ID NOs. 2l7 - 2l 8 , and m0diﬁed Variants thereof. [ 0439 ] In one embodiment , the present disclosure relates to a composition c0mprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense strand of : AD - 20867 , Which comprises SEQ ID NOs. 2l 9 - 220 , and m0diﬁed Variants thereof. [ 0440 ] Various Embodiments of a RNAi Agent to BetaENaC. [ 0441 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20805 , Which comprises SEQ ID NOs. 111 and 112. [ 0442 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand c0mprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20806 , Which comprises SEQ ID NOs.113 and 114. [ 0443 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20807 , Which comprises SEQ ID NOs. llS and ll6. [ 0444 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20808 , Which comprises SEQ ID NOs. ll7 and llS. [ 0445 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15. US 20l2 / 0ll5934 Al. contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20809 , Which comprises SEQ ID NOs.119 and 120. [ 0446 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 208l0 , Which comprises SEQ ID NOs. 121 and 122. [ 0447 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 00ntiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20811 , Which comprises SEQ ID NOs. l23 and l24. [ 0448 ] In one embodiment , the 00mp0sition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20812 , Which comprises SEQ ID NOs. 125 and 126. [ 0449 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 208l3 , Which comprises SEQ ID NOs. 127 and 128. [ 0450 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20814 , Which c0mprises SEQ ID NOs. l29 and l30. [ 0451 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 208l5 , Which comprises SEQ ID NOs. 131 and 132. [ 0452 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 208l6 , Which comprises SEQ ID NOs. l33 and l34. [ 0453 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20817 , Which comprises SEQ ID NOs.135 and 136. [ 0454 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20818 , Which comprises SEQ ID NOs.137 and 138. [ 0455 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20819 , Which comprises SEQ ID NOs.139 and 140. May 10 , 2012. [ 0456 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20820 , Which comprises SEQ ID NOs. 141 and 142. [ 0457 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 2082l , Which comprises SEQ ID NOs. l43 and l44. [ 0458 ] In one embodiment , the 00mpositi0n comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20822 , Which comprises SEQ ID NOs. 145 and 146. [ 0459 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20823 , Which comprises SEQ ID NOs. l47 and l48. [ 0460 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20824 , Which comprises SEQ ID NOs. l49 and lS0. [ 0461 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20825 , Which comprises SEQ ID NOs. 151 and 152. [ 0462 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20826 , Which comprises SEQ ID NOs. lS3 and lS4. [ 0463 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20827 , Which comprises SEQ ID NOs.155 and 156. [ 0464 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 nucleotides from the antisense strand of : AD - 20828 , Which comprises SEQ ID NOs. lS7 and lS8. [ 0465 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 nucleotides from the antisense strand of : AD - 20829 , Which comprises SEQ ID NOs. lS9 and l60. [ 0466 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15. US 20l2 / 0ll5934 Al. contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20830 , Which comprises SEQ ID NOs. 161 and 162. [ 0467 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 2083l , Which comprises SEQ ID NOs. 163 and 164. [ 0468 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 00ntiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20832 , Which comprises SEQ ID NOs. l65 and l66. [ 0469 ] In one embodiment , the 00mp0sition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20833 , Which comprises SEQ ID NOs. 167 and 168. [ 0470 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20834 , Which comprises SEQ ID NOs. 169 and 170. [ 0471 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20835 , Which c0mprises SEQ ID NOs. l7l and l72. [ 0472 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20836 , Which comprises SEQ ID NOs. 173 and 174. [ 0473 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20837 , Which comprises SEQ ID NOs. l75 and l76. [ 0474 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20838 , Which comprises SEQ ID NOs. 177 and 178. [ 0475 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20839 , Which comprises SEQ ID NOs. 179 and 180. [ 0476 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20840 , Which comprises SEQ ID NOs. 181 and 182. May 10 , 2012. [ 0477 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 2084l , Which comprises SEQ ID NOs. 183 and 184. [ 0478 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20842 , Which comprises SEQ ID NOs. l85 and l86. [ 0479 ] In one embodiment , the 00mpositi0n comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20843 , Which comprises SEQ ID NOs. 187 and 188. [ 0480 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20844 , Which comprises SEQ ID NOs. l89 and l90. [ 0481 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20845 , Which comprises SEQ ID NOs. l9l and l92. [ 0482 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20846 , Which comprises SEQ ID NOs. 193 and 194. [ 0483 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20847 , Which comprises SEQ ID NOs. l95 and l96. [ 0484 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20848 , Which comprises SEQ ID NOs. 197 and 198. [ 0485 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 nucleotides from the antisense strand of : AD - 20849 , Which comprises SEQ ID NOs. l99 and 200. [ 0486 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 nucleotides from the antisense strand of : AD - 20850 , Which comprises SEQ ID NOs. 20l and 202. [ 0487 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15. US 20l2 / 0ll5934 Al. contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20851 , Which comprises SEQ ID NOs. 203 and 204. [ 0488 ] In one embodiment , the 00mp0sition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20852 , Which comprises SEQ ID NOs. 205 and 206. [ 0489 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 2086l , Which comprises SEQ ID NOs. 207 and 208. [ 0490 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS 00ntiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20862 , Which c0mprises SEQ ID NOs. 209 and 2l0. [ 0491 ] In one embodiment , the 00mp0sition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20863 , Which comprises SEQ ID NOs. 211 and 212. [ 0492 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20864 , Which comprises SEQ ID NOs. 213 and 214. [ 0493 ] In one embodiment , the c0mposition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20865 , Which comprises SEQ ID NOs. 2l5 and 2l6. [ 0494 ] In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20866 , Which comprises SEQ ID NOs. 217 and 218. [ 0495 ] and In one embodiment , the composition comprises a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 c0ntiguous nucleotides differing by 0 nucleotides from the antisense strand of : AD - 20867 , Which comprises SEQ ID NOs. 219 and 220. [ 0496 ] Various Embodiments of a RNAi Agent to BetaENaC. [ 0497 ] In one embodiment , the c0mposition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20805 , Which comprises SEQ ID NOs. 1 and 2. [ 0498 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. May 10 , 2012. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20806 , Which comprises SEQ ID NOs. 3 and 4. [ 0499 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20807 , Which comprises SEQ ID NOs. 5 and 6. [ 0500 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20808 , Which comprises SEQ ID NOs. 7 and 8. [ 0501 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20809 , Which comprises SEQ ID NOs. 9 and lO. [ 0502 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides fr0m the antisense sequence of : AD - 208l0 , Which comprises SEQ ID NOs. 11 and l2. [ 0503 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 208l l , Which comprises SEQ ID NOs. l3 and 14. [ 0504 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20812 , Which comprises SEQ ID NOs. 15 and 16. [ 0505 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20813 , Which comprises SEQ ID NOs. 17 and l8. [ 0506 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 208l4 , Which comprises SEQ ID NOs. l9 and 20. [ 0507 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. US 20l2 / 0ll5934 Al. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20815 , Which comprises SEQ ID NOs. 21 and 22. [ 0508 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20816 , Which comprises SEQ ID NOs. 23 and 24. [ 0509 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 208l7 , Which comprises SEQ ID NOs. 25 and 26. [ 0510 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 208l8 , Which comprises SEQ ID NOs. 27 and 28. [ 0511 ] In one embodiment , the c0mposition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense sequence of : AD - 208l9 , Which comprises SEQ ID NOs. 29 and 30. [ 0512 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20820 , Which comprises SEQ ID NOs. 3l and 32. [ 0513 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20821 , Which comprises SEQ ID NOs. 33 and 34. [ 0514 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20822 , Which comprises SEQ ID NOs. 35 and 36. [ 0515 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 20823 , Which comprises SEQ ID NOs. 37 and 38. [ 0516 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. May 10 , 2012. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20824 , Which comprises SEQ ID NOs. 39 and 40. [ 0517 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 20825 , Which comprises SEQ ID NOs. 41 and 42. [ 0518 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20826 , Which comprises SEQ ID NOs. 43 and 44. [ 0519 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20827 , Which comprises SEQ ID NOs. 45 and 46. [ 0520 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides fr0m the antisense sequence of : AD - 20828 , Which comprises SEQ ID NOs. 47 and 48. [ 0521 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20829 , Which comprises SEQ ID NOs. 49 and 50. [ 0522 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20830 , Which comprises SEQ ID NOs. 51 and 52. [ 0523 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20831 , Which comprises SEQ ID NOs. 53 and 54. [ 0524 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 20832 , Which comprises SEQ ID NOs. 55 and 56. [ 0525 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. US 20l2 / 0ll5934 Al. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20833 , Which comprises SEQ ID NOs. 57 and 58. [ 0526 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20834 , Which comprises SEQ ID NOs. 59 and 60. [ 0527 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20835 , Which comprises SEQ ID NOs. 6l and 62. [ 0528 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20836 , Which comprises SEQ ID NOs. 63 and 64. [ 0529 ] In one embodiment , the c0mposition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense sequence of : AD - 20837 , Which comprises SEQ ID NOs. 65 and 66. [ 0530 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20838 , Which comprises SEQ ID NOs. 67 and 68. [ 0531 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20839 , Which comprises SEQ ID NOs. 69 and 70. [ 0532 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20840 , Which comprises SEQ ID NOs. 71 and 72. [ 0533 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 2084l , Which comprises SEQ ID NOs. 73 and 74. [ 0534 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. May 10 , 2012. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20842 , Which comprises SEQ ID NOs. 75 and 76. [ 0535 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 20843 , Which comprises SEQ ID NOs. 77 and 78. [ 0536 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20844 , Which comprises SEQ ID NOs. 79 and 80. [ 0537 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20845 , Which comprises SEQ ID NOs. 8l and 82. [ 0538 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides fr0m the antisense sequence of : AD - 20846 , Which comprises SEQ ID NOs. 83 and 84. [ 0539 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20847 , Which comprises SEQ ID NOs. 85 and 86. [ 0540 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20848 , Which comprises SEQ ID NOs. 87 and 88. [ 0541 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20849 , Which comprises SEQ ID NOs. 89 and 90. [ 0542 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence 0f : AD - 20850 , Which comprises SEQ ID NOs. 9l and 92. [ 0543 ] In one embodiment , the composition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides. US 20l2 / 0ll5934 Al. differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20851 , Which comprises SEQ ID NOs. 93 and 94. [ 0544 ] In one embodiment , the 00mp0sition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20852 , Which comprises SEQ ID NOs. 95 and 96. [ 0545 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20861 , Which comprises SEQ ID NOs. 97 and 98. [ 0546 ] In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20862 , Which comprises SEQ ID NOs. 99 and 100. [ 0547 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucle0tides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20863 , Which comprises SEQ ID NOs. lOl and 102. [ 0548 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense sequence of : AD - 20864 , Which comprises SEQ ID NOs. lO3 and 104. [ 0549 ] In one embodiment , the c0mposition comprises a modiﬁed Variant of a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucle0tides from the antisense sequence of : AD - 20865 , Which comprises SEQ ID NOs. lO5 and lO6. [ 0550 ] In one embodiment , the c0mposition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20866 , Which comprises SEQ ID NOs. lO7 and lO8. [ 0551 ] and In one embodiment , the composition comprises a modiﬁed Variant 0f a RNAi agent , Wherein the Variant comprises a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense sequence of : AD - 20867 , Which comprises SEQ ID NOs. 109 and 110. [ 0552 ] ENaC [ 0553 ] In one embodiment , the present disclosure comprisesAD - 20805 ( SEQ ID NOs : 1 and 2 , or SEQ ID NOs : 111 and 112 ) . Various Embodiments of a RNAi Agent to Beta - . May 10 , 2012. [ 0554 ] In one embodiment , the present disclosure comprises AD - 20806 ( SEQ ID NOs : 3 and 4 , or SEQ ID NOs : 113 and 114 ) . [ 0555 ] In one emb0diment , the present disclosure comprises AD - 20807 ( SEQ ID NOs : 5 and 6 , or SEQ ID NOs : 115 and 116 ) . [ 0556 ] In one emb0diment , the present disclosure comprises AD - 20808 ( SEQ ID NOs : 7 and 8 , or SEQ ID NOs : 117 and ll8 ) . [ 0557 ] In one emb0diment , the present disclosure comprises AD - 20809 ( SEQ ID NOs : 9 and 10 , or SEQ ID NOs : ll9 and l20 ) . [ 0558 ] In one emb0diment , the present disclosure comprises AD - 208l0 ( SEQ ID NOs : 11 and l2 , or SEQ ID NOs : l2l and l22 ) . [ 0559 ] In one embodiment , the present disclosure comprises AD - 208ll ( SEQ ID NOs : l3 and l4 , or SEQ ID NOs : l23 and l24 ) . [ 0560 ] In one embodiment , the present disclosure comprises AD - 208l2 ( SEQ ID NOs : lS and l6 , or SEQ ID NOs : l25 and l26 ) . [ 0561 ] In one embodiment , the present disclosure comprises AD - 208l3 ( SEQ ID NOs : l7 and l8 , or SEQ ID NOs : 127 and 128 ) . [ 0562 ] In one embodiment , the present disclosure comprises AD - 208l4 ( SEQ ID NOs : l9 and 20 , or SEQ ID NOs : 129 and 130 ) . [ 0563 ] In one embodiment , the present disclosure comprises AD - 208l 5 ( SEQ ID NOs : 2l and 22 , or SEQ ID NOs : l3l and l32 ) . [ 0564 ] In one embodiment , the present disclosure comprises AD - 20816 ( SEQ ID NOs : 23 and 24 , or SEQ ID NOs : 133 and 134 ) . [ 0565 ] In one embodiment , the present disclosure comprises AD - 208l7 ( SEQ ID NOs : 25 and 26 , or SEQ ID NOs : l35 and l36 ) . [ 0566 ] In one embodiment , the present disclosure comprises AD - 20818 ( SEQ ID NOs : 27 and 28 , or SEQ ID NOs : 137 and 138 ) . [ 0567 ] In one embodiment , the present disclosure comprises AD - 208l 9 ( SEQ ID NOs : 29 and 30 , or SEQ ID NOs : l39 and l40 ) . [ 0568 ] In one embodiment , the present disclosure comprises AD - 20820 ( SEQ ID NOs : 31 and 32 , or SEQ ID NOs : 141 and 142 ) . [ 0569 ] In one embodiment , the present disclosure comprises AD - 2082l ( SEQ ID NOs : 33 and 34 , or SEQ ID NOs : l43 and l44 ) . [ 0570 ] In one embodiment , the present disclosure comprises AD - 20822 ( SEQ ID NOs : 35 and 36 , or SEQ ID NOs : 145 and 146 ) . [ 0571 ] In one embodiment , the present disclosure comprises AD - 20823 ( SEQ ID NOs : 37 and 38 , or SEQ ID NOs : l47 and l48 ) . [ 0572 ] In one embodiment , the present disclosure comprises AD - 20824 ( SEQ ID NOs : 39 and 40 , or SEQ ID NOs : 149 and 150 ) . [ 0573 ] In one embodiment , the present disclosure comprises AD - 20825 ( SEQ ID NOs : 4l and 42 , or SEQ ID NOs : lSl and lS2 ) . [ 0574 ] In one embodiment , the present disclosure comprises AD - 20826 ( SEQ ID NOs : 43 and 44 , or SEQ ID NOs : 153 and 154 ) . US 20l2 / 0ll5934 Al. [ 0575 ] In one embodiment , the present disclosure comprises AD - 20827 ( SEQ ID NOs : 45 and 46 , or SEQ ID NOs : . 155 and 156 ) . [ 0576 ] In one embodiment , the present disclosure comprises AD - 20828 ( SEQ ID NOs : 47 and 48 , or SEQ ID NOs : . 157 and 158 ) . [ 0577 ] In one embodiment , the present disclosure comprises AD - 20829 ( SEQ ID NOs : 49 and 50 , or SEQ ID NOs : . 159 and 160 ) . [ 0578 ] In one embodiment , the present disclosure comprises AD - 20830 ( SEQ ID NOs : 51 and 52 , or SEQ ID NOs : . 161 and 162 ) . [ 0579 ] In one embodiment , the present disclosure comprises AD - 2083l ( SEQ ID NOs : 53 and 54 , or SEQ ID NOs : . 163 and 164 ) . [ 0580 ] In one embodiment , the present disclosure comprises AD - 20832 ( SEQ ID NOs : 55 and 56 , or SEQ ID NOs : . 165 and 166 ) . [ 0581 ] In one embodiment , the present disclosure comprises AD - 20833 ( SEQ ID NOs : 57 and 58 , or SEQ ID NOs : . 167 and 168 ) . [ 0582 ] In one embodiment , the present disclosure comprises AD - 20834 ( SEQ ID NOs : 59 and 60 , or SEQ ID NOs : . 169 and 170 ) . [ 0583 ] In one embodiment , the present disclosure comprises AD - 20835 ( SEQ ID NOs : 6l and 62 , or SEQ ID NOs : . 171 and 172 ) . [ 0584 ] In one embodiment , the present disclosure comprises AD - 20836 ( SEQ ID NOs : 63 and 64 , or SEQ ID NOs : . 173 and 174 ) . [ 0585 ] In one embodiment , the present disclosure comprises AD - 20837 ( SEQ ID NOs : 65 and 66 , or SEQ ID NOs : . 175 and 176 ) . [ 0586 ] In one embodiment , the present disclosure comprises AD - 20838 ( SEQ ID NOs : 67 and 68 , or SEQ ID NOs : . 177 and 178 ) . [ 0587 ] In one embodiment , the present disclosure comprises AD - 20839 ( SEQ ID NOs : 69 and 70 , or SEQ ID NOs : . 179 and 180 ) . [ 0588 ] In one embodiment , the present disclosure comprises AD - 20840 ( SEQ ID NOs : 7l and 72 , or SEQ ID NOs : . 181 and 182 ) . [ 0589 ] In one embodiment , the present disclosure comprises AD - 20841 ( SEQ ID NOs : 73 and 74 , or SEQ ID NOs : . 133 and 134 ) . [ 0590 ] In one embodiment , the present disclosure comprises AD - 20842 ( SEQ ID NOs : 75 and 76 , or SEQ ID NOs : . 185 and 186 ) . [ 0591 ] In one embodiment , the present disclosure comprises AD - 20843 ( SEQ ID NOs : 77 and 78 , or SEQ ID NOs : . 137 and 188 ) . [ 0592 ] In one embodiment , the present disclosure comprises AD - 20844 ( SEQ ID NOs : 79 and 80 , or SEQ ID NOs : . 189 and 190 ) . [ 0593 ] In one embodiment , the present disclosure comprises AD - 20845 ( SEQ ID NOs : 81 and 82 , or SEQ ID NOs : . 191 and 192 ) . [ 0594 ] In one embodiment , the present disclosure comprises AD - 20846 ( SEQ ID NOs : 83 and 84 , or SEQ ID NOs : . 193 and 194 ) . [ 0595 ] In one embodiment , the present disclosure comprises AD - 20847 ( SEQ ID NOs : 85 and 86 , or SEQ ID NOs : . 195 and 196 ) . May 10 , 2012. [ 0596 ] In one embodiment , the present disclosure comprises AD - 20848 ( SEQ ID NOs : 87 and 88 , or SEQ ID NOs : 197 and 198 ) . [ 0597 ] In one emb0diment , the present disclosure comprises AD - 20849 ( SEQ ID NOs : 89 and 90 , or SEQ ID NOs : 199 and 200 ) . [ 0598 ] In one emb0diment , the present disclosure comprises AD - 20850 ( SEQ ID NOs : 91 and 92 , or SEQ ID NOs : 20l and 202 ) . [ 0599 ] In one emb0diment , the present disclosure comprises AD - 20851 ( SEQ ID NOs : 93 and 94 , or SEQ ID NOs : 203 and 204 ) . [ 0600 ] In one emb0diment , the present disclosure comprises AD - 20852 ( SEQ ID NOs : 95 and 96 , or SEQ ID NOs : 205 and 206 ) . [ 0601 ] In one embodiment , the present disclosure comprises AD - 2086l ( SEQ ID NOs : 97 and 98 , or SEQ ID NOs : 207 and 208 ) . [ 0602 ] In one embodiment , the present disclosure comprises AD - 20862 ( SEQ ID NOs : 99 and lO0 , or SEQ ID NOs : 209 and 2l0 ) . [ 0603 ] In one embodiment , the present disclosure comprises AD - 20863 ( SEQ ID NOs : lOl and lO2 , or SEQ ID NOs : 211 and 212 ) . [ 0604 ] In one embodiment , the present disclosure comprises AD - 20864 ( SEQ ID NOs : lO3 and lO4 , or SEQ ID NOs : 213 and 214 ) . [ 0605 ] In one embodiment , the present disclosure comprises AD - 20865 ( SEQ ID NOs : lO5 and 106 , or SEQ ID NOs : 2l5 and 2l6 ) . [ 0606 ] In one embodiment , the present disclosure comprises AD - 20866 ( SEQ ID NOs : 107 and 108 , or SEQ ID NOs : 217 and 218 ) . [ 0607 ] In one embodiment , the present disclosure comprises AD - 20867 ( SEQ ID NOs : lO9 and 110 , or SEQ ID NOs : 2l9 and 220 ) . [ 0608 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20805. [ 0609 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20806. [ 0610 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20807. [ 0611 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20808. [ 0612 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20809. [ 0613 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 208l0. [ 0614 ] In one embodiment , the RNAi agent comprises an. antisense strand that is the exact sequence and length of the antisense strand of AD - 208l 1. [ 0615 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 208l2. [ 0616 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20813. US 20l2 / 0ll5934 Al. [ 0617 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20814. [ 0618 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20815. [ 0619 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 208l6. [ 0620 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 208l7. [ 0621 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 208l8. [ 0622 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 208l9. [ 0623 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20820. [ 0624 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand ofAD - 20821. [ 0625 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20822. [ 0626 ] In one embodiment , the RNAi agent comprises an. antisense strand that is the exact sequence and length of the antisense strand of AD - 20823. [ 0627 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20824. [ 0628 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20825. [ 0629 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20826. [ 0630 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20827. [ 0631 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20828. [ 0632 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20829. [ 0633 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20830. [ 0634 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 2083l. [ 0635 ] In one embodiment , the RNAi agent comprises an. antisense strand that is the exact sequence and length of the antisense strand of AD - 20832. [ 0636 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20833. [ 0637 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20834. May 10 , 2012. [ 0638 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20835. [ 0639 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20836. [ 0640 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20837. [ 0641 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20838. [ 0642 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20839. [ 0643 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20840. [ 0644 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 2084l. [ 0645 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20842. [ 0646 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20843. [ 0647 ] In one embodiment , the RNAi agent comprises an. antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20844. [ 0648 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20845. [ 0649 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20846. [ 0650 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20847. [ 0651 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20848. [ 0652 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20849. [ 0653 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20850. [ 0654 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 2085 1 . [ 0655 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length 0f the antisense strand of AD - 20852. [ 0656 ] In one embodiment , the RNAi agent comprises an. antisense strand that is the exact sequence and length of the antisense strand of AD - 20861. [ 0657 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20862. [ 0658 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20863. US 20l2 / 0ll5934 Al. [ 0659 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20864. [ 0660 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20865. [ 0661 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20866. [ 0662 ] In one embodiment , the RNAi agent comprises an antisense strand that is the exact sequence and length of the antisense strand of AD - 20867. In these Various embodiments , a RNAi agent comprising an antisense strand that is the exact sequence and length of a recited antisense strand of a recited RNAi agent can comprise modiﬁed nucleotides , 3 ' - end caps , and / or other modiﬁcations Which do not alter the sequence or length of the RNAi agent. [ 0663 ] Various Embodiments of a RNAi Agent to BetaENaC. [ 0664 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20805. [ 0665 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20806. [ 0666 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20807. [ 0667 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20808. [ 0668 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20809. [ 0669 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l0. [ 0670 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l l. [ 0671 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l2. [ 0672 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20813. [ 0673 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20814. [ 0674 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20815. [ 0675 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20816. [ 0676 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20817. [ 0677 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20818. [ 0678 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20819. May 10 , 2012. [ 0679 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20820. [ 0680 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches fr0m that of the antisense strand of AD - 20821. [ 0681 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20822. [ 0682 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20823. [ 0683 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20824. [ 0684 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20825. [ 0685 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20826. [ 0686 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20827. [ 0687 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20828. [ 0688 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20829. [ 0689 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20830. [ 0690 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 2083l. [ 0691 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20832. [ 0692 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20833. [ 0693 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20834. [ 0694 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20835. [ 0695 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20836. [ 0696 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20837. [ 0697 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20838. [ 0698 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20839. [ 0699 ] In one embodiment , the RNAi agent comprises an. antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20840. US 20l2 / 0ll5934 Al. [ 0700 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2084l. [ 0701 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20842. [ 0702 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20843. [ 0703 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20844. [ 0704 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20845. [ 0705 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20846. [ 0706 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20847. [ 0707 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20848. [ 0708 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20849. [ 0709 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20850. [ 0710 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2085l. [ 0711 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20852. [ 0712 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2086l. [ 0713 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20862. [ 0714 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20863. [ 0715 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20864. [ 0716 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20865. [ 0717 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20866. [ 0718 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20867. [ 0719 ] Various Embodiments of a RNAi Agent to BetaENaC. [ 0720 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20805 , Wherein the antisense strand optionally further comprises 0 , . May 10 , 2012. l , 2 , 3 , 4 , , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof , e. g. , 0 - l , . etc. ) . [ 0721 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20806 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0722 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20807 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0723 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20808 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0724 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20809 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0725 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20810 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0726 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l l , Wherein the antisense strand optionally ﬁ1rther comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0727 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20812 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0728 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 208l3 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0729 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l4 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0730 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20815 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0731 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 208l6 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0732 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 208l7 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . US 20l2 / 0ll5934 Al. [ 0733 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20818 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0734 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20819 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0735 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20820 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0736 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2082l , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0737 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20822 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0738 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20823 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0739 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20824 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0740 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20825 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0741 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20826 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0742 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20827 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0743 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20828 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0744 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20829 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0745 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20830 , . May 10 , 2012. Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0746 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 2083l , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0747 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20832 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0748 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20833 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0749 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20834 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0750 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20835 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0751 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2083 6 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0752 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20837 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0753 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2083 8 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0754 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 2083 9 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0755 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20840 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0756 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2084l , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0757 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20842 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0758 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3. US 20l2 / 0ll5934 Al. mismatches from that of the antisense strand of AD - 20843 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0759 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20844 , Wherein the antisense strand opti0nally further c0mprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0760 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20845 , Wherein the antisense strand opti0nally further c0mprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0761 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20846 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0762 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20847 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0763 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20848 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0764 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20849 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0765 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20850 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0766 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2085l , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0767 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20852 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0768 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 2086l , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0769 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20862 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0770 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20863 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . May 10 , 2012. [ 0771 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20864 , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0772 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20865 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0773 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , 1 , 2 , or 3 mismatches from that of the antisense strand of AD - 20866 , Wherein the antisense strand optionally ﬁ1rther comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO nt ( or any range thereof ) . [ 0774 ] In one embodiment , the RNAi agent comprises an antisense strand consisting of a sequence With 0 , l , 2 , or 3 mismatches from that of the antisense strand of AD - 20867 , Wherein the antisense strand optionally further comprises 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 nt ( or any range thereof ) . [ 0775 ] Additional Particular Speciﬁc Embodiments [ 0776 ] In Various embodiments , the disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of any RNAi agent disclosed herein. [ 0777 ] Thus , in Various embodiments : . [ 0778 ] The disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand 0f any one 0r more of the folloWing duplexes , or modiﬁed or unmodiﬁed Variants thereof : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 , AD - 20805 , AD - 20806 , AD - 20808 , AD - 20809 , AD - 20810 , AD - 20811 , AD - 20812 , AD - 208l3 , AD - 208l4 , AD - 208l5 , AD - 208l6 , AD - 208l7 , AD - 208l8 , AD - 208l9 , AD - 20820 , AD - 2082l , AD - 20822 , AD - 20823 , AD - 20824 , AD - 20825 , AD - 20827 , AD - 20828 , AD - 20829 , AD - 20830 , AD - 20831 , AD - 20833 , AD - 20835 , AD - 20836 , AD - 20838 , AD - 20839 , AD - 20840 , AD - 20841 , AD - 20842 , AD - 20843 , AD - 20844 , AD - 20845 , AD - 20846 , AD - 20847 , AD - 20849 , AD - 20850 , AD - 2085l , AD - 20852 , AD - 20862 , AD - 20863 , AD - 20864 , AD - 20865 , AD - 20866 , AD - 20867 , or modiﬁed or unmodiﬁed Variants thereof. [ 0779 ] Additional Particular Speciﬁc Embodiments [ 0780 ] In Various embodiments , the disclosure comprises a RNAi agent comprising a ﬁrst and a second strand , Wherein the sequence of the ﬁrst strand comprises at least l5 contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sequence of the ﬁrst strand of , and the sequence of the second strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the sequence of the second strand , of any RNAi agent , disclosed herein. [ 0781 ] Thus , in Vari0us embodiments : . [ 0782 ] The disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the sequence of the ﬁrst strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt fr0m the sequence of the ﬁrst strand of , and the sequence of the second strand comprises at least 15 contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the sequence of the second strand , of any one or more of the folloWing duplexes , or modiﬁed or unmodiﬁed Variants thereof : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 , AD - 20805 , AD - 20806 , . US 20l2 / 0ll5934 Al. AD - 20808 , AD - 20809 , AD - 208l0 , AD - 208ll , AD - 208l2 , AD - 208l3 , AD - 208l4 , AD - 208l5 , AD - 208l6 , AD - 208l7 , AD - 20818 , AD - 20819 , AD - 20820 , AD - 20821 , AD - 20822 , AD - 20823 , AD - 20824 , AD - 20825 , AD - 20827 , AD - 20828 , AD - 20829 , AD - 20830 , AD - 2083l , AD - 20833 , AD - 20835 , AD - 20836 , AD - 20838 , AD - 20839 , AD - 20840 , AD - 2084l , AD - 20842 , AD - 20843 , AD - 20844 , AD - 20845 , AD - 20846 , AD - 20847 , AD - 20849 , AD - 20850 , AD - 20851 , AD - 20852 , AD - 20862 , AD - 20863 , AD - 20864 , AD - 20865 , AD - 20866 , AD - 20867 , or modiﬁed or unmodiﬁed Variants thereof. [ 0783 ] Additional Particular Embodiments. [ 0784 ] In Various embodiments , the disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand c0mprises or consists of the antisense strand of any RNAi agent disclosed herein. [ 0785 ] Thus , the folloWing are proVided as examples of the Various embodiments. [ 0786 ] The disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand 00mprises or consists of the antisense strand 0f : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 , AD - 20805 , AD - 20806 , AD - 20808 , AD - 20809 , AD - 208l0 , AD - 208l l , AD - 208l2 , AD - 208l3 , AD - 208l4 , AD - 20815 , AD - 20816 , AD - 20817 , AD - 20818 , AD - 20819 , AD - 20820 , AD - 20821 , AD - 20822 , AD - 20823 , AD - 20824 , AD - 20825 , AD - 20827 , AD - 20828 , AD - 20829 , AD - 20830 , AD - 2083l , AD - 20833 , AD - 20835 , AD - 20836 , AD - 20838 , AD - 20839 , AD - 20840 , AD - 20841 , AD - 20842 , AD - 20843 , AD - 20844 , AD - 20845 , AD - 20846 , AD - 20847 , AD - 20849 , AD - 20850 , AD - 20851 , AD - 20852 , AD - 20862 , AD - 20863 , AD - 20864 , AD - 20865 , AD - 20866 , AD - 20867 , or modiﬁed or unmodiﬁed Variants th. ereof. [ 0787 ] In Various embodiments , the disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand of any RNAi agent disclosed herein , or modiﬁed or unmodiﬁed Variants thereof , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO or more nt ( or any range thereof , e. g. , 0 - 1 , 1 - 2 , 1 - 3 , 1 - 4 nt , etc. ) . [ 0788 ] Thus , in Various embodiments , the disclosure comprises a RNAi agent comprising a sense and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the antisense strand of : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 , AD - 20805 , AD - 20806 , AD - 20808 , AD - 20809 , AD - 20810 , AD - 20811 , AD - 208l2 , AD - 208l3 , AD - 208l4 , AD - 208l5 , AD - 208l6 , AD - 208l7 , AD - 208l8 , AD - 208l9 , AD - 20820 , AD - 2082l , AD - 20822 , AD - 20823 , AD - 20824 , AD - 20825 , AD - 20827 , AD - 20828 , AD - 20829 , AD - 20830 , AD - 20831 , AD - 20833 , AD - 20835 , AD - 20836 , AD - 20838 , AD - 20839 , AD - 20840 , AD - 2084l , AD - 20842 , AD - 20843 , AD - 20844 , AD - 20845 , AD - 20846 , AD - 20847 , AD - 20849 , AD - 20850 , AD - 2085l , AD - 20852 , AD - 20862 , AD - 20863 , AD - 20864 , AD - 20865 , AD - 20866 , AD - 20867 , or modiﬁed or unmodiﬁed Variants thereof , Wherein the antisense strand optionally further comprises 0 , l , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , or lO or more nt ( or any range thereof , e. g. , 0 - l , l - 2 , l - 3 , l - 4 nt , etc. ) . [ 0789 ] In Various embodiments , the disclosure comprises a RNAi agent comprising a ﬁrst and a second strand , Wherein the sequence of the ﬁrst strand comprises or consists of the sequence of the ﬁrst strand of , and the sequence of the second. May 10 , 2012. strand comprises or consists of the sequence of the second strand of any RNAi agent disclosed herein , or modiﬁed or unmodiﬁed Variants thereof. [ 0790 ] Thus , in Various embodiments , the disclosure comprises a RNAi agent comprising a ﬁrst and a second strand , Wherein the sequence 0f the ﬁrst strand comprises 0r consists of the sequence of the ﬁrst strand of , and the sequence of the second strand comprises or consists of the sequence of the second strand 0f : AD - 20832 ; AD - 20848 ; AD - 20807 ; AD - 20826 ; AD - 20837 ; AD - 20861 ; AD - 20834 , AD - 20805 , AD - 20806 , AD - 20808 , AD - 20809 , AD - 208l0 , AD - 208ll , AD - 208l2 , AD - 208l3 , AD - 208l4 , AD - 208l5 , AD - 208l6 , AD - 208l7 , AD - 208l8 , AD - 208l9 , AD - 20820 , AD - 2082l , AD - 20822 , AD - 20823 , AD - 20824 , AD - 20825 , AD - 20827 , AD - 20828 , AD - 20829 , AD - 20830 , AD - 20831 , AD - 20833 , AD - 20835 , AD - 20836 , AD - 20838 , AD - 20839 , AD - 20840 , AD - 2084l , AD - 20842 , AD - 20843 , AD - 20844 , AD - 20845 , AD - 20846 , AD - 20847 , AD - 20849 , AD - 20850 , AD - 20851 , AD - 20852 , AD - 20862 , AD - 20863 , AD - 20864 , AD - 20865 , AD - 20866 , AD - 20867. [ 0791 ] In one embodiment , the disclosure comprises any one or more RNAi agent listed herein. [ 0792 ] OVerlapping sets of RNAi Agents to Beta - ENaC [ 0793 ] In Various embodiments , the present disclosure relates to groups of RNAi agents to Beta - ENaC With oVerlapping sequences. Thus , the present disclosure encompasses gr0ups 0f RNAi agents Wherein each RNAi agent in the gr0up oVerlaps With each other RNAi agent in the same gr0up by at least 5 , 6 , 7 , 8 , 9 , lO , ll , l2 , l3 , l4 , lS , l6 , l7 , l8 , l9 ormore nucleotides. Particularly , in 0ne embodiment , the oVerlap is at least 12 nt. [ 0794 ] Some 0f the RNAi agents listed herein oVerlap each other in sequence. Table 2 presents a compilation of some of these groups of oVerlapping RNAi agents , Wherein each member of a group oVerlaps With each other member of the same group by at least l2 nt. A l2 - nt portion of the oVerlap of the sense and anti - sense strand are presented. [ 0795 ] Thus , for example , as sh0Wn in Table 2 , the sequences of RNAi agents AD - 20807 andAD - 20832 oVerlap , Wherein the oVerlap in the sense strand comprises the sequence UGAAGAAGUACC ( SEQ ID NO : 223 ) ; these RNAi agents also oVerlap in the anti - sense strand sequence , Wherein the oVerlap comprises the sequence GGUACUUCUUCA ( SEQ ID NO : 224 ) . The RNAi agents AD - 20807 , AD - 20862 and AD - 20832 all oVerlap in the sense strand , Wherein the oVerlap comprises the sequence GAAGAAGUACCU ( SEQ ID NO : 225 ) ; these RNAi agents also oVerlap in the anti - sense strand , Wherein the oVerlap comprises the sequence AGGUACUUCUUC ( SEQ ID NO : 226 ) . Thus , these and other Various sets of oVerlapping RNAi agents presented in Table 2 share common technical features , for example , the oVerlap in the sense and anti - sense strand. [ 0796 ] Particular sets of oVerlapping RNAi agents to BetaENaC are proVided beloW in Table 2. [ 0797 ] The present disclosure thus encompasses any group or subgroup of RNAi agents comprising a common technical feature , Wherein the common technical feature is an oVerlap ( e. g. , of at least 12 nt ) of a sequence in the sense or anti - sense strand. [ 0798 ] Thus : . [ 0799 ] The present disclosure encompasses a RNAi agent comprising : an antisense strand comprising at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the antisense strand , and / or a sense strand comprising at least 15. US 20l2 / 0ll5934 Al. contiguous nucleotides differing by 0 , l , 2 , or 3 nt from the sense strand , of any of the group of : AD - 20807 and AD - 20832 ( or any other group presented in Table 2 ) . [ 0800 ] The present disclosure encompasses a RNAi agent comprising a ﬁrst and a second strand , Wherein the ﬁrst strand 00mprises at least 15 contiguous nucle0tides differing by 0 , 1 , 2 , or 3 nt fr0m the ﬁrst strand of , and / or the second strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nt from the second strand , of any of the group of : AD - 20807 and AD - 20832 ( or any other group presented in Table 2 ) . [ 0801 ] The present disclosure encompasses a RNAi agent comprising a ﬁrst and a second strand , Wherein the ﬁrst strand comprises or consists 0f the sequence of a ﬁrst strand of , and / or the second strand comprises or consists of the sequence of , any of the group of : AD - 20807 and AD - 20832 ( or any other group presented in Table 2 ) . [ 0802 ] The disclose encompasses a RNAi agent comprising a ﬁrst and a second strand ( Wherein the ﬁrst and second strand may optionally be coValently linked , linked Via a loop or linker , or contiguous ) , and Wherein the ﬁrst and / or sec0nd strand comprise , consist essentially of , or consist of sequences With 0 , l , 2 , or 3 nt or by mismatches 0f any of the group of : AD - 20807 and AD - 20832 ( or any other group presented in Table 2 ) , optionally ﬁ1rther comprising 0 - 10 nt or bp. [ 0803 ] The present discl0sure similarly enc0mpasses Various embodiments encompassing groups of oVerlapping RNAi agents presented in Table 2. ADDITIONAL DEFINITIONS. [ 0804 ] The articles “a” and “an” as used herein and in the claims refer to one or more than one ( at least one ) of the grammatical object of the article. [ 0805 ] The terms “RNAi agent , ” “RNAi agents” , “RNAi agent ( s ) ” and the like all refer Without limitation to one or more RNAi agents of the present disclosure. [ 0806 ] The designations of particular example duplexes of RNAi agents to Beta - ENaC disclosed herein on occasion haVe the sufﬁx “b” folloWed by a number. This indicates a batch number. Thus , the sufﬁx “b1” indicates “batch 1 .” Thus , a RNAi duplex designated , for example , “AD - 20807 - bl” is speciﬁcally from batch l and has the same sequence as any RNAi agent designated “AD - 20807”. [ 0807 ] Unless deﬁned otherWise , the technical and scien - tiﬁc terms used herein haVe the same meaning as that usually understood by a specialist familiar With the ﬁeld t0 Which the present disclosure belongs. [ 0808 ] Unless indicated otherWise , all methods , steps , techniques and manipulations that are not speciﬁcally described in detail can be performed and haVe been performed in a manner knoWn per se , as Will be clear to the skilled person. Reference is for example again made to the standard hand - bo0ks and the general background art menti0ned herein and to the ﬁnther references cited therein. [ 0809 ] Claims to the present disclosure are non - limiting and are proVided beloW. [ 0810 ] Although particular embodiments and claims haVe been disclosed herein in detail , this has been done by Way of example for purposes of illustration on1y , and is not intended to be limiting With respect to the scope of the appended claims , or the scope of subject matter of claims of any corresponding future application. In particular , it is c0ntemplated by the inVentors that Various substitutions , alterations , and. May 10 , 2012. modiﬁcations may be made to the present disclosure Without departing fr0m the spirit and sc0pe of the present disclosure as deﬁned by the claims. The choice of nucleic acid starting material , clone of interest , or library type is belieVed to be a matter of routine for a person of 0rdinary skill in the art With knoWledge of the embodiments described herein. Other aspects , adVantages , and modiﬁcations considered to be Within the scope of the folloWing claims. Redrafting of claim scope in later - ﬁled corresponding applicati0ns may be due to limitati0ns by the patent laWs of Various 00untries and should n0t be interpreted as giVing up subject matter of the claims. [ 0811 ] Various additional formulations and obVious Variants of the described RNAi agents to Beta - ENaC can be deVised by those 0f ordinary skill in the art. Non - limiting example RNAi agents to Beta - ENaC are described in the Examples beloW , Which do not limit the scope of the present disclosure as described in the claims. EXAMPLES Example 1. [ 0812 ] Bioinformatics and Beta - ENaC RNAi Agent ( siRNA ) Sequences. [ 0813 ] Beta - ENaC oligonucle0tide design is carried out to identify siRNAs targeting mRNAs encoding the Beta - ENaC gene [ “sodium channel , nonVoltage - gated 1 beta” from human WCBI human symbol SCNN1 B ) and the orthologous sequences from cynomolgus monkey ( Macaca fascicu / aris ) and rat ( Ram / s 001vegicus ) ] . The design process uses the SCNNBl transcripts NM_000336.2 from human ( NCBI Geneld 6338 ) , NM7012648.1 from rat ( N CBI Geneld 24767 ) , and a full length cynomolgus monkey sequence ( described herein ) . [ 0814 ] All siRNA duplexes are designed to haVe 100% identity to all three SCNNBl transcripts. All sequences are from Transcript NM7000336. [ 0815 ] Unmodiﬁed and modiﬁed sequences are listed in Table l. Unmodiﬁed sequences include both the sense and antisense sequences Which are listed as SEQ ID NO : 111 to 220. The relatiVe positions of the ﬁrst residue as compared to. the human Beta - ENaC transcript in SEQ ID NO : 222 are als0 proVided. [ 0816 ] As described beloW , Table 1 also proVides example modiﬁed Variants of these sequences ( SEQ ID NO : 1 to 110 ) . For the Table 1 columns , “S” represents the sense strand , “AS” represents the antisense strand , and “Posn” represents the position of the ﬁrst nucleotide. Modiﬁed nucleotides , as indicated by loWer case letters ( e. g. , “c” and “u” ) are as described in Table lA , beloW. [ 0817 ] In the sequences in Table 1 , the modiﬁed and unmodiﬁed sequences can optionally comprise the sequence “dedT” at the 3 ' end. Thus , for example , AD - 20805 can optionally haVe the m0diﬁed sequence cAGuGAcuAcAAcAcGAcchsdT ( SEQ ID NO : 429 ) in the sense strand and GGUCGUGUUGuAGUcACUGdedT ( SEQ ID NO : 43 0 ) in the anti - sense strand. As noted in Table 1A , beloW , dT is 2 ' - deoxy - thymidine - 5 ' - phosphate and sdT is 2 ' - deoxy Thymidine 5 ' - phosphorothioate. US 20l2 / 0l15934 Al May lO , 20l2. . . . 45 TABLE 1 Beta—ENaC sequences Duplex SEQ SEQ ID ID Modified sequence ID Unmodified sequence Posn AD - S 1 CAGuGACuACAAcACGACC 111 CAGUGACUACAACACGACC 1298 20805. AS 2 GGUCGUGUUGuAGUCACUG 112 GGUCGUGUUGUAGUCACUG 1298. AD - S 3 AHGACAGAGAAGGCAcuuC 113 AUGACAGAGAAGGCACUUC 1011 20806. AS 4 GAAGUGCCUUCUCUGUcAU 114 GAAGUGCCUUCUCUGUCAU 1011. AD— S 5 GuGAAGAAGuAccuchGA llS GUGAAGAAGUACCUGCUGA 183 20807. AS 6 UCAGCAGGuACUUCUUCAC 116 UCAGCAGGUACUUCUUCAC 183. AD— S ' 7 GuGACuACAACACGACCuA 117 GUGACUACAACACGACCUA 1300 20808. AS 8 uAGGUCGUGUUGuAGUCAC 118 UAGGUCGUGUUGUAGUCAC 1300. AD— S 9 GGuGGAGGCCCACACCAAC 119 GGUGGAGGCCCACACCAAC 1919 20809. AS 10 GUUGGUGUGGGCCUCCACC 120 GUUGGUGUGGGCCUCCACC 1919. AD - S 11 uGGuGGAGGCCCACACCAA 121 UGGUGGAGGCCCACACCAA 1918 208lO. AS 12 UUGGUGUGGGCCUCCACCA 122 UUGGUGUGGGCCUCCACCA 1918. AD - S 13 uuCCAAGAcCACAuGAucC 123 UUCCAAGACCACAUGAUCC 1347 20811. AS 14 GGAUCAUGUGGUCUUGGAA 124 GGAUCAUGUGGUCUUGGAA 1347. AD— S 15 AchGGGAGGucAGCGucu 125 AGCUGGGAGGUCAGCGUCU 402 20812. AS 16 AGACGCUGACCUCCCAGCU 126 AGACGCUGACCUCCCAGCU 402. AD— S 17 GGGAGAAAuACuGCAACAA 127 GGGAGAAAUACUGCAACAA 1408 20813. AS 18 UUGUUGCAGuAUUUCUCCC 128 UUGUUGCAGUAUUUCUCCC 1408. AD— S 19 CCAGuuuGchuCuGGAuG 129 CCAGUUUGGCUUCUGGAUG 1748 20814. AS 20 CAUCCAGAAGCCAAACUGG 130 CAUCCAGAAGCCAAACUGG 1748. AD— S 21 AGuGACuAcAAcAcGAccu 131 AGUGACUACAACACGACCU 1299 20815. AS 22 AGGUCGUGUUGuAGUCACU 132 AGGUCGUGUUGUAGUCACU 1299. AD— S 23 AAuAuCAcccuGAGCAGGA 133 AAUAUCACCCUGAGCAGGA 1626 20816. AS 24 UCCUGCUCAGGGUGAuAUU 134 UCCUGCUCAGGGUGAUAUU 1626. AD - S 25 CCuGCAGGCCACCAACAuC 135 CCUGCAGGCCACCAACAUC 836 20817. AS 26 GAUGUUGGUGGCCUGCAGG 136 GAUGUUGGUGGCCUGCAGG 836. AD - S 27 AuCACCCuGAGCAGGAAGG 137 AUCACCCUGAGCAGGAAGG 1629 20818. AS 28 CCUUCCUGCUCAGGGUGAU 138 CCUUCCUGCUCAGGGUGAU 1629. US 20l2 / 0l15934 Al May lO , 20l2. . . . 46 TABLE l—continued Beta—ENaC sequences Duplex SEQ SEQ ID ID Modified sequence ID Unmodified sequence Posn AD— S 29 GCuGGGAGGuCAGCGuCuC 139 GCUGGGAGGUCAGCGUCUC 403 20819. AS 30 GAGACGCUGACCUCCCAGC 140 GAGACGCUGACCUCCCAGC 403. AD - S 31 GAGCuGGGAGGuCAGCGuC 141 GAGCUGGGAGGUCAGCGUC 401 20820. AS 32 GACGCUGACCUCCCAGCUC 142 GACGCUGACCUCCCAGCUC 401. AD - S 33 GuGGCCAGuuuGGCuuCuG 143 GUGGCCAGUUUGGCUUCUG 1744 20821. AS 34 CAGAAGCCAAACUGGCCAC 144 CAGAAGCCAAACUGGCCAC 1744. AD - S 35 CAGuuuGchuCuGGAuGG 145 CAGUUUGGCUUCUGGAUGG 1749 20822. AS 36 CCAUCCAGAAGCcAAACUG 146 CCAUCCAGAAGCCAAACUG 1749. AD— S 37 GGcCAGuuuGGCuuCuGGA 147 GGCCAGUUUGGCUUCUGGA 1746 20823. AS 38 UCCAGAAGCCAAACUGGCC 148 UCCAGAAGCCAAACUGGCC 1746. AD— S 39 CuGGGuGGCCAGuuuGGCu 149 CUGGGUGGCCAGUUUGGCU 1740 20824. AS 40 AGCCAAACUGGCcACCcAG 150 AGCCAAACUGGCCACCCAG 1740. AD - S 41 uCuACAGuGACuACAACAC 151 UCUACAGUGACUACAACAC 1294 20825. AS 42 GUGUUGuAGUCACUGuAGA 152 GUGUUGUAGUCACUGUAGA 1294. AD - S 43 GCAuGACAGAGAAGGCACu 153 GCAUGACAGAGAAGGCACU 1009 20826. AS 44 AGUGCCUUCUCUGUCAUGC 154 AGUGCCUUCUCUGUCAUGC 1009. AD - S 45 AuAuCACCCuGAGCAGGAA 155 AUAUCACCCUGAGCAGGAA 1627 20827. AS 46 UUCCUGCUCAGGGUGAuAU 156 UUCCUGCUCAGGGUGAUAU 1627. AD— S 47 cuACAGuGAcuACAAcAcG 157 CUACAGUGACUACAACACG 1295 20828. AS 48 CGUGUUGuAGUCACUGuAG 158 CGUGUUGUAGUCACUGUAG 1295. AD— S 49 uAuCACccuGAGCAGGAAG 159 UAUCACCCUGAGCAGGAAG 1628 20829. AS 50 CUUCCUGCUcAGGGUGAuA 160 CUUCCUGCUCAGGGUGAUA 1628. AD— S 51 uGCAGGCCACCAACAuCuu 161 UGCAGGCCACCAACAUCUU 838 20830. AS 52 AAGAUGUUGGUGGCCUGcA 162 AAGAUGUUGGUGGCCUGCA 838. AD - S 53 CAuGACAGAGAAGGCACuu 163 CAUGACAGAGAAGGCACUU 1010 20831. AS 54 AAGUGCCUUCUCUGUCAUG 164 AAGUGCCUUCUCUGUCAUG 1010. AD - S 55 uGAAGAAGuACCuGCuGAA 165 UGAAGAAGUACCUGCUGAA 184 20832. AS 56 UUCAGCAGGuACUUCUUCA 166 UUCAGCAGGUACUUCUUCA 184. US 20l2 / 0l15934 Al May lO , 20l2. . . . 47 TABLE l—continued Beta—ENaC sequences Duplex SEQ SEQ ID ID Modified sequence ID Unmodified sequence Posn AD - S 57 GCuGGuGGAGGCCCACACc 167 GCUGGUGGAGGCCCACACC 1916 20833. AS 58 GGUGUGGGCCUCCACCAGC 168 GGUGUGGGCCUCCACCAGC 1916. AD - S 59 uACAGuGAcuAcAACACGA 169 UACAGUGACUACAACACGA 1296 20834. AS 60 UCGUGUUGuAGUcACUGuA 170 UCGUGUUGUAGUCACUGUA 1296. AD— S 61 AcAGAGAAGGcAcuuccuu l7l ACAGAGAAGGCACUUCCUU 1014 20835. AS 62 AAGGAAGUGCCUUCUCUGU 172 AAGGAAGUGCCUUCUCUGU 1014. AD— S 63 ACAGuGACuACAACACGAC l73 ACAGUGACUACAACACGAC lZ97 20836. AS 64 GUCGUGUUGuAGUCACUGU 174 GUCGUGUUGUAGUCACUGU 1297. AD— S 65 uGAGCuGGGAGGuCAGCGu 175 UGAGCUGGGAGGUCAGCGU 400 20837. AS 66 ACGCUGACCUCCCAGCUCA 176 ACGCUGACCUCCCAGCUCA 400. AD - S 67 uGGCCAGuuuGGCuuCuGG 177 UGGCCAGUUUGGCUUCUGG 1745 20838. AS 68 CCAGAAGCCAAACUGGCCA 178 CCAGAAGCCAAACUGGCCA 1745. AD - S 69 uGuCuCAGGAGcGGGACcA 179 UGUCUCAGGAGCGGGACCA 1600 20839. AS 70 UGGUCCCGCUCCUGAGAcA 180 UGGUCCCGCUCCUGAGACA 1600. AD— S 71 GuGGAGGcccAcACCAAcu lBl GUGGAGGCCCACACCAACU 1920 2084O. AS 72 AGUUGGUGUGGGCCUCcAC 182 AGUUGGUGUGGGCCUCCAC 1920. AD— S 73 GGGuGGCCAGuuuGGCuuC 183 GGGUGGCCAGUUUGGCUUC 1742 20841. AS 74 GAAGCCAAACUGGCCACCC lS4 GAAGCCAAACUGGCCACCC 1742. AD— S 75 GGuGGCcAGuuuGGCuucu lS5 GGUGGCCAGUUUGGCUUCU 1743 20842. AS 76 AGAAGCCAAACUGGCCACC l86 AGAAGCCAAACUGGCCACC 1743. AD— S 77 uCACcCuGAGcAGGAAGGG lB7 UCACCCUGAGCAGGAAGGG 1630 20843. AS 78 CCCUUCCUGCUCAGGGUGA 188 CCCUUCCUGCUCAGGGUGA 1630. AD— S 79 GCcAGuuuGchuCuGGAu lS9 GCCAGUUUGGCUUCUGGAU 1747 20844. AS 80 AUCCAGAAGCCAAACUGGC 190 AUCCAGAAGCCAAACUGGC 1747. AD - S 81 AGCuGGuGGAGGcCCACAC 191 AGCUGGUGGAGGCCCACAC 1915 20845. AS 82 GUGUGGGCCUCCACCAGCU 192 GUGUGGGCCUCCACCAGCU 1915. AD - S 83 AMCuCCAuGGCuGACuGGC 193 AUCUCCAUGGCUGACUGGC 1545 20846. AS 84 GCCAGUCAGCCAUGGAGAU l94 GCCAGUCAGCCAUGGAGAU 1545. US 20l2 / 0l15934 Al May lO , 20l2. . . . 48 TABLE l—continued Beta - ENaC sequences Duplex SEQ SEQ ID ID Modified sequence ID Unmodified sequence Posn AD - S 85 GGCAuGACAGAGAAGGCAC 195 GGCAUGACAGAGAAGGCAC 1008 20847. AS 86 GUGCCUUCUCUGUcAUGCC 196 GUGCCUUCUCUGUCAUGCC 1008. AD— S 87 GGAGAAAuACuGCAACAAC l97 GGAGAAAUACUGCAACAAC l409 20848. AS 88 GUUGUUGCAGuAUUUCUCC 198 GUUGUUGCAGUAUUUCUCC 1409. AD— S 89 uGGGuGGCCAGuuuGGCuu 199 UGGGUGGCCAGUUUGGCUU l74l 20849. AS 9O AAGCCAAACUGGCCACCcA 200 AAGCCAAACUGGCCACCCA 1741. AD— S 91 GAGCuGGuGGAGGCCCACA 20l GAGCUGGUGGAGGCCCACA 1914 2085O. AS 92 UGUGGGCCUCcACCAGCUC 202 UGUGGGCCUCCACCAGCUC 1914. AD— S 93 GACAGAGAAGGCACuuCCu 203 GACAGAGAAGGCACUUCCU 10l3 2085l. AS 94 AGGAAGUGCCUUCUCUGUC 204 AGGAAGUGCCUUCUCUGUC 1013. AD - S 95 AGuuuGGCuuCuGGAuGGG 205 AGUUUGGCUUCUGGAUGGG 1750 20852. AS 96 CCCAUCCAGAAGCCAAACU 206 CCCAUCCAGAAGCCAAACU 1750. AD - S 97 uGACAGAGAAGGcACuucC 207 UGACAGAGAAGGCACUUCC 10l2 20861. AS 98 GGAAGUGCCUUCUCUGUCA 208 GGAAGUGCCUUCUCUGUCA 1012. AD - S 99 GAAGAAGuACCuGCuGAAG 209 GAAGAAGUACCUGCUGAAG 185 20862. AS 100 CUUCAGcAGGuACUUCUUC 210 CUUCAGCAGGUACUUCUUC 185. AD - S 101 uCuCCAuGGCuGACuGGCC 211 UCUCCAUGGCUGACUGGCC 1546 20863. AS 102 GGCCAGUcAGCCAUGGAGA 212 GGCCAGUCAGCCAUGGAGA 1546. AD - S 103 CuGGuGGAGGCCCACACCA 213 CUGGUGGAGGCCCACACCA 1917 20864. AS 104 UGGUGUGGGCCUCcACcAG 214 UGGUGUGGGCCUCCACCAG 1917. AD— S 105 cAGAGAAGGcAcuuccuuc 215 CAGAGAAGGCACUUCCUUC 1015 20865. AS 106 GAAGGAAGUGCCUUCUCUG 216 GAAGGAAGUGCCUUCUCUG 1015. AD— S 107 cuGcAGGccAccAAcAucu 217 CUGCAGGCCACCAACAUCU 837 20866. AS 108 AGAUGUUGGUGGCCUGCAG 218 AGAUGUUGGUGGCCUGCAG 837. AD— S 109 GGGcAuGAcAGAGAAGGcA 219 GGGCAUGACAGAGAAGGCA 1007 20867. AS 110 UGCCUUCUCUGUCAUGCCC 220 UGCCUUCUCUGUCAUGCCC 1007. . US 20l2 / 0ll5934 Al. [ 0818 ] Modiﬁcations of the sequences of RNAi agents of SEQ ID NO : 111 to 220 are easily conceiVed by one of skill in the art. Examples and non - limiting modiﬁcations 0f these sequences are conceiVed and are also listed in Table l , e. g. , the sense and antisense ( AS ) sequences in SEQ ID NO : 1 to 110. [ 0819 ] Some modiﬁcations are placed at sites predicted to be sensitiVe to endonucleases. Some modiﬁcations are designed to eliminate an immune response to the siRNA While preserVing actiVity. In general , the sense strand is heaVily modiﬁed , and the antisense strand lightly modiﬁed. Some modiﬁcations serVe more than one purpose. [ 0820 ] The sequences in Table 1 and other tables are represented by these abbreViations : . TABLE lA. . ABBREVLATIONS. . AbbreViation Nuc1eotide ( s ) . . adenosine - 5Lphosphate cythﬁne - 55phosphate guanosine - 55phosphate 2Ldeoxy - ﬁankﬁne - 5Lphosphate uridine - 5 ' - phosphate. 2 ' - O - methylcytidine - 5 ' - phosphate. 2 ' - O - methyluridine - 5 ' - ph0sphate 2 ' - deoxy Thymidine 5 ' - phosphorothi0ate. g=o<2%mo>. S. . [ 0821 ] siRNA Sequence Selection. [ 0822 ] A total of 55 sense and 55 antisense human SCNNB1 - deriVed siRNA 01igos ( RNAi agents to BetaENaC ) are synthesized , as described in Example 2. The sense and their respectiVe antisense oligos are annealed into duplexes. Example 1A OVerlapping Sets of Beta - ENaC RNAi Agents. [ 0823 ] The present disclosure also relates to groups of RNAi agents to Beta - ENaC With oVerlapping sequences. May 10 , 2012. Thus , the present disclosure encompasses groups of RNAi agents Wherein each RNAi agent in the group oVerlaps With each other RNAi agent in the same group by at least 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , lS , 16 , 17 , 18 , 19 or more nucleotides. Particularly , in one emb0diment , the oVerlap is at least 12 nt. [ 0824 ] Some of the RNAi agents listed herein oVerlap each other in sequence. Table 2 presents a compilation of some of these groups of oVerlapping RNAi agents , Wherein each member of a group oVerlaps With each other member of the same group by at least 12 nt. A 12 - nt portion of the oVerlap of the sense and anti - sense strand are presented. [ 0825 ] Thus , for example , as sh0Wn in Table 2 , the sequences of RNAi agents AD - 20807 andAD - 20832 oVerlap , Wherein the oVerlap in the sense strand comprises the sequence UGAAGAAGUACC ( SEQ ID NO : 223 ) ; these RNAi agents also oVerlap in the anti - sense strand sequence , Wherein the oVerlap comprises the sequence GGUACUUCUUCA ( SEQ ID NO : 224 ) . The RNAi agents AD - 20807 , AD - 20862 and AD - 20832 all oVerlap in the sense strand , Wherein the oVerlap comprises the sequence GAAGAAGUACCU ( SEQ ID NO : 225 ) ; these RNAi agents also oVerlap in the anti - sense strand , Wherein the oVerlap comprises the sequence AGGUACUUCUUC ( SEQ ID NO : 226 ) . Thus , these and other Various sets of oVerlapping RNAi agents presented in Table 2 share common technical features , for example , the oVerlap in the sense and anti - sense strand. [ 0826 ] Particular sets of oVerlapping RNAi agents to BetaENaC are proVided beloW in Table 2. [ 0827 ] The present disclosure thus encompasses any group or subgroup of RNAi agents comprising a common technical feature , Wherein the common technical feature is an oVerlap ( e. g. , of at least 12 nt ) of a sequence in the sense or anti - sense strand. TABLE 2. . Pos. Sense overlap. SEQ Anti— sense ID overlap. SEQ OVerlapping RNAi agents to ID Beta—ENaC. . 183. 184. 185. 186. 187. 188. 189. 190. 400. 401. UGAAGAAGUACC. GAAGAAGUACCU. AAGAAGUACCUG. AGAAGUACCUGC. GAAGUACCUGCU. AAGUACCUGCUG. AGUACCUGCUGA. GUACCUGCUGAA. GAGCUGGGAGGU. AGCUGGGAGGUC. 223 GGUACUUCUUCA 224 AD—20807 , AD—20832. 225 AGGUACUUCUUC 226 AD—20807 , AD—20862 , 20832. 227 CAGGUACUUCUU 228 AD—20807 , AD—20862 , 20832. 229 GCAGGUACUUCU 230 AD—20807 , AD—20862 , 20832. 231 AGCAGGUACUUC 232 AD—20807 , AD—20862 , 20832. 233 CAGCAGGUACUU 234 AD - 20807 , AD - 20862 , 20832. 235 UCAGCAGGUACU 236 AD - 20807 , AD - 20862 , 20832. 237 UUCAGCAGGUAC 238 AD—20862 , AD—20832. 239 ACCUCCCAGCUC 240 AD - 20820 , AD - 20837. 241 GACCUCCCAGCU 242 AD - 20820 , AD - 20812 , . 20837. US 20l2 / 0ll5934 Al. 50. TABLE 2—continued. . SEQ Anti - sense. SEQ Overlapping RNAi agents to. . Pos Sense overlap ID over1ap ID Beta - ENaC 402 GCUGGGAGGUCA 243 UGACCUCCCAGC 244 AD—20820 , AD—208l9 , AD— 208l2 , AD—20837 403 CUGGGAGGUCAG 245 CUGACCUCCCAG 246 AD—208l9 , AD—208l2 , AD— 20837 404 UGGGAGGUCAGC 247 GCUGACCUCCCA 248 AD—20820 , AD—208l9 , AD— 20837 405 GGGAGGUCAGCG 249 CGCUGACCUCCC 250 AD—20820 , AD—208l9 , AD— 208l2 , AD - 20837 406 GGAGGUCAGCGU 25l ACGCUGACCUCC 252 AD—208l9 , AD—20837 407 GAGGUCAGCGUC 253 GACGCUGACCUC 254 AD—20820 , AD—208l9 , AD— 208l2 408 AGGUCAGCGUCU 255 AGACGCUGACCU 256 AD—208l9 , AD—208l2 836 CUGCAGGCCACC 257 GGUGGCCUGCAG 258 AD—20866 , AD—208l7 837 UGCAGGCCACCA 259 UGGUGGCCUGCA 260 AD - 20866 , AD - 20830 , AD - 208l7 838 GCAGGCCACCAA 26l UUGGUGGCCUGC 262 AD—20866 , AD—20830 , AD— 208l7 839 CAGGCCACCAAC 263 GUUGGUGGCCUG 264 AD - 20866 , AD - 20830 , AD - 208l7 840 AGGCCACCAACA 265 UGUUGGUGGCCU 266 AD—20866 , AD—20830 , AD— 208l7 84l GGCCACCAACAU 267 AUGUUGGUGGCC 268 AD—20866 , AD—20830 , AD— 208l7 842 GCCACCAACAUC 269 GAUGUUGGUGGC 270 AD - 20866 , AD - 20830 , AD - 208l7 843 CCACCAACAUCU 27l AGAUGUUGGUGG 272 AD—20866 , AD—20830 1007 GGCAUGACAGAG 273 CUCUGUCAUGCC 274 AD—20847 , AD—20867 lO08 GCAUGACAGAGA 275 UCUCUGUCAUGC 276 AD - 20826 , AD - 20867 lO09 CAUGACAGAGAA 277 UUCUCUGUCAUG 278 AD—20826 , AD—2083l , AD— 20867 lOl0 AUGACAGAGAAG 279 CUUCUCUGUCAU 280 AD - 20826 , AD - 2083l , AD - 20867 , AD - 20806 lOll UGACAGAGAAGG 28l CCUUCUCUGUCA 282 AD—20826 , AD—2083l , AD— 20867 , AD—20806 , AD—2086l lOl2 GACAGAGAAGGC 283 GCCUUCUCUGUC 284 AD - 2085l , AD - 20847 , AD - 20826 , AD - 2083l , AD - 20867 , AD—20806 , AD—2086l lOl3 ACAGAGAAGGCA 285 UGCCUUCUCUGU 286 AD—2085l , AD—20835 , AD— 20847 , AD - 20826 , AD - 2083l , AD - 20867 , AD - 20806 , AD - 2086l lOl4 CAGAGAAGGCAC 287 GUGCCUUCUCUG 288 AD—2085l , AD—20835 , AD— 20865 , AD—20826 , AD—2083l , AD - 20806 , AD - 2086l lOl5 AGAGAAGGCACU 289 AGUGCCUUCUCU 290 AD - 2085l , AD - 20835 , AD - . 20865 , AD—20826 , AD—20831 , AD—20806 , AD—20861. May 10 , 2012. US 20l2 / 0ll5934 Al. 51. TABLE 2—continued. . SEQ Anti - sense. SEQ Overlapping RNAi agents to. . Pos Sense overlap ID over1ap ID Beta - ENaC. lOl6 GAGAAGGCACUU 291 AAGUGCCUUCUC 292 AD—20851 , AD—20835 , AD— 20865 , AD - 20831 , AD - 20806 , AD—20861. 1017 AGAAGGCACUUC 293 GAAGUGCCUUCU 294 AD - 20851 , AD - 20835 , AD - 20865 , AD—20806 , AD—20861. 1018 GAAGGCACUUCC 295 GGAAGUGCCUUC 296 AD - 20851 , AD - 20835 , AD - 20865 , AD—20861. 1019 AAGGCACUUCCU 297 AGGAAGUGCCUU 298 AD—20851 , AD—20835 , AD— 20865. 1020 AGGCACUUCCUU 299 AAGGAAGUGCCU 300 AD—20835 , AD—20865. 1294 CUACAGUGACUA 301 UAGUCACUGUAG 302 AD - 20828 , AD - 20825. 1295 UACAGUGACUAC 303 GUAGUCACUGUA 304 AD - 20834 , AD - 20825. 1296 ACAGUGACUACA 305 UGUAGUCACUGU 306 AD—20828 , AD—20834 , AD— 20825 , AD - 20836. 1297 CAGUGACUACAA 307 UUGUAGUCACUG 308 AD—20834 , AD—20805 , AD— 20825. 1298 AGUGACUACAAC 309 GUUGUAGUCACU 310 AD—20828 , AD—20834 , AD— 20805 , AD - 20825 , AD - 20836. 1299 GUGACUACAACA 311 UGUUGUAGUCAC 3l2 AD - 20834 , AD - 20805 , AD - 20808 , AD - 20825. 1300 UGACUACAACAC 313 GUGUUGUAGUCA 314 AD - 20828 , AD - 20834 , AD - 20805 , AD - 20808 , AD - 20825 , AD—20815 , AD—20836. 1301 GACUACAACACG 315 CGUGUUGUAGUC 316 AD—20828 , AD—20834 , AD— 20805 , AD—20808 , AD—20836. 1302 ACUACAACACGA 317 UCGUGUUGUAGU 318 AD—20834 , AD—20805 , AD— 20808. l303 CUACAACACGAC 319 GUCGUGUUGUAG 320 AD—20805 , AD—20808 , AD— 20815 , AD - 20836. l304 UACAACACGACC 321 GGUCGUGUUGUA 322 AD—20805 , AD—20808. 1305 ACAACACGACCU 323 AGGUCGUGUUGU 324 AD - 20808 , AD - 20815. 1408 GGAGAAAUACUG 325 CAGUAUUUCUCC 326 AD - 20813 , AD - 20848. 1409 GAGAAAUACUGC 327 GCAGUAUUUCUC 328 AD—20813 , AD—20848. 1410 AGAAAUACUGCA 329 UGCAGUAUUUCU 330 AD—20813 , AD—20848. 1411 GAAAUACUGCAA 331 UUGCAGUAUUUC 332 AD - 20813 , AD - 20848. 1412 AAAUACUGCAAC 333 GUUGCAGUAUUU 334 AD - 20813 , AD - 20848. l4l3 AAUACUGCAACA 335 UGUUGCAGUAUU 336 AD—20813 , AD—20848. l4l4 AUACUGCAACAA 337 UUGUUGCAGUAU 338 AD—20813 , AD—20848. 1545 UCUCCAUGGCUG 339 CAGCCAUGGAGA 340 AD - 20846 , AD - 20863. 1546 CUCCAUGGCUGA 341 UCAGCCAUGGAG 342 AD - 20846 , AD - 20863. 1547 UCCAUGGCUGAC 343 GUCAGCCAUGGA 344 AD—20846 , AD—20863. 1548 CCAUGGCUGACU 345 AGUCAGCCAUGG 346 AD—20846 , AD—20863. 1549 CAUGGCUGACUG 347 CAGUCAGCCAUG 348 AD - 20846 , AD - 20863. May 10 , 2012. US 20l2 / 0ll5934 Al. 52. TABLE 2—continued. . SEQ Anti - sense. SEQ Overlapping RNAi agents to. . Pos Sense overlap ID over1ap ID Beta - ENaC. 1550 AUGGCUGACUGG 349 CCAGUCAGCCAU 350 AD—20846 , AD—20863. 1551 UGGCUGACUGGC 351 GCCAGUCAGCCA 352 AD - 20846 , AD - 20863. 1626 AUAUCACCCUGA 353 UCAGGGUGAUAU 354 AD - 20816 , AD - 20827. 1627 UAUCACCCUGAG 355 CUCAGGGUGAUA 356 AD—20816 , AD—20827 , AD— 20829. 1628 AUCACCCUGAGC 357 GCUCAGGGUGAU 358 AD—20816 , AD—20827 , AD— 20829 , AD - 20818. 1629 UCACCCUGAGCA 359 UGCUCAGGGUGA 360 AD—20816 , AD—20827 , AD— 20829 , AD - 20843 , AD - 20818. 1630 CACCCUGAGCAG 361 CUGCUCAGGGUG 362 AD - 20816 , AD - 20827 , AD - 20829 , AD - 20843 , AD - 20818. 1631 ACCCUGAGCAGG 363 CCUGCUCAGGGU 364 AD - 20816 , AD - 20827 , AD - 20829 , AD—20843 , AD—20818. 1632 CCCUGAGCAGGA 365 UCCUGCUCAGGG 366 AD - 20816 , AD - 20827 , AD - 20829 , AD—20843 , AD—20818. 1633 CCUGAGCAGGAA 367 UUCCUGCUCAGG 368 AD—20827 , AD—20829 , AD— 20843 , AD - 20818. l634 CUGAGCAGGAAG 369 CUUCCUGCUCAG 370 AD - 20829 , AD - 20843 , AD - 20818. 1635 UGAGCAGGAAGG 371 CCUUCCUGCUCA 372 AD—20843 , AD—20818. 1740 UGGGUGGCCAGU 373 ACUGGCCACCCA 374 AD - 20824 , AD - 20849. 1741 GGGUGGCCAGUU 375 AACUGGCCACCC 376 AD—20824 , AD—20841 , AD— 20849. 1742 GGUGGCCAGUUU 377 AAACUGGCCACC 378 AD - 20824 , AD - 20842 , AD - 20841 , AD - 20849. l743 GUGGCCAGUUUG 379 CAAACUGGCCAC 380 AD—20824 , AD—20842 , AD— 20821 , AD—20841 , AD—20849. 1744 UGGCCAGUUUGG 381 CCAAACUGGCCA 382 AD - 20824 , AD - 20842 , AD - 20821 , AD—20838 , AD—20841 , AD—20849. 1745 GGCCAGUUUGGC 383 GCCAAACUGGCC 384 AD - 20824 , AD - 20842 , AD - 20821 , AD - 20838 , AD - 20841 , AD - 20823 , AD - 20849. l746 GCCAGUUUGGCU 385 AGCCAAACUGGC 386 AD—20844 , AD—20824 , AD— 20842 , AD—20821 , AD—20838 , AD - 20841 , AD - 20823 , AD - 20849. 1747 CCAGUUUGGCUU 387 AAGCCAAACUGG 388 AD—20814 , AD—20844 , AD— 20842 , AD—20821 , AD—20838 , AD—20841 , AD—20823 , AD— 20849. 1748 CAGUUUGGCUUC 389 GAAGCCAAACUG 390 AD - 20814 , AD - 20844 , AD - 20842 , AD—20821 , AD—20838 , AD—20841 , AD—20822 , AD— 20823. 1749 AGUUUGGCUUCU 391 AGAAGCCAAACU 392 AD - 20814 , AD - 20844 , AD - . 20842 , AD - 20821 , AD - 20852 , AD—20838 , AD—20822 , AD— 20823. May 10 , 2012. US 20l2 / 0ll5934 Al. TABLE 2—continued. May 10 , 2012. . SEQ Anti - sense. Pos Sense overlap ID over1ap. SEQ Overlapping RNAi agents to ID Beta - ENaC. . 1750 GUUUGGCUUCUG 393 CAGAAGCCAAAC. 394 AD—20814 , AD—20844 , AD—. 20s21 , AD - 20852 , AD - 20838 , AD—20822 , AD—20823. 1751 UUUGGCUUCUGG 395 CCAGAAGCCAAA 396 AD - 20814 , AD - 20844 , AD - 20852 , AD—20838 , AD—20822 , . AD - 20823. 1752 UUGGCUUCUGGA 397 UCCAGAAGCCAA 398 AD—20814 , AD—20844 , AD— 20852 , AD - 20822 , AD - 20823. 1753 UGGCUUCUGGAU 399 AUCCAGAAGCCA 400 AD—20814 , AD—20844 , AD— 20852 , AD - 20822. 1754 GGCUUCUGGAUG 401 CAUCCAGAAGCC 402 AD - 20814 , AD - 20852 , AD - . 20822. 1755 GCUUCUGGAUGG 403 CCAUCCAGAAGC 404 AD - 20852 , AD - 20822. 1914 AGCUGGUGGAGG 405 CCUCCACCAGCU 406 AD—20850 , AD—20845. 1915 GCUGGUGGAGGC 407 GCCUCCACCAGC 408 AD—20850 , AD—20845 , AD—. 20833. 1916 CUGGUGGAGGCC 409 GGCCUCCACCAG 410 AD—20850 , AD—20845 , AD— 20833 , AD—20864. 1917 UGGUGGAGGCCC 411 GGGCCUCCACCA 412 AD—20810 , AD—20850 , AD— 20845 , AD - 20833 , AD - 20864. 1918 GGUGGAGGCCCA 413 UGGGCCUCCACC 414 AD—20809 , AD—20810 , AD— 20850 , AD - 20845 , AD - 20833 , . AD - 20864. 1919 GUGGAGGCCCAC 415 GUGGGCCUCCAC 416 AD - 20809 , AD - 20810 , AD - 20850 , AD—20845 , AD—20833 , AD—20864 , AD—20840. 1920 UGGAGGCCCACA 417 UGUGGGCCUCCA 418 AD—20809 , AD—20810 , AD— 20850 , AD—20845 , AD—20833 , AD - 20864 , AD - 20840. 1921 GGAGGCCCACAC 419 GUGUGGGCCUCC 420 AD - 20809 , AD - 20810 , AD - 20845 , AD - 20833 , AD - 20864 , . AD—20840. 1922 GAGGCCCACACC 421 GGUGUGGGCCUC 422 AD - 20809 , AD - 20810 , AD - 20833 , AD—20864 , AD—20840. 1923 AGGCCCACACCA 423 UGGUGUGGGCCU 424 AD—20809 , AD—20810 , AD— 20864 , AD—20840. 1924 GGCCCACACCAA 425 UUGGUGUGGGCC 426 AD—20809 , AD—20810 , AD—. 20840. 1925 GCCCACACCAAC 427 GUUGGUGUGGGC 428 AD—20809 , AD—20840. . [ 0828 ] The position ( “Po s” ) in NM_00033 6.2 is indicated. lZ examplary nt of the oVerlap in the sense and anti - sense strand are presented ; in many cases , the oVerlap is actually longer. Example 2 Synthesis of Beta - ENaC RNAi Agent Sequences. [ 0829 ] The modiﬁed Beta - ENaC RNAi agent sequences listed as SEQ ID NO : 1 to 110 in Table 1 are synthesized on MerMade 192 synthesizer at 1 umol scale. [ 083 0 ] For all the sequences in the list , ‘endolight chemistry is applied as detailed beloW. [ 0831 ] All pyrimidines ( cytosine and uridine ) in the sense strand contain 2 ' - O - Methyl bases ( 2 ' O - Methyl C and 2 ' - O - Methyl U ) . [ 0832 ] In the antisense strand , pyrimidines adjacent to ( i. e. , toWards the 5 ' position ) ribo A nucleoside are replaced With their corresponding 2 - O - Methyl nucleosides. [ 0833 ] A tWo - base dedT extension at 3 ' end of both sense and anti sense sequences is introduced. US 20l2 / 0ll5934 Al. [ 0834 ] The sequence ﬁle is conVerted to a text ﬁle to make it compatible for loading in the MerMade 192 synthesis softWare. [ 0835 ] Synthesis , CleaVage and deprotecti0n : . [ 0836 ] The synthesis of Beta - ENaC sequences uses solid supported oligonucleotide synthesis using phosphoramidite chemistry. [ 0837 ] The synthesis of the aboVe sequences is performed at 1 um scale in 96 Well plates. The amidite solutions are prepared at 0.1M concentration and ethyl thio tetrazole ( 0.6M in Acetonitrile ) is used as actiVator. [ 0838 ] The synthesized sequences are cleaVed and de - protected in 96 Well plates , using methylamine in the ﬁrst step and ﬁuoride reagent in the second step. The crude sequences are precipitated using acetone : ethan0l ( 80 : 20 ) mix and the pellets are re - suspended in 0.2M sodium acetate buffer. Samples from each sequence are analyzed by LC - MS to conﬁrm the identity , UV for quantiﬁcation and a selected set of samples by IEX chromatography to determine purity. [ 0839 ] Puriﬁcation and Desalting : . [ 0840 ] Beta - ENaC sequences are puriﬁed on AKTA explorer puriﬁcation system using Source lSQ column. A c0lumn temperature of 65 C is maintained during puriﬁcation. Sample injection and collection is performed in 96 Well ( 1.8 mL - deep Well ) plates. A single peak corresponding to the full length sequence is c0llected in the eluent. The puriﬁed sequences are desalted on a Sephadex G25 column using AKTA puriﬁer. The desalted Beta - ENaC sequences are analyzed for concentration ( by UV measurement at A260 ) and purity ( by ion exchange HPLC ) . [ 0841 ] The single strands are then submitted for annealing. [ 0842 ] A detailed list of Beta - ENaC single strands and duplexes are shoWn in Table l , aboVe. The duplexes are used in in Vitro screening to test their ability to knock doWn BetaENaC gene leVel. Example 3 In Vitro Screening of Beta - ENaC RNAi Agents. [ 0843 ] The Beta - ENaC RNAi agents are screened in Vitro to determine their ability to knock doWn Beta - ENaC gene leVel. [ 0844 ] Cell Culture and Transfections : . [ 0845 ] H44l ( ATCC , Manassas , Va. ) cells are groWn to near conﬁuence at 37° C. in an atmosphere of 5% CO2 in RPMI 1640 ( ATCC ) supplemented With 10% FBS , streptomycin , and glutamine ( ATCC ) before being released from the plate by trypsinization. ReVerse transfection is carried out by adding 5 111 of Opti - MEM to 5 111 of siRNA duplexes per Well into a 96 - Well plate along With lO 111 of Opti - MEM plus 0.2 111 of Lipofectamine RNAiMax per Well ( InVitrogen , Carlsbad Calif. cat #13778 - 1 50 ) and incubated at room temperature for 15 minutes. 80 111 of complete grthh media Without antibiotic containing 2.0><l04 H44l cells are then added. Cells are incubated for 24 hours prior to RNA puriﬁcation. Experiments are performed at 0.1 or 10 nM ﬁnal duplex concentration for single dose screens With each of the 55 Beta - ENaC duplexes. Each siRNA is transfected 3 times at each of the doses tested. The results are shoWn in Table 3. [ 0846 ] A subset of duplexes that shoWs robust silencing in the lO nM and 0. l nM screens is assayed oVer a range of concentrations from 10 nM to 10 fM using serial dilutions to determine their IC5O. The results are shoWn in Table 4. May 10 , 2012. [ 0847 ] Total RNA Isolation : . [ 0848 ] Cells are harVested and lysed in l40 111 of Lysis / Binding Solution then mixed for 1 minute at 850 rpm using an Eppendorf Thermomixer ( the mixing speed Was the same throughout the process ) . [ 0849 ] A MagMAX - 96 Total RNA Isolati0n Kit ( Applied Biosystem , Foster City Calif. , part # : AMl830 ) is used to isolate total RNA. TWenty micro liters of magnetic beads and Lysis / Binding Enhancer mixture are added into cell - lysate and mixed for 5 minutes. Magnetic beads are captured using magnetic stand and the supernatant is remoVed Without disturbing the beads. After remoVing supernatant , magnetic beads are Washed With Wash. [ 0850 ] Solution 1 ( isopropan0l added ) and mixed for 1 minute. Beads are capture again and supernatant remoVed. Beads are then Washed With 150 111 Wash Solution 2 ( Ethanol added ) , captured and supernatant is remoVed. 50 ul of DNase mixture ( MagMax turbo DNase Buffer and Turbo DNase ) is then added to the beads and they are mixed for lO to lS minutes. After mixing , 100 111 of RNA Rebinding Solution is added and mixed f0r 3 minutes. Supernatant is remoVed and magnetic beads are Washed again With 150 111 Wash Solution 2 and mixed for 1 minute and supernatant is remoVed com - . pletely. The magnetic beads are mixed for 2 minutes to dry before RNA is eluted With 50 111 of Water. [ 0851 ] cDNA synthesis : . [ 0852 ] ABI High capacity cDNA reVerse transcription kit ( Applied Bi0systems , Foster City , Calif. , Cat #43688l3 ) is used for cDNA synthesis. Amaster mix of 2 111 lO>< Buffer , 0.8 111 25>< dNTPs , 2 111 Random primers , 1 111 ReVerse Transcriptase , 1 111 RNase inhibitor and 3 .2 111 of H2O per reaction are added into 10 111 total RNA. cDNA is generated using a Bio - Rad C - 1000 or S - 1000 thermal cycler ( Hercules , Calif. ) through the folloWing steps : 25° C. lO min , 37° C. l20 min , 85° C. 5 sec , 4° C. h0ld. [ 0853 ] Real Time PCR : . [ 0854 ] 2 111 of cDNA are added to a master mix containing 0.5 ul GAPDH TaqMan Probe. [ 0855 ] ( Applied Biosystems. Cat #4326317E ) , 0.5 111 BetaENaC TaqMan probe ( Applied Biosystems cat #Hs00l65722_ml ) and 5 111 Roche Probes Master Mix ( Roche Cat #0488730l00l ) in a total of lO piper Well in a LightCycler 480 384 Well plate ( Roche cat #047297400l ) . Real time PCR is done in a LightCycler 480 Real Time PCR machine ( Roche ) . Each duplex is tested in tWo independent transfections and each transfections is assayed in duplicate. [ 0856 ] Real time data are analyzed using the AACt meth0d. Each sample is normalized to GAPDH expression and knockdoWn is assessed relatiVe to cells transfected With the nontargeting duplex AD - 1955. IC50s are deﬁned using a 4 parameter ﬁt model in XLﬁt. [ 0857 ] The results are shoWn beloW. Table 3 shoWs the results of experiments performed at 0. l nM or lO nM ﬁnal duplex concentrations for single dose screens With each of the 55 Beta - ENaC duplexes. The “Fraction message remaining” indicates the residual gene leVel , at 10 nm or 0.1 nM. Thus “0.17” inthe second column for AD - 20832 - b1 indicates that , at a concentration of lO nM , there Was l7% residual gene leVel , or 83% knockdoWn of expression. Note also that the sufﬁx “bl” indicates “batch l.” Thus , for example , a RNAi agent With the designation “AD - 20832 - b1” has the same sequence as a RNAi agent designated “AD - 20832”. US 20l2 / 0ll5934 Al. TABLE 3. May 10 , 2012. TABLE 4. . 10 nM and 0.1 nM kn0ckdoWn 0f Beta - ENaC. . Beta - ENaC dose resp0nse screen. . Fracti0n Fraction. . message message Standard Standard. remaining remaining deViation deViation. At 10 nM At0.1nM At 10 nM At0.1nM AD - 20832 - b1 0.17 0.33 0.04 0.03 AD - 20848 - b1 0.17 0.49 0.01 0.04 AD - 20807 - b1 0.18 0.26 0.02 0.05 AD - 20826 - b1 0.19 0.49 0.02 0.22 AD - 20837 - b1 0.19 0.51 0.04 0.04 AD - 20861 - b1 0.19 0.71 0.02 0.29 AD - 20834 - b1 0.20 0.34 0.06 0.05 AD - 20806 - b1 0.22 0.60 0.02 0.15 AD - 20851 - b1 0.23 0.55 0.04 0.07 AD - 20865 - b1 0.24 0.64 0.02 0.05 AD - 20811 - b1 0.25 0.52 0.17 0.23 AD - 20819 - b1 0.27 0.60 0.01 0.07 AD - 20839 - b1 0.27 0.55 0.06 0.05 AD - 20835 - b1 0.28 0.63 0.07 0.21 AD - 20825 - b1 0.30 0.72 0.11 0.15 AD - 20867 - b1 0.30 0.68 0.00 0.20 AD - 20813 - b1 0.34 0.56 0.17 0.36 AD - 20823 - b1 0.34 0.75 0.05 0.05 AD - 20805 - b1 0.36 0.86 0.02 0.09 AD - 20831 - b1 0.36 0.60 0.01 0.21 AD - 20862 - b1 0.38 0.93 0.02 0.29 AD - 20808 - b1 0.40 0.81 0.13 0.16 AD - 20827 - b1 0.40 2.55 0.07 1.44 AD - 20828 - b1 0.42 0.89 0.11 0.25 AD - 20812 - b1 0.47 0.74 0.32 0.36 AD - 20836 - b1 0.48 1.07 0.11 0.27 AD - 20822 - b1 0.49 0.94 0.11 0.09 AD - 20810 - b1 0.53 0.87 0.25 0.20 AD - 20824 - b1 0.54 1.12 0.08 0.33 AD - 20844 - b1 0.55 0.98 0.07 0.28 AD - 20814 - b1 0.60 1.30 0.09 0.12 AD - 20838 - b1 0.65 1.18 0.07 0.18 AD - 20816 - b1 0.66 1.38 0.05 0.17 AD - 20845 - b1 0.72 1.18 0.01 0.27 AD - 20820 - b1 0.75 0.89 0.06 0.14 AD - 20830 - b1 0.75 0.94 0.04 0.24 AD - 20866 - b1 0.77 1.24 0.03 0.57 AD - 20809 - b1 0.78 1.05 0.05 0.03 AD - 20833 - b1 0.79 0.99 0.01 0.35 AD - 20821 - b1 0.80 0.99 0.07 0.14 AD - 20846 - b1 0.83 1.13 0.10 0.15 AD - 20818 - b1 0.88 1.36 0.04 0.62 AD - 20817 - b1 0.89 1.11 0.11 0.19 AD - 20843 - b1 0.92 1.64 0.11 0.16 AD - 20840 - b1 0.93 1.13 0.15 0.30 AD - 20847 - b1 0.94 0.99 0.64 0.12 AD - 20815 - b1 0.96 2.06 0.23 0.99 AD - 20842 - b1 0.96 1.37 0.16 0.28 AD - 20852 - b1 0.96 1.30 0.17 0.17 AD - 20863 - b1 0.99 0.84 0.24 0.11 AD - 20864 - b1 0.99 1.36 0.05 0.74 AD - 20850 - b1 1.00 1.22 0.14 0.14 AD - 20829 - b1 1.08 1.39 0.26 0.70 AD - 20849 - b1 1.11 1.31 0.27 0.17 AD - 20841 - b1 1.12 1.37 0.10 0.48. . [ 0858 ] All the RNAi agents to Beta - ENaC used in these experiments Were the modiﬁed sequences ( SEQ ID NO : 1 to llO ) listed in Table l. [ 0859 ] Table 4 shoWs the results of experiments Wherein a subset of duplexes that shoW robust silencing in the lO nM and 0.1 nM screens is assayed oVer a range of concentrations from lO nM to 10 fM using serial dilutions to determine their IC50. . H441 NeW ( AVerage H441 Old ( AVerage. . . . of 4 replicates ) of 8 rep1icates ) . IC50 IC50. Standard Standard. Duplex_ID IC50nM deViation IC50nM deViation AD - 20807 0.05 0.03 0.04 0.06 AD - 20826 0.14 0.05 0.05 0.07 AD - 20832 0.05 0.02 0.04 0.05 AD - 20834 0.06 0.03 0.03 0.06 AD - 20848 0.25 0.14 0.13 0.17 AD - 20861 0.13 0.08 0.09 0.06. Example 4. In ViVo Analysis 0f Beta - ENaC RNAi Agents AD - 20807 and AD - 20832. [ 0860 ] In in ViVo experiments , tWo Beta - ENaC RNAi agents , AD - 20807 and AD - 20832 , are tested for the ability to knock doWn Beta - ENaC gene leVel in Wh0le lungs in rats. The purpose is to determine the dose responses. Immunostimulation is also measured. [ 0861 ] The Rat strain used is Sprague - Daney ; indiViduals haVe an approximate Weight of 280 - 300 grams. Rats are dosed once a day for tWo days. They are then sacriﬁced about 24 hrs after the second dose. The left lung is taken and ground f0r qPCR determination of Beta - ENaC leVels ; the right lung frozen and stored. . . TABLE 5 Rat Rats per Group Numbers Formulation Concentration group 1 1 - 5 D5W NA 5 2 6 - 10 AD1955 10 mg / kg 5 3 11 - 15 AD20191 10 mg / kg 5 4 16 - 20 AD20807 10 mg / kg 5 5 12 - 25 AD20807 3 mg / kg 5 6 26 - 30 AD20807 1 mg / kg 5 7 31 - 35 AD20832 10 mg / kg 4 * 8 36 - 40 AD20832 3 mg / kg 5 9 41 - 45 AD20832 1 mg / kg 5. . * In 111e gr0up 0f 4 , 5 rats are initially d0sed , but 1 in each gr0up d0es n0t surViVe 111e experiment and is not included in the ﬁnal data. [ 0862 ] Both RNAi agents to Beta - ENaC , AD20807 and AD20832 , shoW reductions in Beta - ENaC leVels in a dosedependent manner. For AD20807 , the leVel of Beta - ENaC is reduced by approximately 30% , 40% , and 50% at dosages of 1 , 3 and lO mg / kg , respectiVely. [ 0863 ] In contrast , the Beta - ENaC ( bENaC ) RNAi agents do not decrease the leVel of Alpha - ENaC ( aENaC ) . There is , hoWeVer , an increase in Alpha - ENaC With administration of AD20832. [ 0864 ] NegatiVe Controls Include : . [ 0865 ] D5W : a solution of 5% dextrose in Water ; it is the Vehicle used to dilute the siRNA When dosing ; AD1955 : a siRNA Which does not speciﬁcally target either Alpha - or Beta - ENaC , but targets ﬁreﬁy luciferase ; and AD20l9l : a siRNA Which does not bind to Beta - ENaC , but targets rat Alpha - ENaC ; and AD - 9201 , Which targets Alpha - ENaC ( not used in this particular example ) . US 20l2 / 0ll5934 Al. [ 0866 ] Thus , speciﬁc knock - doWn of Beta - ENaC is seen With RNAi agent AD20807 and AD20832 in this experiment. Example 5. In ViVo Analysis of Beta - ENaC AD - 20834. [ 0867 ] In in ViVo experiments , Beta - ENaC RNAi agent AD20834 is tested for its ability to knock doWn Beta - ENaC gene leVel in Whole lungs in rats. The purp0se is to determine the dosage responses. Immunostimulation is also measured. [ 0868 ] The rat strain is Sprague - Daney ; indiViduals haVe an approximate Weight of 280 - 300 grams. Rats are dosed once a day for tWo days. They are then sacriﬁced about 24 hours after the second dose. The left lung is taken and ground for qPCR determination of Beta - ENaC leVels ; the right lung is frozen and stored. TABLE 6. . Group rat #s F0rmu1ati0n concentrati0n rats per gr0up. . 1 1 - 5 D5W NA 5 2 6 - 10 AD1955 10 mg / kg 4 * 3 11 - 15 AD20191 10 mg / kg 5 4 16 - 20 AD20834 10 mg / kg 5 5 21 - 25 AD20834 3 mg / kg 5 6 26 - 30 AD20834 1 mg / kg 4 * . . * In the groups of 4 , 5 rats are initially dosed , but 1 in each group does not suine the experiment and is n0t included in the ﬁnal data. [ 0869 ] Assuming a Weight of 300 grams ( 0.3 kg ) the folloWing dilutions are made : . lO mg / kg=3 mg 0f siRNA in a 200 uL Volume=l 5 mg / mL. 3 mg / kg : 1 mg of siRNA in a 200 uL Volume : 5 mg / mL. 1 mg / kg=0.3 mg of siRNA in a 200 uL Volume=1.5 mg / mL. [ 0870 ] The data are normalized t0 PPIB [ Peptidyl - prolyl cis - trans isomerase B , used as a housekeeping ( nonnalization ) gene ] . [ 0871 ] The experiments shoW that Beta - ENaC RNAi agent AD20834 demonstrates an approximately 40% reduction in Beta - ENaC leVel in Sprague - Daney rats. This effect is spe - ciﬁc to Beta - ENaC. [ 0872 ] The controls are as folloWs : D5W ( 5% dextrose in Water ) is a negatiVe control , not shoWing an effect on AlphaENaC or Beta - ENaC leVels. AD195 5 , a control siRNA Which does not bind to Alpha - or Beta - ENaC , als0 shoWing little effect on Alpha - or Beta - ENaC leVel. The positiVe control siRNA AD20l 9l , Which targets Alpha - but not Beta - ENaC , demonstrates an approximately 50% reduction in AlphaENaC leVel , but not Beta - ENaC. [ 0873 ] Thus , a dosage of lO mg / kg of Beta - ENaC RNAi agentAD20834 demonstrates at least about 40% inhibition of Beta - ENaC gene expression in Sprague - Daney rats. Example 6. [ 0874 ] Analysis of Beta - ENaC RNAi Agents. [ 0875 ] Additional experimentation is done With BetaENaC RNAi agents AD20807 , AD20832 , AD20834 , AD20848 , and AD20861 in ViVo in Sprague - Daney rats. Rats are dosed at lO mg / kg in D5W on day 1 and day 2 , and are sacriﬁced on day 3 , and the lungs are collected. [ 0876 ] The results are sh0Wn in FIG. 1. The results shoW qPCR data from the left lung , normalized to the control gene PPIB. [ 0877 ] The controls in FIG. 1 are as folloWs : D5W ( 5% dextrose in Water ) is a negatiVe control , not shoWing an effect. May 10 , 2012. on Alpha - ENaC or Beta - ENaC leVels. The positiVe control is AD - 9201 , Which targets Alpha - ENaC ( aENaC ) . [ 0878 ] The results , shoWn in FIG. 1 , shoW a statistically signiﬁcant and speciﬁc knock - doWn of Beta - ENaC ( bENaC ) by AD20807 , AD20832 , AD20834 , AD20848 , and AD2086l . The expression of the Beta - ENaC gene is inhibited by at least about 40% at a concentration of 10 mg / kg of these RNAi agents in Sprague - Daney rats. Example 7. [ 0879 ] In Vitro effect of Beta - ENaC RNAi Agent AD20832 on ENaC Channel Functional ActiVity in Human Bronchial Epithelial Cells. [ 0880 ] Human Bronchial Epithelial Cells ( HBEC ) are transfected With the indicated siRNA , including Beta - ENaC RNAi agent AD20832. Transfected cells are seeded onto SnapWell inserts and cultured for 24 hours. Subsequently , the apical culture medium is remoVed from each insert and the cells cultured at Air Liquid Interface ( ALI ) . Cells are assayed for ENaC and CFTR actiVity at Day 8 post - ALI as described. To control for cell Viability , ENaC ﬁmction is normalized to CFTR actiVity and the data presented as a percentage relatiVe to the untransfected control ( FIG. 2A ) . As an additional Viability 00ntrol , trans - membrane resistance is also measured ( FIG. 2B ) . Expression analysis of alpha and beta ENaC subunit mRNA is performed for each insert and normalized to GAPDH expression. ( FIG. 2C ) . The data demonstrate that a 70% inhibition of mRNA expression is sufﬁcient to generate a 50% functional inhibition of ENaC channel. This is true for knockdoWn of either alpha or beta subunits , Where each is compared to untransfected ( neg ) and non - speciﬁc ( ns ) siRNA controls. The data also shoW that beta ENaC siRNA does not inhibit alpha ENaC mRNA expression and Vice Versa. [ 0881 ] Methods : ENaC Functional ActiVity in Human Bronchial Epithelial Cells. [ 0882 ] Human Bronchial Epithelial Cells ( HBEC ) are purchased from Lonza and passaged once before freezing in grthh media ( BEGM plus singlequots—Lonza ) . Subsequently , cells are thaWed , expanded to conﬁuence and split 1 : 10 for transfection. Once at 80% conﬁuence , each ﬁask of cells is transfected With the indicated siRNA at 30 nM , using 4 L / mL Lipofectamine 2000 in a total Volume of 30 mL transfection media ( l : l mix of BEGM ( Lonza ) and DMEM high glucose ( Gibco ) With no additiVes ) . At 24 hours posttransfection , cells are seeded onto 6 Well SnapWell inserts ( Co star ) at 2.5><105 cells / insert in differentiation medium ( 50 : 50 mix of BEBM and DMEM / high glucose With singlequots ( minus the tri - iodothreonine and retinoic acid supplements , With all - trans retinoic acid added separately at 50 nM ) . Cells are supplemented With 0.5 mL differentiation media apically and 2.5 mL differentiation media basolaterally. FolloWing a further 24 hours of culture on the inserts the basolateral media is replaced and the apical media is remoVed , thus taking the cells to Air Liquid Interface ( ALI ) culture. Cells are assayed f0r ENaC and CFTR actiVity at Day 8 ( D8 ) Post - ALI. [ 0883 ] To assess the ion transport phenotype of the transfected cells the SnapWell inserts are mounted in Vertical Diffusion Chambers ( Costar ) and are bathed continuously With gassed Ringer solution ( 5% CO2 in Oz ; pH 7.4 ) maintained at 37° C. containing ( in mM ) : l20 NaCl , 25 NaHCO3 , 3.3 KH2PO4 , 0.8 K2HPO4 , l.2 CaCl2 , l.2 MgCl2 , and lO glucose ( Osmolarity maintained betWeen 280 and 300 mosmol / l ) . Cells are Voltage clamped to 0 mV ( model EVC4000 ; WPI ) . Trans - membrane resistance ( TM res ) is measured by apply - . US 20l2 / 0ll5934 Al. ing a 2 - mV pulse at 30 - s interVals and calculating TM res using Ohms laW. Short circuit current data are recorded using a PoWerLab Workstation ( ADI Instruments ) . ActiVity of the ENaC channel in each group is assessed by the change in short - circuit current folloWing the apical addition of lO MM of the ENaC blocker Amiloride ( Amil0ride - sensitiVe current ) . Chloride secretion Via CFTR is assessed by the change in short circuit current folloWing apical and basolateral addition of 0.6 11M Forskolin Which is knoWn to actiVate CFTR ( Forskolin response ) . For each insert the Amiloride - sensitiVe current is normalized to the Forsk0lin response and the data presented as a percentage relatiVe to the untransfected control. At the end of the study each insert is lysed for RNA analysis ( 300 11L RLT Buffer4Qiagen ) and samples retained for subsequent analysis of mRNA knockdoWn by rtPCR as described. ABBREVIATIONS [ 0884 ] ALI Air - Liquid Interface [ 0885 ] BEGM Bronchial Epithelial Grthh Medium [ 0886 ] D6 , D8 Day 6 , Day 8 [ 0887 ] DMEM Dulbeccos Modiﬁed Eagle Medium [ 0888 ] HBEC Human Bronchial Epithelial Cells [ 0889 ] TM res Trans - membrane resistance EQUIVALENTS [ 0890 ] A composition comprising a RNAi agent compris - . ing a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of a RNAi agent speciﬁc to Beta - ENaC proVided in Table 1. [ 0891 ] The composition of paragraph [ 00879 ] , Wherein the c0mposition further comprises a second RNAi agent to BetaENaC. [ 0892 ] The composition of paragraph [ 00879 ] , Wherein the antisense strand is 30 or feWer nucleotides in length. [ 0893 ] The composition of paragraph [ 00879 ] , Wherein the sense strand and the antisense strand fonn a duplex region lS to 30 nucleotide pairs in length. [ 0894 ] The composition of paragraph [ 00879 ] , Wherein the antisense strand and the sense strand are independently l9 to 23 nucleotides in length. [ 0895 ] The composition of paragraph [ 00879 ] , Wherein the RNAi agent comprises a modiﬁcation that causes the RNAi agent to haVe increased stability in a biological sample or enVironment. [ 0896 ] The composition of paragraph [ 00879 ] , Wherein the RNAi agent comprises at least one modiﬁed backbone and / or at least one 2 ' - modiﬁed nucleotide. [ 0897 ] The composition of paragraph [ 00879 ] , Wherein the RNAi agent comprises : . [ 0898 ] a ) at least one 5 ' - uridine - adenine - 3 ' ( 5 ' - ua - 3 ' ) dinucleotide , Wherein the uridine is a 2 ' - modiﬁed nucleotide ; and / or. [ 0899 ] b ) at least one 5 ' - uridine - guanine - 3 ' ( 5 ' - ug - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide ; and / or. [ 0900 ] c ) at least one 5 ' - cytidine - adenine - 3 ' ( 5 ' - ca - 3 ' ) dinucleotide , Wherein the 5 ' - cytidine is a 2 ' - m0diﬁed nucleotide ; and / or. [ 0901 ] d ) at least one 5 ' - uridine - uridine - 3 ' ( 5 ' - uu - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide. May 10 , 2012. [ 0902 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent comprises a 2 ' - modiﬁcation selected from the group consisting of : 2 ' - deoxy , 2 ' - deoxy - 2 ' - ﬁuoro , 2 ' - O - methyl , 2 ' - O - methoxyethyl ( 2 ' - O - MOE ) , 2 ' - O - aminopropyl ( 2 ' - O - AP ) , 2 ' - O - dimethylaminoethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylaminopr0pyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylaminoethyloxyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O7 N - methylacetamido ( 2 ' - O - NMA ) . [ 0903 ] The composition of cla paragraph [ 00879 ] l , Wherein the RNAi agent comprises a blunt end. [ 0904 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent comprises an oVerhang haVing 1 to 4 unpaired nucleotides. [ 0905 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent comprises an oVerhang at the 3 ' - end of the antisense strand of the RNAi agent. [ 0906 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent is ligated to one or more agent selected from : diagnostic compound , reporter group , cr0ss - linking agent , nuclease - resistance conferring moiety , natural or unusual nucleobase , lipophilic molecule , cholesterol , lipid , lectin , steroid , uVaol , hecigenin , diosgenin , terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanol - deriVatized lithocholic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate lS - mer , natural polymer , loW - or medium - molecular Weight polymer , inulin , cyclodextrin , hyaluronic acid , protein , protein - binding agent , integrin - targeting molecule , polycationic , peptide , p0lyamine , peptide mimic , and / or transferrin. [ 0907 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 60% at a 00ncentration of 10 nM in H44l cells in Vitro. [ 0908 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 70% at a concentration of lO nM in H44l cells in Vitro. [ 0909 ] The comp0sition of paragraph [ 0087 9 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 80% at a concentration of lO nM in H44l cells in Vitro. [ 0910 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 90% at a concentration of 10 nM in H44l cells in Vitro. [ 0911 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi has an EC50 of no more than about 0.1 nM. [ 0912 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi has an EC50 of no more than about 0.01 nM. [ 0913 ] The composition of paragraph [ 0087 9 ] , Wherein the RNAi has an EC50 of no more than about 0.00l nM. [ 0914 ] A comp0sition comprising a RNAi agent comprising a ﬁrst strand and a second strand , Wherein the ﬁrst strand and second strand comprise at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides fr0m the ﬁrst and second strand , respectiVely , of a RNAi agent speciﬁc to BetaENaC proVided in Table l. [ 0915 ] The composition of paragraph [ 0089 9 ] , Wherein the composition comprises a second RNAi agent to Beta - ENaC. [ 0916 ] The composition of paragraph [ 0089 9 ] , Wherein the second strand is 30 or feWer nucleotides in length. [ 0917 ] The composition of paragraph [ 0089 9 ] , Wherein the ﬁrst strand and the second strand form a duplex region 15 to 30 nucleotide pairs in length. US 20l2 / 0ll5934 Al. [ 0918 ] The composition of paragraph [ 00899 ] , Wherein the ﬁrst strand and the second strand are independently 19 to 23 nucleotides in length. [ 0919 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises a modiﬁcation that causes the RNAi agent to haVe increased stability in a biological sample or enVironment. [ 0920 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises a pho sphorothioate and / or a 2 ' - modi - ﬁed nucleotide. [ 0921 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises : . [ 0922 ] at least one 5 ' - uridine - adenine - 3 ' ( 5 ' - ua - 3 ' ) dinucleotide , Wherein the uridine is a 2 ' - modiﬁed nucleotide ; and / or at least one 5 ' - uridine - guanine - 3 ' ( 5 ' - ug - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide ; . [ 0923 ] and / or at least one 5 ' - cytidine - adenine - 3 ' ( 5 ' - ca - 3 ' ) dinucleotide , Wherein the 5 ' - cytidine is a 2 ' - m0diﬁed nucleotide ; . [ 0924 ] and / or at least one 5 ' - uridine - uridine - 3 ' ( 5 ' - uu - 3 ' ) dinucleotide , Wherein the 5 ' - uridine is a 2 ' - modiﬁed nucleotide. [ 0925 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises one or more 2 ' - m0diﬁcations selected from the group consisting of : 2 ' - deoxy , 2 ' - deoxy - 2 ' - ﬁuoro , 2 ' - O - methyl , 2 ' - O - methoxyethyl ( 2 ' - O - MOE ) , 2 ' - O - aminopropyl ( 2 ' - O - AP ) , 2 ' - O - dimethylaminoethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylaminopropyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylaminoethyl0xyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O7 N - methylacetamido ( 2 ' - O - NMA ) . [ 0926 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises a blunt end. [ 0927 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises an oVerhang haVing 1 to 4 unpaired nucleotides. [ 0928 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent comprises an oVerhang at the 3 ' - end 0f the antisense strand. [ 0929 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent is ligated to one or more agents , the agent selected from a : diagnostic compound , reporter group , crosslinking agent , nuclease - resistance conferring moiety , natural or unusual nucleobase , lipophilic molecule , cholesterol , lipid , lectin , steroid , uVaol , hecigenin , diosgenin , terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanol - deriVatized lithocholic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate 15 - mer , natural polymer , loW - or medium - molecular Weight polymer , inulin , cyclodextrin , hyaluronic acid , pr0tein , protein - binding agent , integrin - targeting molecule , polycationic , peptide , polyamine , peptide mimic , and / or transferrin. [ 093 0 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 60% at a concentration of lO nM in H44l cells in Vitro. [ 0931 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 70% at a concentration of lO nM in H441 cells in Vitro. [ 093 2 ] The composition of paragraph [ 00899 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 80% at a c0ncentration of lO nM in H441 cells in Vitro. May 10 , 2012. [ 0933 ] The composition of paragraph [ 0089 9 ] , Wherein the RNAi agent is capable of inhibiting expression of the BetaENaC gene by at least about 90% at a concentration of 10 nM in H44l cells in Vitro. [ 0934 ] The composition of paragraph [ 0089 9 ] , Wherein the RNAi has an EC50 of no more than ab0ut 0.1 nM. [ 0935 ] The composition of paragraph [ 0089 9 ] , Wherein the RNAi has an EC50 of no more than about 0.01 nM. [ 093 6 ] The composition of paragraph [ 0089 9 ] , Wherein the RNAi has an EC50 of no more than about 0.00l nM. [ 0937 ] A method 0f treating a Beta - ENaC - related disease in an indiVidual , comprising the step of administering to the indiVidual a therapeutically effectiVe amount of a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contigu0us nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of a RNAi agent spe - ciﬁc to Beta - ENaC proVided in Table l. [ 0938 ] The method of paragraph [ 009l 9 ] , Wherein the Beta - ENaC - related disease is cystic ﬁbrosis , pseudohypoal - d0steronism type 1 ( PHA1 ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and / or 0besity - ass0ciated hypertension. [ 0939 ] The method of paragraph [ 009l 9 ] , Wherein the Beta - ENaC - related disease is cystic ﬁbrosis. [ 0940 ] The method of paragraph [ 009l 9 ] , Wherein the method ﬁnther comprises the step of administering an additional treatment for cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHA1 ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and / or obesity - associated hypertension. [ 0941 ] The method of paragraph [ 00919 ] , Wherein the 00mpositi0n comprises a sec0nd RNAi agent to Beta - ENaC. [ 0942 ] The method of paragraph [ 00919 ] , Wherein the method ﬁ1rther comprises the step of administering an additional RNAi agent t0 Beta - ENaC. [ 0943 ] The method of paragraph [ 00919 ] , further comprising the administration of an additional treatment. [ 0944 ] The method of paragraph [ 00919 ] , Wherein the additional treatment is a composition. [ 0945 ] The method of paragraph [ 009l 9 ] , Wherein the additional treatment is a method. [ 0946 ] The method of paragraph [ 009l 9 ] , Wherein the additional treatment and the RNAi agent can be administered in any order. [ 0947 ] A method of inhibiting the expression of the BetaENaC gene in an indiVidual , comprising the step of administering to the indiVidual a therapeutically effectiVe amount of a composition comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 , or 3 nucleotides from the antisense strand of a RNAi agent speciﬁc to Beta - ENaC proVided in Table 1. [ 0948 ] The method of paragraph [ 00929 ] , Wherein the indiVidual is afﬁicted With or susceptible to a Beta - ENaC - related disease. [ 0949 ] The method of paragraph [ 00929 ] , Wherein the Beta - ENaC - related disease is cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHA1 ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and / or obesity - associated hypertension. [ 0950 ] The method of paragraph [ 00929 ] , Wherein the Beta - ENaC - related disease is cystic ﬁbrosis. [ 0951 ] The method of paragraph [ 00932 ] , further comprising the administration of an additional treatment. US 20l2 / 0ll5934 Al. [ 0952 ] The method of paragraph [ 00933 ] , Wherein the additional treatment is a composition. [ 0953 ] The method of paragraph [ 00933 ] , Wherein the additional treatment is a method. [ 0954 ] The method of paragraph [ 00933 ] , Wherein the additi0nal treatment and the RNAi agent can be administered in any order. [ 0955 ] A medicament for use in an RNAi formulation comprising a RNAi agent comprising a sense strand and an antisense strand , Wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the antisense strand of a RNAi agent speciﬁc to Beta - ENaC proVided in Table l. [ 0956 ] Any composition aboVe in a phannaceutically effectiVe formulation. May 10 , 2012. [ 0957 ] The composition according to paragraph [ 00879 ] , for use in a method of treating a Beta - ENaC - related disease in an indiVidual , the method comprising the step of administering to the indiVidual a therapeutically effectiVe amount of a composition according to paragraph [ 00879 ] . [ 0958 ] The use of a composition according to paragraph [ 00879 ] , in the manufacture of a medicament for the treatment of a Beta - ENaC - related disease. [ 0959 ] The use of paragraph [ 00940 ] , Wherein the BetaENaC - related disease is cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkal0sis , hypokalemia , and / or obesity - associated hyperten - s1on. [ 0960 ] The composition of paragraph [ 00879 ] , Wherein all the pyrimidines are 2 ' O - methyl - modiﬁed nucleotides. [ 0961 ] The composition of paragraph [ 00899 ] , Wherein all the pyrimidines are 2 ' O - methyl - modiﬁed nucleotides. . SEQUENCE LISTING. <160> NUMBER OF SEQ ID NOS : 430. <210> SEQ ID NO 1. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : ArtifiCial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 1. cagugacuac aacacgacc. <210> SEQ ID NO 2. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : ArtifiCia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 2. ggucguguug uagucacug. <2l0> SEQ ID NO 3. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : ArtifiCial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 3. augacagaga aggcacuuc. <2l0> SEQ ID NO 4. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : ArtifiCial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 4. gaagugccuu cucugucau. <210> SEQ ID NO 5 <21l> LENGTH : l9. 19. 19. 19. 19. US 20l2 / 0ll5934 Al. 60. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 5. gugaagaagu accugcuga. <210> SEQ ID NO 6. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 6. ucagcaggua cuucuucac. <210> SEQ ID NO 7. <2ll> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 7. gugacuacaa cacgaccua. <2l0> SEQ ID NO 8. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 8. uaggucgugu uguagucac. <2l0> SEQ ID NO 9. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 9. gguggaggcc cacaccaac. <210> SEQ ID NO 10. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO. guuggugugg gccuccacc. <2l0> SEQ ID NO 11. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 6l. —continued. May 10 , 2012. . <400> SEQUENCE : ll. ugguggaggc ccacaccaa. <2l0> SEQ ID NO lZ. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 12. uugguguggg ccuccacca. <2l0> SEQ ID NO l3. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l3. uuccaagacc acaugaucc. <210> SEQ ID NO 14. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l4. ggaucaugug gucuuggaa. <210> SEQ ID NO 15. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 15. agcugggagg ucagcgucu. <2l0> SEQ ID NO l6. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l6. agacgcugac cucccagcu. <210> SEQ ID NO 17. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l7. gggagaaaua cugcaacaa. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 62. —continued. . <210> SEQ ID NO 18. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l8. uuguugcagu auuucuccc 19. <2l0> SEQ ID NO l9. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 19. ccaguuuggc uucuggaug 19. <2l0> SEQ ID NO 20. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 20. cauccagaag ccaaacugg 19. <210> SEQ ID NO 21. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 21. agugacuaca acacgaccu 19. <210> SEQ ID NO 22. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 22. aggucguguu guagucacu 19 <210> SEQ ID NO 23. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 23. aauaucaccc ugagcagga 19. <210> SEQ ID NO 24 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 63. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 24. uccugcucag ggugauauu. <210> SEQ ID NO 25. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 25. ccugcaggcc accaacauc. <210> SEQ ID NO 26. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 26. gauguuggug gccugcagg. <2l0> SEQ ID NO 27. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 27. aucacccuga gcaggaagg. <2l0> SEQ ID NO 28. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 28. ccuuccugcu cagggugau. <210> SEQ ID NO 29. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 29. gcugggaggu cagcgucuc. <2l0> SEQ ID NO 30. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 64. —continued. May 10 , 2012. . <400> SEQUENCE : 30. gagacgcuga ccucccagc. <2l0> SEQ ID NO 3l. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 31. gagcugggag gucagcguc. <2l0> SEQ ID NO 32. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 32. gacgcugacc ucccagcuc. <210> SEQ ID NO 33. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 33. guggccaguu uggcuucug. <210> SEQ ID NO 34. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 34. cagaagccaa acuggccac. <2l0> SEQ ID NO 35. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 35. caguuuggcu ucuggaugg. <210> SEQ ID NO 36. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 36. ccauccagaa gccaaacug. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 65. —continued. . <210> SEQ ID NO 37. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 37. ggccaguuug gcuucugga 19. <2l0> SEQ ID NO 38. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 38. uccagaagcc aaacuggcc 19. <2l0> SEQ ID NO 39. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 39. cuggguggcc aguuuggcu 19. <210> SEQ ID NO 40. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 40. agccaaacug gccacccag 19. <210> SEQ ID NO 41. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 41. ucuacaguga cuacaacac 19 <210> SEQ ID NO 42. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 42. guguuguagu cacuguaga 19. <210> SEQ ID NO 43 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 66. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 43. gcaugacaga gaaggcacu. <210> SEQ ID NO 44. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 44. agugccuucu cugucaugc. <210> SEQ ID NO 45. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 45. auaucacccu gagcaggaa. <2l0> SEQ ID NO 46. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 46. uuccugcuca gggugauau. <2l0> SEQ ID NO 47. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 47. C ' LlElC agugac uacaacacg. <210> SEQ ID NO 48. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 48. cguguuguag ucacuguag. <2l0> SEQ ID NO 49. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 67. —continued. May 10 , 2012. . <400> SEQUENCE : 49. uaucacccug agcaggaag. <2l0> SEQ ID NO 50. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 50. cuuccugcuc agggugaua. <2l0> SEQ ID NO 51. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 51. ugcaggccac caacaucuu. <210> SEQ ID NO 52. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 52. aagauguugg uggccugca. <210> SEQ ID NO 53. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 53. caugacagag aaggcacuu. <2l0> SEQ ID NO 54. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 54. aagugccuuc ucugucaug. <210> SEQ ID NO 55. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 55. ugaagaagua ccugcugaa. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 68. —continued. . <210> SEQ ID NO 56. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 56. uucagcaggu acuucuuca 19. <2l0> SEQ ID NO 57. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 57. gcugguggag gcccacacc 19. <2l0> SEQ ID NO 58. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 58. ggugugggcc uccaccagc 19. <210> SEQ ID NO 59. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 59. uacagugacu acaacacga 19. <210> SEQ ID NO 60. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 60. ucguguugua gucacugua 19 <210> SEQ ID NO 6l. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 61. acagagaagg cacuuccuu 19. <210> SEQ ID NO 62 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 69. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 62. aaggaagugc cuucucugu. <210> SEQ ID NO 63. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 63. acagugacua caacacgac. <210> SEQ ID NO 64. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 64. gucguguugu agucacugu. <2l0> SEQ ID NO 65. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 65. ugagcuggga ggucagcgu. <2l0> SEQ ID NO 66. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 66. acgcugaccu cccagcuca. <210> SEQ ID NO 67. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 67. uggccaguuu ggcuucugg. <2l0> SEQ ID NO 68. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 70. —continued. May 10 , 2012. . <400> SEQUENCE : 68. ccagaagcca aacuggcca. <2l0> SEQ ID NO 69. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 69. ugucucagga gcgggacca. <2l0> SEQ ID NO 70. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 7O. uggucccgcu ccugagaca. <210> SEQ ID NO 71. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 71. guggaggccc acaccaacu. <210> SEQ ID NO 72. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 72. aguuggugug ggccuccac. <2l0> SEQ ID NO 73. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 73. ggguggc C ag uuuggcuuc. <210> SEQ ID NO 74. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 74. gaagccaaac uggccaccc. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 2012 7l. —continued. . <210> SEQ ID NO 75. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 75. gguggccagu uuggcuucu 19. <2l0> SEQ ID NO 76. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 76. agaagccaaa cuggccacc 19. <2l0> SEQ ID NO 77. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 77. ucacccugag caggaaggg 19. <210> SEQ ID NO 78. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 78. cccuuccugc ucaggguga 19. <210> SEQ ID NO 79. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 79. gccaguuugg cuucuggau 19 <210> SEQ ID NO 80. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 80. auccagaagc caaacuggc 19. <210> SEQ ID NO 81 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 72. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 81. agcuggugga ggcccacac. <210> SEQ ID NO 82. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 82. gugugggccu ccaccagcu. <210> SEQ ID NO 83. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 83. aucuccaugg cugacuggc. <2l0> SEQ ID NO 84. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 84. gccagucagc cauggagau. <2l0> SEQ ID NO 85. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 85. ggcaugacag agaaggcac. <210> SEQ ID NO 86. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 86. gugccuucuc ugucaugcc. <2l0> SEQ ID NO 87. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 73. —continued. May 10 , 2012. . <400> SEQUENCE : 87. ggagaaauac ugcaacaac. <2l0> SEQ ID NO 88. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 88. gmgmmmguwmmmc. <2l0> SEQ ID NO 89. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 89. uggguggcca guuuggcuu. <210> SEQ ID NO 90. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 90. aagccaaacu ggccaccca. <210> SEQ ID NO 91. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 91. gagcuggugg aggcccaca. <2l0> SEQ ID NO 92. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 92. ugugggccuc caccagcuc. <210> SEQ ID NO 93. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 93. gacagagaag gcacuuccu. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 2012 74. —continued. . <210> SEQ ID NO 94. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 94. aggaagugcc uucucuguc 19. <2l0> SEQ ID NO 95. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 95. aguuuggcuu cuggauggg 19. <2l0> SEQ ID NO 96. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 96. cccauccaga agccaaacu 19. <210> SEQ ID NO 97. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 97. ugacagagaa ggcacuucc 19. <210> SEQ ID NO 98. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 98. ggaagugccu ucucuguca 19 <210> SEQ ID NO 99. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 99. gaagaaguac cugcugaag 19. <210> SEQ ID NO 100 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 75. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 100. cuuc agcagg uacuucuuc. <210> SEQ ID NO 101. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lOl. ucuccauggc ugacuggcc. <210> SEQ ID NO 102. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO2. ggccagucag ccauggaga. <2l0> SEQ ID NO lO3. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 103. cugguggagg cccacacca. <2l0> SEQ ID NO lO4. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO4. uggugugggc cuccaccag. <210> SEQ ID NO 105. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO5. cagagaaggc acuuccuuc. <2l0> SEQ ID NO lO6. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 76. —continued. May 10 , 2012. . <400> SEQUENCE : lO6. gaaggaagug ccuucucug. <2l0> SEQ ID NO lO7. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 107. cugcaggcca ccaacaucu. <2l0> SEQ ID NO lO8. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO8. agauguuggu ggccugcag. <210> SEQ ID NO 109. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lO9. gggcaugaca gagaaggca. <210> SEQ ID NO 110. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 110. ugccuucucu gucaugccc. <2l0> SEQ ID NO 111. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 111 cagugacuac aacacgacc. <210> SEQ ID NO 112. <21l> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 112. ggucguguug uagucacug. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 2012 77. —continued. . <210> SEQ ID NO 113. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 113. augacagaga aggcacuuc 19. <2l0> SEQ ID NO ll4. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 114. gaagugccuu cucugucau 19. <2l0> SEQ ID NO llS. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : llS. gugaagaagu accugcuga 19. <210> SEQ ID NO 116. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 116. ucagcaggua cuucuucac 19. <210> SEQ ID NO 117. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 117. gugacuacaa cacgaccua 19 <210> SEQ ID NO ll8. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 118. uaggucgugu uguagucac 19. <210> SEQ ID NO 119 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 78. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 119. gguggaggcc cacaccaac. <210> SEQ ID NO 120. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZ0. guuggugugg gccuccacc. <210> SEQ ID NO 121. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZl. ugguggaggc ccacaccaa. <2l0> SEQ ID NO lZ2. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 122. uugguguggg ccuccacca. <2l0> SEQ ID NO l23. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZ3. uuccaagacc acaugaucc. <210> SEQ ID NO 124. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZ4. ggaucaugug gucuuggaa. <2l0> SEQ ID NO lZ5. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 79. —continued. May 10 , 2012. . <400> SEQUENCE : lZ5. agcugggagg ucagcgucu. <2l0> SEQ ID NO lZ6. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 126. agacgcugac cucccagcu. <2l0> SEQ ID NO l27. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZ7. gggagaaaua cugcaacaa. <210> SEQ ID NO 128. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lZ8. uuguugcagu auuucuccc. <210> SEQ ID NO 129. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 129. ccaguuuggc uucuggaug. <2l0> SEQ ID NO l30. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l30 cauccagaag ccaaacugg. <210> SEQ ID NO 131. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l3l. agugacuaca acacgaccu. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 80. —continued. . <210> SEQ ID NO 132. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l32. aggucguguu guagucacu 19. <2l0> SEQ ID NO l33. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 133. aauaucaccc ugagcagga 19. <2l0> SEQ ID NO l34. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l34. uccugcucag ggugauauu 19. <210> SEQ ID NO 135. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l35. ccugcaggcc accaacauc 19. <210> SEQ ID NO 136. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 136. gauguuggug gccugcagg 19. <2l0> SEQ ID NO l37. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 137. aucacccuga gcaggaagg 19. <210> SEQ ID NO 138 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 81. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 138. ccuuccugcu cagggugau. <210> SEQ ID NO 139. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l39. gcugggaggu cagcgucuc. <210> SEQ ID NO 140. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l40. gagacgcuga ccucccagc. <2l0> SEQ ID NO l4l. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 14l. gagcugggag gucagcguc. <2l0> SEQ ID NO l42. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l42. gacgcugacc ucccagcuc. <210> SEQ ID NO 143. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l43. guggccaguu uggcuucug. <2l0> SEQ ID NO l44. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 82. —continued. May 10 , 2012. . <400> SEQUENCE : l44. cagaagccaa acuggccac. <2l0> SEQ ID NO l45. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 145. caguuuggcu ucuggaugg. <2l0> SEQ ID NO l46. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l46. ccauccagaa gccaaacug. <210> SEQ ID NO 147. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l47. ggccaguuug gcuucugga. <210> SEQ ID NO 148. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 148. uccagaagcc aaacuggcc. <2l0> SEQ ID NO l49. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l49. cuggguggcc aguuuggcu. <210> SEQ ID NO 150. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lS0. agccaaacug gccacccag. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 83. —continued. . <210> SEQ ID NO 151. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l5l. ucuacaguga cuacaacac 19. <2l0> SEQ ID NO lE2. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 152. guguuguagu cacuguaga 19. <2l0> SEQ ID NO lS3. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : lS3. gcaugacaga gaaggcacu 19. <210> SEQ ID NO 154. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : lS4. agugccuucu cugucaugc 19. <210> SEQ ID NO 155. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 155. auaucacccu gagcaggaa 19 <210> SEQ ID NO 156. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 156. uuccugcuca gggugauau 19. <210> SEQ ID NO 157 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 84. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 157. cuacagugac uacaacacg. <210> SEQ ID NO 158. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lE8. cguguuguag ucacuguag. <210> SEQ ID NO 159. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lS9. uaucacccug agcaggaag. <2l0> SEQ ID NO l60. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 160. cuuccugcuc agggugaua. <2l0> SEQ ID NO l6l. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l6l. ugcaggccac caacaucuu. <210> SEQ ID NO 162. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l62. aagauguugg uggccugca. <2l0> SEQ ID NO l63. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 85. —continued. May 10 , 2012. . <400> SEQUENCE : l63. caugacagag aaggcacuu. <2l0> SEQ ID NO l64. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 164. aagugccuuc ucugucaug. <2l0> SEQ ID NO l65. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l65. ugaagaagua ccugcugaa. <210> SEQ ID NO 166. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l66. uucagcaggu acuucuuca. <210> SEQ ID NO 167. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 167. gcugguggag gcccacacc. <2l0> SEQ ID NO l68. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l68 ggugugggcc uccaccagc. <210> SEQ ID NO 169. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l69. uacagugacu acaacacga. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 86. —continued. . <210> SEQ ID NO 170. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l70. ucguguugua gucacugua 19. <2l0> SEQ ID NO l7l. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 171. acagagaagg cacuuccuu 19. <2l0> SEQ ID NO l72. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l72. aaggaagugc cuucucugu 19. <210> SEQ ID NO 173. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l73. acagugacua caacacgac 19. <210> SEQ ID NO 174. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 174. gucguguugu agucacugu 19 <210> SEQ ID NO 175. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 175. ugagcuggga ggucagcgu 19. <210> SEQ ID NO 176 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 87. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 176. acgcugaccu cccagcuca. <210> SEQ ID NO 177. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l77. uggccaguuu ggcuucugg. <210> SEQ ID NO 178. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l78. ccagaagcca aacuggcca. <2l0> SEQ ID NO l79. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 179. ugucucagga gcgggacca. <2l0> SEQ ID NO l80. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l80. uggucccgcu ccugagaca. <210> SEQ ID NO 181. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lSl. guggaggccc acaccaacu. <2l0> SEQ ID NO lS2. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 88. —continued. May 10 , 2012. . <400> SEQUENCE : l82. aguuggugug ggccuccac. <2l0> SEQ ID NO l83. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 183. ggguggc C ag uuuggcuuc. <2l0> SEQ ID NO lB4. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l84. gaagccaaac uggccaccc. <210> SEQ ID NO 185. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lS5. gguggccagu uuggcuucu. <210> SEQ ID NO 186. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 186. agaagccaaa cuggccacc. <2l0> SEQ ID NO lS7. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l87 ucacccugag caggaaggg. <210> SEQ ID NO 188. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : lS8. cccuuccugc ucaggguga. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 89. —continued. . <210> SEQ ID NO 189. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l89. gccaguuugg cuucuggau 19. <2l0> SEQ ID NO l90. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 190. auccagaagc caaacuggc 19. <2l0> SEQ ID NO l9l. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l9l. agcuggugga ggcccacac 19. <210> SEQ ID NO 192. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : l92. gugugggccu ccaccagcu 19. <210> SEQ ID NO 193. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 193. aucuccaugg cugacuggc 19 <210> SEQ ID NO 194. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 194. gccagucagc cauggagau 19. <210> SEQ ID NO 195 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 90. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 195. ggcaugacag agaaggcac. <210> SEQ ID NO 196. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l96. gugccuucuc ugucaugcc. <210> SEQ ID NO 197. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l97. ggagaaauac ugcaacaac. <2l0> SEQ ID NO l98. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 198. gmgmmmguwmmmc. <2l0> SEQ ID NO l99. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : l99. uggguggcca guuuggcuu. <210> SEQ ID NO 200. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 200. aagccaaacu ggccaccca. <2l0> SEQ ID NO 20l. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 9l. —continued. May 10 , 2012. . <400> SEQUENCE : 20l. gagcuggugg aggcccaca. <2l0> SEQ ID NO 202. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 202. ugugggccuc caccagcuc. <2l0> SEQ ID NO 203. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 203. gacagagaag gcacuuccu. <210> SEQ ID NO 204. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 204. aggaagugcc uucucuguc. <210> SEQ ID NO 205. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 205. aguuuggcuu cuggauggg. <2l0> SEQ ID NO 206. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 206 cccauccaga agccaaacu. <210> SEQ ID NO 207. <21l> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 207. ugacagagaa ggcacuucc. Agent. Agent. Agent. Agent. Agent. Agent. l9. l9. 19. l9. l9. l9. l9. US 20l2 / 0l15934 Al May lO , 20l2 92. —continued. . <210> SEQ ID NO 208. <2ll> LENGTH : l9. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 208. ggaagugccu ucucuguca 19. <2l0> SEQ ID NO 209. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 209. gaagaaguac cugcugaag 19. <2l0> SEQ ID NO 210. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 2l0. cuucagcagg uacuucuuc 19. <210> SEQ ID NO 211. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 21l. ucuccauggc ugacuggcc 19. <210> SEQ ID NO 212. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 212. ggccagucag ccauggaga 19 <210> SEQ ID NO 213. <211> LENGTH : 19. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 213. cugguggagg cccacacca 19. <210> SEQ ID NO 214 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. 93. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 214. uggugugggc cuccaccag. <210> SEQ ID NO 215. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 215. cagagaaggc acuuccuuc. <210> SEQ ID NO 216. <2ll> LENGTH : l9. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 2l6. gaaggaagug ccuucucug. <2l0> SEQ ID NO 217. <211> LENGTH : 19. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 217. cugcaggcca ccaacaucu. <2l0> SEQ ID NO 2l8. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 218. agauguuggu ggccugcag. <210> SEQ ID NO 219. <2ll> LENGTH : l9. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 219. gggcaugaca gagaaggca. <2l0> SEQ ID NO 220. <211> LENGTH : 19. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 19. l9. l9. l9. l9. l9. US 20l2 / 0ll5934 Al. 94. May 10 , 2012. . —continued <400> SEQUENCE : 220 ugccuucucu gucaugccc 19 <210> SEQ ID NO 221 <211> LENGTH : 2280 <212> TYPE : DNA <213> ORGANISM : Cynomolgus <400> SEQUENCE : 221 ggtacccagc ttgcttgttc tttttgcaga agctcagaat aaacgctcaa ctttggcaga 60 tcaattcccc ggggatccga attcgccacc atgcacgtga agaagtacct gctgaagtgc 120 ctgcaccggc tgcagaaggg ccccggctac acgtacaagg agctgctggt gtggtactgc 180 gataacacca acacccacgg ccccaagcgt atcatctgcg aggggcccaa gaagaaagcc 240 gtgtggttcc tgctcaccct gctcttcact gctctcgtct gctggcagtg gggcatcttc 300 atcaggacct acttgagctg ggaggtcagc gtctccctct ccgtaggctt caagaccatg 360 gacttccccg ccgtcaccat ctgcaatgct agccccttca agtattccaa agtcaagcat 42O ttgctgaagg acctggatga gctgatggaa gctgtcctgg agagaatcct ggctcctgag 480 ctaagccatg ccaatgccac caggaccctg aactcttcca tctggaacca cacaccactg 540 gtccttattg atgaacggaa cccccaccac cccatggtcc tcgatctctt tggagataac 600 cacaatggct taacaaacag ctcagcatca gaaaagatct gtaatgccca tgggtgcaaa 66O atggccatga gactatgtag cctcaacggg acccagtgca ccttccggaa cttcaccagc 720 gctacccagg cagtgacaga gtggtacagc ctgcaggcca ccaacatctt tgcgcaggtg 780 ccgcagcagg agctggtgga gatgagctac cccggcgagc agatgatcct ggcctgcctg 84O tttggagctg agccctgcaa ctaccggaac ttcacgtcca tcttctaccc tcactatggc 90O aactgttaca tcttcaactg gggcatgaca gagaaggcac ttccttcggc caaccctgga 960 cctgaatttg gcctgaagtt gatcctggac ataggccagg aagactacgt ccccttcctc 1020 gcgtccacgg ctggggtcag gctgatgctt cacgagcaga ggtcataccc cttcatcaga 108O gacgagggca tctatgccat gtcggggaca gagacgtcca tcggggtact cgtggacaag 1140 cttcagcgca tgggggagcc ctacagcccg tgcaccgtga atggctccga ggtccccgtc 1200 caaaacttct acagtgacta caacacgacc tactccatcc aggcctgtct tcgctcctgc 126O ttccaagacc acatgatccg tagctgcaag tgtgggcact acctctaccc actgccccgt 132O ggggagaaat actgcaacaa ccgggacttc ccagactggg cccattgcta ctcagatctg 1380 cagatgagcg tggcgcagag agagacctgc attggcatgt gcaaggaatc ctgcaatgac 1440 acccagtaca agatgactat ctccatggct gactggcctt ctgaggcctc tgaggactgg 150O attttccacg tcttgtctca ggagcgggac caaagcacca atatcaccct gagcaggaag 1560 ggaattgtca agctcaacat ctacttccaa gaatttaact atcgcaccat tgaagaatca 1620 gcagccaata acctcgtctg gctgctctca aatctgggtg gccagtttgg cttctggatg 168O gggggctctg tgctgtgcct catcgagttt ggggagatca tcatcgactt tgtgtggatc 174O accatcatca agctggtggc cttggccaag agcctccggc agcggcgagc ccaagccagc 1800 tactccggcc caccgcccac ggtggctgag ctggtggagg cccacaccaa cttcggctac 1860 cagcctgaca cggccccccg cagccccaac accgggccct accccagtga gcaggccctg 192O. US 20l2 / 0ll5934 Al. 95. May 10 , 2012. . —continued cccatcccgg gcaccccgcc ccccaactat gactccctgc gtctgcagcc actggacgtc 198O atcgagtctg acagtgaggg tgatgccatc taagcggccg cctagaaata gcttgatctg 2040 gttaccacta aaccagcctc aagaacaccc gaatggagtc tctaagctac ataataccaa 2100 cttacacttt acaaaatgtt gtcccccaaa atgtagccat tcgtatctgc tcctaataaa 2160 aagaaagttt cttcacattc taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaccccc 2220 cccccccccc ccctgcagag atctgctagc ttgagtattc tatagagtca cctaaatact 2280 <210> SEQ ID NO 222 <21l> LENGTH : 2597 <212> TYPE : DNA <213> ORGANISM : Homo sapien <400> SEQUENCE : 222 gtgcttcccc gcccctgaac ctgctccctc ccagtcggtc tcgccgcgct cgccgggtgt 60 cccagtgtca ccaacactcg gccgccgccg ccagcttggc gcgcaccgcc gcctccgcca 120 ccgccgacag cgcgcatcct ccgtgtcccc gctccgccgc ccgagcaggt gccactatgc 18O acgtgaagaa gtacctgctg aagggcctgc atcggctgca gaagggcccc ggctacacgt 240 acaaggagct gctggtgtgg tactgcgaca acaccaacac ccacggcccc aagcgcatca 300 tctgtgaggg gcccaagaag aaagccatgt ggttcctgct caccctgctc ttcgccgccc 360 tcgtctgctg gcagtggggc atcttcatca ggacctactt gagctgggag gtcagcgtct 42O ccctctccgt aggcttcaag accatggact tccctgccgt caccatctgc aatgctagcc 480 ccttcaagta ttccaaaatc aagcatttgc tgaaggacct ggatgagctg atggaagctg 54O tcctggagag aatcctggct cctgagctaa gccatgccaa tgccaccagg aacctgaact 600 tctccatctg gaaccacaca cccctggtcc ttattgatga acggaacccc caccacccca 66O tggtccttga tctctttgga gacaaccaca atggcttaac aagcagctca gcatcagaaa 720 agatctgtaa tgcccacggg tgcaaaatgg ccatgagact atgtagcctc aacaggaccc 78O agtgtacctt ccggaacttc accagtgcta cccaggcatt gacagagtgg tacatcctgc 84O aggccaccaa catctttgca caggtgccac agcaggagct agtagagatg agctaccccg 900 gcgagcagat gatcctggcc tgcctattcg gagctgagcc ctgcaactac cggaacttca 96O cgtccatctt ctaccctcac tatggcaact gttacatctt caactggggc atgacagaga 102O aggcacttcc ttcggccaac cctggaactg aattcggcct gaagttgatc ctggacatag 108O gccaggaaga ctacgtcccc ttccttgcgt ccacggccgg ggtcaggctg atgcttcacg 1140 agcagaggtc ataccccttc atcagagatg agggcatcta cgccatgtcg gggacagaga 1200 cgtccatcgg ggtactcgtg gacaagcttc agcgcatggg ggagccctac agcccgtgca 126O ccgtgaatgg ttctgaggtc cccgtccaaa acttctacag tgactacaac acgacctact 1320 ccatccaggc ctgtcttcgc tcctgcttcc aagaccacat gatccgtaac tgcaactgtg 1380 gccactacct gtacccactg ccccgtgggg agaaatactg caacaaccgg gacttcccag 144O actgggccca ttgctactca gatctacaga tgagcgtggc gcagagagag acctgcattg 150O gcatgtgcaa ggagtcctgc aatgacaccc agtacaagat gaccatctcc atggctgact 1560 ggccttctga ggcctccgag gactggattt tccacgtctt gtctcaggag cgggaccaaa 1620 gcaccaatat caccctgagc aggaagggaa ttgtcaagct caacatctac ttccaagaat 168O. US 20l2 / 0ll5934 Al. 96. . —continued ttaactatcg caccattgaa gaatcagcag ccaataacat cgtctggctg ctctcgaatc 174O tgggtggcca gtttggcttc tggatggggg gctctgtgct gtgcctcatc gagtttgggg 1800 agatcatcat cgactttgtg tggatcacca tcatcaagct ggtggccttg gccaagagcc 1860 tacggcagcg gcgagcccaa gccagctacg ctggcccacc gcccaccgtg gccgagctgg 1920 tggaggccca caccaacttt ggcttccagc ctgacacggc cccccgcagc cccaacactg 1980 ggccctaccc cagtgagcag gccctgccca tcccaggcac cccgcccccc aactatgact 2040 ccctgcgtct gcagccgctg gacgtcatcg agtctgacag tgagggtgat gccatctaac 2100 cctgcccctg cccaccccgg gcggctgaaa ctcactgagc agccaagact gttgcccgag 216O gcctcactgt atggtgccct ctccaaaggg tcgggagggt agctctccag gccagagctt 2220 gtgtccttca acagagaggc cagcggcaac tggtccgtta ctggccaagg gctctgtaga 2280 atcacggtgc tggtacagga tgcaggaata aattgtatct tcacctggtt cctaccctcg 2340 tccctacctg tcctgatcct ggtcctgaag acccctcgga acaccctctc ctggtggcag 2400 gccacttccc tcccagtgcc agtctccatc caccccagag aggaacaggc gggtgggcca 246O tgtggttttc tccttcctgg ccttggctgg cctctggggc aggggtggtg gagagatgga 2520 agggcatcag gtgtagggac cctgccaagt ggcacctgat ttactctaga aaataaaagt 2580 agaaaatact gagtcca 2597 <210> SEQ ID NO 223 <211> LENGTH : 12 <212> TYPE : RNA <213> ORGANISM : Artificial <220> FEATURE : <223> OTHER INFORMATION : RNAi Agent <400> SEQUENCE : 223 ugaagaagua cc 12 <210> SEQ ID NO 224 <211> LENGTH : 12 <212> TYPE : RNA <213> ORGANISM : Artificia1 <220> FEATURE : <223> OTHER INFORMATION : RNAi Agent <400> SEQUENCE : 224 gguacuucuu ca 12 <210> SEQ ID NO 225 <21l> LENGTH : 12 <212> TYPE : RNA <213> ORGANISM : Artificial <220> FEATURE : <223> OTHER INFORMATION : RNAi Agent <400> SEQUENCE : 225 gaagaaguac cu 12. <2l0> SEQ ID NO 226. <2l1> LENGTH : : RNA. <2l2> TYPE. lZ. <2l3> ORGANISM : Artificial <220> FEATURE : <223> OTHER INFORMATION : RNAi Agent. May 10 , 2012. US 20l2 / 0ll5934 Al. 97. —continued. May 10 , 2012. . <400> SEQUENCE : 226. agguacuucu uc. <2l0> SEQ ID NO 227. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 227. aagaaguacc ug. <2l0> SEQ ID NO 228. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 228. cagguacuuc uu. <210> SEQ ID NO 229. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 229. agaaguaccu gc. <210> SEQ ID NO 230. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 230. gcagguacuu cu. <2l0> SEQ ID NO 23l. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 23l gaaguaccug cu. <210> SEQ ID NO 232. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 232. agcagguacu uc. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 20l2 98. —continued. . <210> SEQ ID NO 233. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 233. aaguaccugc ug 12. <2l0> SEQ ID NO 234. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 234. cagcagguac uu 12. <2l0> SEQ ID NO 235. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 235. aguaccugcu ga 12. <210> SEQ ID NO 236. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 236. ucagcaggua cu 12. <210> SEQ ID NO 237. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 237. guaccugcug aa 12 <210> SEQ ID NO 238. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 238. uucagcaggu ac 12. <210> SEQ ID NO 239 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. 99. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 239. gagcugggag gu. <210> SEQ ID NO 240. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 240. accucccagc uc. <210> SEQ ID NO 241. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 24l. agcugggagg uc. <2l0> SEQ ID NO 242. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 242. gaccucccag cu. <2l0> SEQ ID NO 243. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 243. gcugggaggu ca. <210> SEQ ID NO 244. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 244. ugaccuccca gc. <2l0> SEQ ID NO 245. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. lO0. —continued. May 10 , 2012. . <400> SEQUENCE : 245. cugggagguc ag. <2l0> SEQ ID NO 246. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 246. cugaccuccc ag. <2l0> SEQ ID NO 247. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 247. ugggagguca gC. <210> SEQ ID NO 248. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 248. gcugaccucc ca. <210> SEQ ID NO 249. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 249. gggaggucag cg. <2l0> SEQ ID NO 250. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 250 cgcugaccuc cc. <210> SEQ ID NO 251. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 25l. ggaggucagc gu. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 lO1. —continued. . <210> SEQ ID NO 252. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 252. acgcugaccu CC 12. <2l0> SEQ ID NO 253. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 253. gaggucagcg uc 12. <2l0> SEQ ID NO 254. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 254. gacgcugacc uc 12. <210> SEQ ID NO 255. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 255. aggucagcgu cu 12. <210> SEQ ID NO 256. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 256. agacgcugac cu 12 <210> SEQ ID NO 257. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 257. cugcaggcca CC 12. <210> SEQ ID NO 258 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. lO2. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 258. gguggccugc ag. <210> SEQ ID NO 259. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 259. ugcaggccac ca. <210> SEQ ID NO 260. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 260. ugguggccug ca. <2l0> SEQ ID NO 26l. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 26l. gcaggccacc aa. <2l0> SEQ ID NO 262. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 262. uugguggccu gc. <210> SEQ ID NO 263. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 263. caggccacca ac. <2l0> SEQ ID NO 264. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. lO3. —continued. May 10 , 2012. . <400> SEQUENCE : 264. guugguggcc ug. <2l0> SEQ ID NO 265. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 265. aggccaccaa ca. <2l0> SEQ ID NO 266. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 266. uguugguggc cu. <210> SEQ ID NO 267. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 267. ggccaccaac au. <210> SEQ ID NO 268. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 268. auguuggugg cc. <2l0> SEQ ID NO 269. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 269 gccaccaaca uc. <210> SEQ ID NO 270. <21l> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 270. gauguuggug gC. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 lO4. —continued. . <210> SEQ ID NO 271. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 27l. ccaccaacau cu 12. <2l0> SEQ ID NO 272. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 272. agauguuggu gg 12. <2l0> SEQ ID NO 273. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 273. ggcaugacag ag 12. <210> SEQ ID NO 274. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 274. cucugucaug CC 12. <210> SEQ ID NO 275. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 275. gcaugacaga ga 12 <210> SEQ ID NO 276. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 276. ucucugucau gc 12. <210> SEQ ID NO 277 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. lO5. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 277. caugacagag aa. <210> SEQ ID NO 278. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 278. uucucuguca ug. <210> SEQ ID NO 279. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 279. augacagaga ag. <2l0> SEQ ID NO 280. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 280. cuucucuguc au. <2l0> SEQ ID NO 28l. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 28l. ugacagagaa gg. <210> SEQ ID NO 282. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 282. ccuucucugu ca. <2l0> SEQ ID NO 283. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. lO6. —continued. May 10 , 2012. . <400> SEQUENCE : 283. gacagagaag gc. <2l0> SEQ ID NO 284. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 284. gccuucucug uc. <2l0> SEQ ID NO 285. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 285. acagagaagg ca. <210> SEQ ID NO 286. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 286. ugccuucucu gu. <210> SEQ ID NO 287. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 287. cagagaaggc ac. <2l0> SEQ ID NO 288. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 288 gugccuucuc ug. <210> SEQ ID NO 289. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 289. agagaaggca cu. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 lO7. —continued. . <210> SEQ ID NO 290. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 290. agugccuucu cu 12. <2l0> SEQ ID NO 29l. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 291. gagaaggcac uu 12. <2l0> SEQ ID NO 292. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 292. aagugccuuc uc 12. <210> SEQ ID NO 293. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 293. agaaggcacu uc 12. <210> SEQ ID NO 294. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 294. gaagugccuu cu 12 <210> SEQ ID NO 295. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 295. gaaggcacuu CC 12. <210> SEQ ID NO 296 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. lO8. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 296. ggaagugccu uc. <210> SEQ ID NO 297. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 297. aaggcacuuc cu. <210> SEQ ID NO 298. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 298. aggaagugcc uu. <2l0> SEQ ID NO 299. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 299. aggcacuucc uu. <2l0> SEQ ID NO 300. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 300. aaggaagugc cu. <210> SEQ ID NO 301. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 30l. cuacagugac ua. <2l0> SEQ ID NO 302. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. lO9. —continued. May 10 , 2012. . <400> SEQUENCE : 302. uagucacugu ag. <2l0> SEQ ID NO 303. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 303. uacagugacu ac. <2l0> SEQ ID NO 304. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 304. guagucacug ua. <210> SEQ ID NO 305. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 305. acagugacua ca. <210> SEQ ID NO 306. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 306. uguagucacu gu. <2l0> SEQ ID NO 307. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 307 cagugacuac aa. <210> SEQ ID NO 308. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 308. uuguagucac ug. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 llO. —continued. . <210> SEQ ID NO 309. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 309. agugacuaca ac 12. <2l0> SEQ ID NO 3l0. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 310. guuguaguca cu 12. <2l0> SEQ ID NO 3ll. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 3ll. gugacuacaa ca 12. <210> SEQ ID NO 312. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 312. uguuguaguc ac 12. <210> SEQ ID NO 313. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 313. ugacuacaac ac 12 <210> SEQ ID NO 3l4. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 314. guguuguagu ca 12. <210> SEQ ID NO 315 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. lll. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 315. gacuacaaca cg. <210> SEQ ID NO 316. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 3l6. cguguuguag uc. <210> SEQ ID NO 317. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 3l7. acuacaacac ga. <2l0> SEQ ID NO 3l8. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 318. ucguguugua gu. <2l0> SEQ ID NO 3l9. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 319. cuacaacacg ac. <210> SEQ ID NO 320. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 320. gucguguugu ag. <2l0> SEQ ID NO 32l. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. ll2. —continued. May 10 , 2012. . <400> SEQUENCE : 32l. uacaacacga CC. <2l0> SEQ ID NO 322. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 322. ggucguguug ua. <2l0> SEQ ID NO 323. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 323. acaacacgac cu. <210> SEQ ID NO 324. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 324. aggucguguu gu. <210> SEQ ID NO 325. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 325. ggagaaauac ug. <2l0> SEQ ID NO 326. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 326 caguauuucu CC. <210> SEQ ID NO 327. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 327. gagaaauacu gc. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 ll3. —continued. . <210> SEQ ID NO 328. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 328. gcaguauuuc uc 12. <2l0> SEQ ID NO 329. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 329. agaaauacug ca 12. <2l0> SEQ ID NO 330. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 330. ugcaguauuu cu 12. <210> SEQ ID NO 331. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 33l. gaaauacugc aa 12. <210> SEQ ID NO 332. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 332. uugcaguauu uc 12 <210> SEQ ID NO 333. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 333. aaauacugca ac 12. <210> SEQ ID NO 334 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. ll4. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 334. guugcaguau uu. <210> SEQ ID NO 335. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 335. aauacugcaa ca. <210> SEQ ID NO 336. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 336. uguugcagua uu. <2l0> SEQ ID NO 337. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 337. auacugcaac aa. <2l0> SEQ ID NO 338. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 338. uuguugcagu au. <210> SEQ ID NO 339. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 339. ucuccauggc ug. <2l0> SEQ ID NO 340. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. llS. —continued. May 10 , 2012. . <400> SEQUENCE : 340. cagccaugga ga. <2l0> SEQ ID NO 34l. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 341. cuccauggcu ga. <2l0> SEQ ID NO 342. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 342. ucagccaugg ag. <210> SEQ ID NO 343. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 343. uccauggcug ac. <210> SEQ ID NO 344. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 344. gucagccaug ga. <2l0> SEQ ID NO 345. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 345 ccauggcuga cu. <210> SEQ ID NO 346. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 346. agucagccau gg. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 ll6. —continued. . <210> SEQ ID NO 347. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 347. cauggcugac ug 12. <2l0> SEQ ID NO 348. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 348. cagucagcca ug 12. <2l0> SEQ ID NO 349. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 349. auggcugacu gg 12. <210> SEQ ID NO 350. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 350. ccagucagcc au 12. <210> SEQ ID NO 351. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 351. uggcugacug gc 12 <210> SEQ ID NO 352. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 352. gccagucagc ca 12. <210> SEQ ID NO 353 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. ll7. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 353. auaucacccu ga. <210> SEQ ID NO 354. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 354. ucagggugau au. <210> SEQ ID NO 355. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 355. uaucacccug ag. <2l0> SEQ ID NO 356. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 356. cucaggguga ua. <2l0> SEQ ID NO 357. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 357. aucacccuga gc. <210> SEQ ID NO 358. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 358. gcucagggug au. <2l0> SEQ ID NO 359. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. ll8. —continued. May 10 , 2012. . <400> SEQUENCE : 359. ucacccugag ca. <2l0> SEQ ID NO 360. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 360. ugcucagggu ga. <2l0> SEQ ID NO 36l. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 36l. cacccugagc ag. <210> SEQ ID NO 362. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 362. cugcucaggg ug. <210> SEQ ID NO 363. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 363. acccugagca gg. <2l0> SEQ ID NO 364. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 364 ccugcucagg gu. <210> SEQ ID NO 365. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 365. cccugagcag ga. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 ll9. —continued. . <210> SEQ ID NO 366. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 366. uccugcucag gg 12. <2l0> SEQ ID NO 367. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 367. ccugagcagg aa 12. <2l0> SEQ ID NO 368. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 368. uuccugcuca gg 12. <210> SEQ ID NO 369. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 369. cugagcagga ag 12. <210> SEQ ID NO 370. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 370. cuuccugcuc ag 12 <210> SEQ ID NO 371. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 37l. ugagcaggaa gg 12. <210> SEQ ID NO 372 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. l20. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 372. ccuuccugcu ca. <210> SEQ ID NO 373. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 373. uggguggcca gu. <210> SEQ ID NO 374. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 374. acuggccacc ca. <2l0> SEQ ID NO 375. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 375. ggguggccag uu. <2l0> SEQ ID NO 376. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 376. aacuggccac cc. <210> SEQ ID NO 377. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 377. gguggccagu uu. <2l0> SEQ ID NO 378. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. l21. —continued. May 10 , 2012. . <400> SEQUENCE : 378. aaacuggcca cc. <2l0> SEQ ID NO 379. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 379. guggccaguu ug. <2l0> SEQ ID NO 380. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 380. caaacuggcc ac. <210> SEQ ID NO 381. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 38l. uggccaguuu gg. <210> SEQ ID NO 382. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 382. ccaaacuggc ca. <2l0> SEQ ID NO 383. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 383. ggccaguuug gc. <210> SEQ ID NO 384. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 384. gccaaacugg cc. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 l22. —continued. . <210> SEQ ID NO 385. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 385. gccaguuugg cu 12. <2l0> SEQ ID NO 386. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 386. agccaaacug gc 12. <2l0> SEQ ID NO 387. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 387. ccaguuuggc uu 12. <210> SEQ ID NO 388. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 388. aagccaaacu gg 12. <210> SEQ ID NO 389. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 389. caguuuggcu uc 12 <210> SEQ ID NO 390. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 390. gaagccaaac ug 12. <210> SEQ ID NO 391 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. l23. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 39l. aguuuggcuu cu. <210> SEQ ID NO 392. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 392. agaagccaaa cu. <210> SEQ ID NO 393. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 393. guuuggcuuc ug. <2l0> SEQ ID NO 394. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 394. cagaagccaa ac. <2l0> SEQ ID NO 395. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 395. uuuggcuucu gg. <210> SEQ ID NO 396. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 396. ccagaagcca aa. <2l0> SEQ ID NO 397. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. l24. —continued. May 10 , 2012. . <400> SEQUENCE : 397. uuggcuucug ga. <2l0> SEQ ID NO 398. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 398. uccagaagcc aa. <2l0> SEQ ID NO 399. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 399. uggcuucugg au. <210> SEQ ID NO 400. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 400. auccagaagc ca. <210> SEQ ID NO 401. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 40l. ggcuucugga ug. <2l0> SEQ ID NO 402. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 402 cauccagaag cc. <210> SEQ ID NO 403. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 403. gcuucuggau gg. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 l25. —continued. . <210> SEQ ID NO 404. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 404. ccauccagaa gc 12. <2l0> SEQ ID NO 405. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 405. agcuggugga gg 12. <2l0> SEQ ID NO 406. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 406. ccuccaccag cu 12. <210> SEQ ID NO 407. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 407. gcugguggag gc 12. <210> SEQ ID NO 408. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 408. gccuccacca gc 12 <210> SEQ ID NO 409. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 409. cugguggagg CC 12. <210> SEQ ID NO 410 <2ll> LENGTH : lZ. US 20l2 / 0ll5934 Al. l26. —continued. May 10 , 2012. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 410. ggccuccacc ag. <210> SEQ ID NO 411. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 4ll. ugguggaggc CC. <210> SEQ ID NO 412. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 4l2. gggccuccac ca. <2l0> SEQ ID NO 4l3. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 413. gguggaggcc ca. <2l0> SEQ ID NO 4l4. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 414. ugggccucca cc. <210> SEQ ID NO 415. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 415. guggaggccc ac. <2l0> SEQ ID NO 4l6. <211> LENGTH : 12. <2l2> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. Agent. Agent. Agent. Agent. Agent. Agent. Agent. 12. l2. lZ. l2. l2. lZ. US 20l2 / 0ll5934 Al. l27. —continued. May 10 , 2012. . <400> SEQUENCE : 416. gugggccucc ac. <2l0> SEQ ID NO 4l7. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 417. uggaggccca ca. <2l0> SEQ ID NO 4l8. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 4l8. ugugggccuc ca. <210> SEQ ID NO 419. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 419. ggaggcccac ac. <210> SEQ ID NO 420. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 420. gugugggccu cc. <2l0> SEQ ID NO 42l. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1 <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 42l gaggcccaca cc. <210> SEQ ID NO 422. <2ll> LENGTH : lZ. <212> TYPE : RNA. <213> ORGANISM : Artificial <220> FEATURE : . <223> OTHER INFORMATION : RNAi. <400> SEQUENCE : 422. ggugugggcc uc. Agent. Agent. Agent. Agent. Agent. Agent. lZ. lZ. 12. l2. lZ. l2. lZ. US 20l2 / 0l15934 Al May lO , 2012 l28. —continued. . <210> SEQ ID NO 423. <2ll> LENGTH : lZ. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 423. aggcccacac ca 12. <2l0> SEQ ID NO 424. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 424. uggugugggc cu 12. <2l0> SEQ ID NO 425. <211> LENGTH : 12. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 425. ggcccacacc aa 12. <210> SEQ ID NO 426. <211> LENGTH : 12. <2l2> TYPE : RNA. <213> ORGANISM : Artificia1. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 426. uugguguggg CC 12. <210> SEQ ID NO 427. <2ll> LENGTH : lZ. <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 427. gcccacacca ac 12 <210> SEQ ID NO 428. <211> LENGTH : 12. <212> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 428. guuggugugg gc 12. <210> SEQ ID NO 429 <2ll> LENGTH : l9. US 20l2 / 0ll5934 Al. l29. May 10 , 2012. —continued. . <212> TYPE : RNA. <2l3> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 429. cagugacuac aacacgacc. <210> SEQ ID NO 430. <211> LENGTH : 19. <2l2> TYPE : RNA. <213> ORGANISM : Artificial. <220> FEATURE : . <223> OTHER INFORMATION : RNAi Agent. <400> SEQUENCE : 430. gguc guguug uagucacug. 19. l9. . We claim : . 1. A composition comprising a RNAi agent comprising a ﬁrst strand and a second strand , Wherein : . a. the sequence of the ﬁrst strand comprises at least lS contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the sequence of SEQ ID NO : 198 , or. b. the sequence of the ﬁrst strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 or 3 nucleotides from the sequence of SEQ ID NO : 128 ; and. Wherein the ﬁrst and / or the second strand are m0diﬁed or unmodiﬁed. 2. The composition of claim 1 , Wherein the composition. further comprises a second RNAi agent to Beta - ENaC. 3. The 00mposition of claim 1 , Wherein the RNAi agent comprises at least one modiﬁed backbone and / or at least one 2 ' - modiﬁed nucleotide. 4. The composition of claim 1 , Wherein the RNAi agent is ligated to one or more agents , Wherein the one or more agents are selected from : diagnostic compound , reporter group , cross - linking agent , nuclease - resistance conferring moiety , natural or unusual nucleobase , lipophilic molecule , cholesterol , lipid , lectin , steroid , uVaol , hecigenin , diosgenin , terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanolderiVatized lithocholic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate 15 - mer , natural polymer , loW - or medium - molecular Weight p0lymer , inulin , cyclodextrin , hyaluronic acid , protein , protein - binding agent , integrin - targeting m0lecule , polycationic , peptide , polyamine , peptide mimic , and transferrin. 5. A composition comprising a RNAi agent comprising a ﬁrst strand and a second strand , Wherein : . a. the sequence of the ﬁrst strand comprises the sequence of. SEQ ID NO : l98 , or. b. the sequence of the ﬁrst strand comprises the sequence of SEQ ID NO : l28 ; and. Wherein the ﬁrst and / or the second strand are modiﬁed or unmodiﬁed. 6. The composition of claim 5 , Wherein the compositi0n. further comprises a second RNAi agent to Beta - ENaC. 7. The composition of claim 5 , Wherein the RNAi agent comprises a phosphorothioate and / or a 2 ' - m0diﬁed nucleotide. 8. The composition of claim 5 , Wherein the RNAi agent is ligated to one or more agents , Wherein the one or m0re agents are selected from : diagnostic compound , reporter group , cross - linking agent , nuclease - resistance conferring m0iety , natural or unusual nucleobase , lipophilic molecule , cholesterol , lipid , lectin , steroid , uVa0l , hecigenin , diosgenin , terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanolderiVatized lithoch0lic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate 15 - mer , natural polymer , loW - or medium - molecular Weight polymer , inulin , cyclodextrin , hyaluronic acid , protein , pr0tein - binding agent , integrin - targeting molecule , polycationic , peptide , polyamine , peptide mimic , and transferrin. 9. A method of treating a Beta - ENaC - related disease in an indiVidual , the method comprising the step of administering to the indiVidual a therapeutically effectiVe amount of a composition comprising a pharmaceutically acceptable carrier and a RNAi agent comprising a ﬁrst strand and a second strand , Wherein : . a. the sequence of the ﬁrst strand comprises at least 15 contiguous nucleotides differing by 0 , 1 , 2 , or 3 nucleotides from the sequence of SEQ ID NO : l98 , or. b. the sequence of the ﬁrst strand comprises at least lS contiguous nucleotides differing by 0 , l , 2 or 3 nucleotides from the sequence of SEQ ID NO : l28 ; and. Wherein the ﬁrst and / or the second strand are modiﬁed or unmodiﬁed. 1 0. The method of claim 9 , Wherein the Beta - ENaC - related disease is cystic ﬁbrosis , pseud0hyp0aldosteronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and / or obesity - associated hypertension. 11. The method of claim 9 , Wherein the method further comprises the step of administering an additional treatment for cystic ﬁbrosis , pseudohypoaldosteronism type 1 ( PHAl ) , Liddles syndrome , hypertension , alkalosis , hypokalemia , and / or obesity - associated hypertension. 12. The method of claim 11 , Wherein the method further comprises the step of administering an additional RNAi agent t0 Beta - ENaC. 13. A composition comprising a RNAi agent c0mprising a ﬁrst strand and a second strand , Wherein : . US 20l2 / 0ll5934 Al. a. the sequence of the ﬁrst strand is the sequence of SEQ ID NO : 198 , and / or the sequence of the second strand is the sequence of SEQ ID NO : 197 ; or. b. the sequence of the ﬁrst strand is the sequence of SEQ ID NO : l28 , and / or the sequence of the second strand is the sequence of SEQ ID NO : l27 ; and. Wherein the ﬁrst and / or the second strand are m0diﬁed or unmodiﬁed. 14. The composition of claim 13 , Wherein the RNAi agent 00mprises 0ne 0r more 2 ' - modiﬁcati0ns selected from the gr0up c0nsisting of : . 2 ' - deoxy , 2 ' - deoxy - 2 ' - ﬁuoro , 2 ' - O - methyl , 2 ' - O - methoxy - . ethyl ( 2 ' - O - MOE ) , 2 ' - O - aminopropyl ( 2 ' - O - AP ) , 2 ' - O - dimethylaminoethyl ( 2 ' - O - DMAOE ) , 2 ' - O - dimethylaminopropyl ( 2 ' - O - DMAP ) , 2 ' - O - dimethylaminoethyloxyethyl ( 2 ' - O - DMAEOE ) , and 2 ' - O—N - methylacetamido ( 2 ' - O - NMA ) . 15. The composition 0f claim 13 , Wherein the RNAi agent is ligated to one or more agents , Wherein the one or more agents are selected from : diagnostic compound , reporter group , cross - linking agent , nuclease - resistance conferring m0iety , natural or unusual nucleobase , lipophilic m0lecule , cholesterol , lipid , lectin , steroid , uVaol , hecigenin , diosgenin , . May 10 , 2012. terpene , triterpene , sarsasapogenin , Friedelin , epifriedelanolderiVatized lithocholic acid , Vitamin , carbohydrate , dextran , pullulan , chitin , chitosan , synthetic carbohydrate , oligo lactate 15 - mer , natural polymer , loW - or medium - molecular Weight polymer , inulin , cyclodextrin , hyaluronic acid , protein , protein - binding agent , integrin - targeting molecule , polycationic , peptide , polyamine , peptide mimic , and transferrin. 16. The composition of claim 13 , Wherein the composition comprises a second RNAi agent to Beta - ENaC. 17. The composition of claim 13 , Wherein the RNAi agent comprises a phosphorothioate and / or a 2 ' - modiﬁed nucleotide. 18. A pharmaceutical composition comprising a therapeutically effectiVe amount of a composition of claim 1 and a phannaceutically acceptable carrier. 19. A pharmaceutical composition comprising a therapeutically effectiVe amount 0f a 00mposition of claim 5 and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition comprising a therapeutically effectiVe amount of a composition of claim 13 and a pharmaceutically acceptable carrier. $ $ $ $ $